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DISSERTATION ABSTRACT 
Translocator Protein 18 kDa: from Biomarker to Function 
Meredith K. Loth 
Translocator Protein 18 kDa (TSPO) is a protein  that is expressed at low levels in the brain, 
but upon brain injury or inflammation, increases its expression  in the areas of the brain specific 
to injury. In this way, TSPO can be used as a biomarker of brain inflammation and injury. TSPO 
is primarily expressed in two cell types, microglia and astrocytes, and is used as a marker 
of reactive gliosis in various brain pathologies. Currently, there is a paucity of knowledge on 
the function(s) of TSPO in glial cells. Recent studies using conditional and global TSPO 
knockout mice have questioned the role of TSPO in translocating cholesterol across the outer 
mitochondrial membrane as the first step in steroidogenesis.   
In the brain, microglia and astrocytes exhibit distinct spatial and temporal patterns of TSPO 
upregulation. These differential patterns are not well characterized across disease models and in 
particular, are poorly characterized in the early stages of disease, prior to behavioral and clinical 
disease manifestations. Importantly, these distinct patterns of TSPO upregulation may indicate 
different functions of TSPO in microglia and astrocytes.  
We examined TSPO levels in a neurodegenerative transgenic mouse model of Sandhoff 
disease and longitudinally compared TSPO levels to behavioral manifestations of disease and other 
neuropathological endpoints (neurodegeneration, reactive gliosis, ganglioside accumulation). This 
study confirmed TSPO upregulation prior to neurodegeneration in a brain region-dependent and 
disease course-dependent way. In brain regions with increased TSPO levels, there was a 
differential pattern of glial cell activation with astrocytes being activated earlier than microglia 
during the progression of disease. Immunofluorescent confocal imaging confirmed that TSPO 
colocalizes with both microglia and astrocyte markers, but the glial source of the TSPO response 
differs by brain region and age in SD mice.  
We next wanted to gain insight into the function of TSPO in microglia. We previously 
demonstrated that TSPO ligands (TSPO-L) (1-100 nM) induced intracellular ROS production 
which was abrogated by NADPH oxidase (NOX2) inhibitors, thereby indicating an association 
between TSPO and NOX2.  To further elucidate the relationship between TSPO and NOX, we 
determined the source of ROS production resulting from microglia exposure to TSPO-L. 
Intracellular and extracellular ROS production was inhibited by NOX inhibitors, but not by a 
mitochondria permeability transition pore inhibitor, indicating that the source of ROS production 
is from NOX and not from mitochondria. These findings were confirmed using the mitochondria 
specific ROS probe MitoSOX.   
To further explore the TSPO-NOX2 association, we used 3 molecular approaches to 
examine protein-protein interactions under unstimulated or stimulated conditions (100 ng/mL 
lipopolysaccharide (LPS) for 18 hours) in primary microglia. 1) Co-immunoprecipitation (co-IP) 
revealed that the NOX2 subunits, gp91phox (gp91) and p22phox (p22), co-IP with TSPO supporting 
a protein-protein interaction. TSPO’s association with gp91 and p22 decreased with activation, but 
TSPO’s association with VDAC, a mitochondrial protein, remained constant. These findings 
suggest that microglia activation changes the dynamics of the TSPO-NOX2 interaction. 2) 
Confocal imaging and colocalization analysis of TSPO/gp91 or TSPO/p22 immunofluorescence 
confirmed that TSPO colocalizes with both NOX subunits. Under stimulated conditions, TSPO 
associated with gp91 and TSPO associated with p22, exhibit significantly decreased colocalization 
with VDAC suggesting a movement from the mitochondria to other cellular compartments. 3) 
Duolink Proximity Ligation Assay confirmed that TSPO interacts with p22, gp91 and VDAC. Our 
results suggest a novel TSPO-gp91-p22 interaction with VDAC in primary microglia that is 
disrupted by microglia activation and may be involved with redox homeostasis with significant 
implications for a new understanding of TSPO glial cell biology.  
In summary, the present studies have strengthened the use of TSPO as a preclinical 
biomarker, confirmed its specific spatiotemporal upregulation in two cell types and have provided 
a new potential function of TSPO in microglia that has the possibility to revolutionize the TSPO 
field and to inform neurotoxicity assessments and neurological disease treatments.  
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Dedication 
This research is dedicated to anyone that can benefit from these scientific advances, whether they 
help inform those who are exposed to neurotoxicants, or those with a neurodegenerative disorder. 
May these advances expand and improve your treatment options, lessen your time to 
diagnosis, and help future scientists garner more knowledge and generate better solutions to
inform researchers, physicians, and public health policy.  
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Chapter 1: Introduction & Background 
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INTRODUCTION 
Burden of neurological disorder to public health 
In 2006, the WHO estimated that neurological disorders affect as many as a billion people 
worldwide, and that this number is only expected to increase. This is a statistic that is relevant to 
all as neurological disorders do not discriminate: they can affect any age, gender, race, and 
socioeconomic status. Further, there are a wide variety of etiologies for neurological disorders, 
including genetic and environmental factors, as well as interactions between those genetic and 
environmental factors, thereby increasing the likelihood one can be affected by a neurological 
disorder. 
Global burden of disease (GBD) can be measured in multiple ways, including in terms of 
mortality, morbidity, and disability. In 1993 a GBD study conducted by the WHO, the World Bank 
and the Harvard Public School of Public Health, determined that while many neurological 
disorders or injuries caused little to no direct deaths (mortality), they were major causes of 
disability or years of healthy life lost (DALYs), and therefore still a major contributor of burden 
of disease. Specifically, neurological disorders contributed to 92 million DALYs worldwide in 
2005 and this is expected to increase to 103 million DALYs by 2030.  Additionally, the burden of 
neurological disorders is expected to increase by the year 2030 regardless of income.  Therefore, 
there is a demand to reduce the burden of neurological disorders. Reducing the burden of 
neurological diseases can be accomplished through multiple methods including but not limited to 
raising awareness, taking precaution, or getting treatment to delay the progression of disease, as 
most neurological disorders are currently incurable.   
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Reactive gliosis: a hallmark response to brain injury 
Brain injury can occur through multiple modalities including stroke, ischemia, traumatic 
brain injury, neurotoxicant exposure, or various neurodegenerative diseases. Still, regardless of the 
type or mechanism of brain injury, the archetypal response of glial cells is reactive gliosis where 
both microglia and astrocytes become reactive and undergo morphological changes, increase 
proliferation, and modulate growth factor and cytokine release (Chen & Guilarte 2008; McNeela 
et al 2018; Maeda et al 2007). Reactive gliosis generally has a graded morphological response that 
is associated with the degree of damage in various forms of brain pathology (Raivich et al 1999). 
Acutely, reactive gliosis provides a mechanism for limiting the progression of injury. Following 
chronic activation, the ability of reactive gliosis to limit injury or disease progression decreases 
and, in some cases, transitions into a harmful state (McNeela et al 2018). ). Glial cell activation 
occurs not only at the sites of primary injury, but also at secondary sites (Chen and Guilarte, 2008) 
given that as microglia are activated, they can recruit bystanding microglia to become phagocytes, 
recruit leukocytes and monocytes from the periphery, and eventually astrocytes to become reactive 
(Raivich et al 1999). 
Historically, assessment of reactive gliosis was only possible through postmortem autopsy 
or invasive biopsies. However, with the advent of positron emission tomography (PET) imaging 
and in vivo  imaging techniques, we are able to image specific proteins and biomarkers within the 
living and active brain. To this end, translocator protein 18 kDa (TSPO) is located exclusively in 
glial cells in the brain parenchyma and has been used as a sensitive biomarker of reactive gliosis 
and inflammation associated with a variety of brain insults including chemical-induced 
neurotoxicity (Kuhlmann and Guilarte 1997, 1999, 2000; Guilarte et al 2003; Chen and Guilarte 
2006; Chen et al 2004), ischemia (Gerhard et al 2000); TBI (Coughlin et al 2015, 2017); and 
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multiple neurodegenerative diseases with an inflammatory component such as Alzheimer’s 
disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Zika virus, 
et cetera. (Zimmer et al 2014; Gerard et al 2006; Zurcher et al 2014; Politis et al 2012; Kuszpit et 
al 2017). Increased TSPO expression during injury is predominately localized to glial cells, 
suggesting a role of TSPO in reactive gliosis.  Because of the high degree of sensitivity and 
specificity of increased TSPO levels during brain injury, TSPO has been used as a biomarker to 
identify injured brain regions, track the progression of injury/ disease, and monitor recovery and 
efficacy of therapies and treatments. TSPO distribution can also be visualized and quantified both 
ex vivo using receptor autoradiography and in vivo using PET and single photon emission 
computed tomography (SPECT) imaging with the high affinity and specific TSPO ligands that are 
available and can be radiolabeled (Chen and Guilarte, 2008). These characteristics make TSPO it 
a powerful tool in assessing neurotoxicity and neurodegenerative disease progression and 
recovery. 
TSPO Background 
Translocator protein 18 kDa (TSPO) was discovered in 1977 by Braestrup and Squires. At 
the time, TSPO was referred to as the peripheral benzodiazepine receptor (PBR) as it was described 
as a high affinity benzodiazepine binding site in rat peripheral tissue, specifically the kidney 
(Braestrup & Squires, 1977). The objective of the original experiment by Braestrup and Squires 
was to find the brain receptor for benzodiazepines using [3H]-diazepam. In using kidney membrane 
preparations as their negative control for the central-type benzodiazepine receptor (CBR), they 
observed high levels of [3H]-diazepam specific binding, specifically within the mitochondrial 
fraction of the kidney (Braestrup & Squires 1977). Thus, even in from its nascence, the TSPO field 
has been filled with surprises, contradictions, and, enigmas.   
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Subsequent studies showed that TSPO/PBR and CBR differ in their pharmacological 
properties. CBR binds benzodiazepines with high affinity (nM) and mediates anxiolytic and 
anticonvulsant properties of benzodiazepines. CBR is able to inhibit the firing of action potentials 
by coupling to the γ-aminobutyric acid (GABA)A receptor on the plasma membrane and modulate 
the GABAA-regulated opening of Cl
- channels (Tallman et al., 1978).  While TSPO also binds to 
the benzodiazepine valium with high affinity, there is a distinction between the ligands to which 
these two receptors can bind.  7-chloro-5-(4-chlorophenyl)-1-methyl-1,3-
dihydrobenzo[e][1,4]diazepin-2-one (Ro5-4864) is a derivative of valium that binds to TSPO at 
nanomolar concentrations but to CBR at low affinity (uM concentrations).  Conversely, 
clonazepam binds with low affinity (uM) to TSPO, but with high affinity (nM) to CBR 
(Schoemaker et al., 1981).  TSPO also demonstrates anatomical, structural, and functional 
differences from CBR, which will be discussed later on in this chapter. 
TSPO was originally named peripheral benzodiazepine receptor. However, in 2006, 
researchers collaborated to rename the protein (Papadopoulos et al 2006). PBR was considered to 
be a misnomer for several reasons. First, multiple other ligands besides benzodiazepines had been 
identified in their ability to bind to TSPO including 1-(2-chlorophenyl)-N-methyl-(1-
methypropyl)-3-isoquinoline carboxamine (PK11195) (Benavides et al 1983), cholesterol 
(Lacapere et al 2001; Bernassau et al 1993), and protoporphyrin IX (Taketani et al 1995; Vanhee 
et al 2011).  Additionally, as TSPO had been demonstrated to be in the central nervous system 
(CNS) in addition to peripheral organs, peripheral was no longer accurate. Finally, it was 
determined that as TSPO translocated cholesterol, its new name could partially reflect this 
function.  
TSPO Biology & Physiology 
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TSPO Structure 
The crystal structure of TSPO has been partially resolved in two different species of 
bacteria: Bacillus cereus (Guo et al 2015) and Rhodobacter sphaeroides (Li et al 2015), and in one 
species of rodent Mus. musculus (Jaremko et al 2014).  TSPO is a protein consisting of 5 
transmembrane helices and 169 amino acids. In several studies, this protein is determined to be at 
the outer mitochondrial membrane (OMM) with the C-terminus outside of the OMM and the N-
terminus in the intermembrane space between the OMM and the inner mitochondrial membrane 
(IMM). Loops 1 and 3 are extra-mitochondrial and loops 2 and 4 are intra-mitochondrial (Jaremko 
et al 2014) (Figure 1.1 A). Multiple binding sites and domains have been identified within the 
structure of TSPO including the binding sites for: synthetic ligands (PK11195, Ro5-4864), 
porphyrin, cholesterol (Cholesterol Recognition Amino acid Consensus, CRAC), and diazepam 
binding inhibitor (DBI) (Alho et al 1991; Murail et al 2008; Vanhee et al 2011; Selvaraj et al 2017) 
(See Figure 1.1B for selected binding sites).  
TSPO homologs exists in the animal kingdom in bacteria, insects, and mammals (Yeliseev 
et al 2000; Selveraj et al 2015), as well as in plants including the well-studied Arabidopsis thaliana 
(Guillaumot et al 2009) and other plants such as Solanum tuberosum (Corsi et al 2004). Two 
notable exceptions to the evolutionary conservation of TSPO are Escherichia coli and 
Saccharomyces cerevisiae (Liu et al 2014). The human TSPO sequence shares homologies with 
the following species:  33% R. sphaeroides; 43% Drosophila melanogaster; and 81% Mus 
musculus. Not only is TSPO structurally conserved across species, but TSPO is also functionally 
conserved in some cases (Yeliseev, Kruegar, & Kaplan, 1997). In expressing rat TSPO in TspO- 
R. sphaeroides, rat TSPO was able to perform the functions of this bacterial TspO: to negatively 
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regulate photosynthesis genes in response to oxygen. Further specificity was demonstrated by 
antagonizing this effect with the TSPO ligand PK11195.  
TSPO: monomers, dimers, and oligomers 
There is evidence that the structure of TSPO can exist either as a monomer, homodimer 
(Lacapere et al 2001; Jaipuria et al 2017) or high level oligomer (Delavoie et al 2003; Teboul et al 
2012; Jaipuria et al 2017). Lacapere and colleagues demonstrated that monomeric TSPO is 
associated with both PK11195 and cholesterol binding. Providing further supporting evidence for 
the association of monomeric TSPO with cholesterol binding, Jaipuria et al demonstrated that 
cholesterol binding to the CRAC motifs of a TSPO homodimer, leads to structural changes in the 
protein and induces dissociation of the monomers. The separation of the TSPO homodimer 
exposes a GxxxG binding motif that provides TSPO monomers an interface to interact with itself 
(this is the interface where TSPO homodimers associate) or with other proteins, as the GxxxG 
motif has been identified as a motif that is sufficient to mediate dimerization and has substantial 
oligomerization potential (Brosig & Langosch 1998; Russ & Engleman 2000). Further, the 
oligomeric status of TSPO varies across cell types. Molecular weights of multiples 18 kDa have 
been identified in various cell types including testicular Leydig cells, breast cancer cells, murine 
macrophages, and brain tissue (Delavoie et al 2003; Loth, unpublished data).  
TSPO oligomeric state also varies across species as was noted in Teboul et al 2012 in the 
single particle analysis of transmission electron microscopy (TEM). That is, image analysis 
suggested the presence of four monomers for mammalian TSPO as compared to a dimer for 
bacterial TSPO. Several studies have reported a functional dimer for bacteria (Korkhov et al 2010; 
Yeliseev & Kaplan 2000) whereas monomers and polymers have been described as functional 
units for mammalian species (Lacapere et al 2001; Delavoie et al 2003).  
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Additionally, Delavoie and colleagues provided evidence that during periods of increased 
ROS expression, the equilibrium of TSPO binding shifts towards forming polymeric TSPO 
(Delavoie et al 2003). This would indicate that in pathological conditions that are associated with 
high levels of ROS, the equilibrium of TSPO would shift towards forming oligomers. Taken 
together, these data indicate that TSPO polymerization is an ongoing, dynamic process that may 
be partially regulated by ligand binding such as cholesterol as well as by ROS. The functional 
implications of TSPO’s oligomeric state remain to be fully ascertained.  
TSPO Subcellular Localization 
TSPO has been shown to be predominantly at the outer mitochondrial membrane (OMM) 
in multiple types of tissues and cells: rat adrenal glands, (Anholt et al 1986), testis, lung, kidney, 
heart, liver, and skeletal muscle (Antkiewicz-Michlauk et al 1988; O”Beirne et al 1990). 
Additionally, immune electron microscopy studies in our lab have indicated TSPO is at the OMM 
in primary murine microglia (See Chapter 4, Figure 11). Subcellular fractionation studies also 
confirmed the OMM in that digitonin treatment of rat adrenal mitochondria released TSPO and 
monamine oxidase, (a marker of the OMM), but not cytochrome oxidase, a marker of the inner 
mitochondrial membrane (IMM) (Anholt et al 1986). Notably, other studies in the guinea pig lung, 
have supported TSPO’s localization to the IMM (Mukherjee & Das 1989) through TSPO binding 
sites that were associated with the IMM marker, succinic dehydrogenase. Furthermore, Mukherjee 
& Das observed a decrease in Ro binding to the mitochondrial membrane under hypotonic 
conditions and not under isotonic conditions, which they concluded suggests the location of the 
receptors is inside the mitochondria. Additionally, in immunoprecipitation studies, TSPO has been 
shown to be associated with VDAC, an OMM protein (McEnery et al 1998; Gatliffe et al 2014; 
Loth et al 2018, see Chapter 4).  Moreover, immunohistochemical studies of TSPO with confocal 
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microscopy and electron microscopy have confirmed the localization of TSPO to the outer 
mitochondrial membrane and other subcellular compartments such as the mitochondrial associated 
membrane (MAM) and plasma membrane (Bribes et al, 2004; Chapter 4, Figure 11).   
However, other studies have indicated subcellular localizations of TSPO that are non-
mitochondrial. In some cases this occur within the same cell type, and in other cases this is across 
cell types. For example, Olsen et al 1988 reported TSPO in erythrocytes, which are cells which 
exude their mitochondria prior to leaving the bone marrow. The authors hypothesize that TSPO in 
this case is localized to the plasma membrane (Olsen et al 1988). Neutrophils also express TSPO, 
but have lower levels of mitochondria due to the apparent decrease of mitochondrial content along 
the granulocyte differentiation pathway (Woods & Williams 1996). TSPO is thought to be at the 
plasma membrane in neutrophils for this reason, as well as based on the experiment by Zavala et 
al 1991 where in exposing live, intact neutrophils to a TSPO antibody, neutrophils released an 
oxidative burst. Additionally, in the mouse adrenal cortex, Oke et al 1992 determined through 
confocal microscopy and 3-D reconstruction that in cells from the zona fasciculate, there was 
TSPO cell surface staining.  In addition to the plasma membrane, TSPO has been suggest to be the 
nuclei and perinuclear areas from human breast tumor biopsies, breast tumor cell lines, and glial 
cells after injury (Marangos et al 1982; Schoemaker at al 1983; Hardwick et al., 1999; Kuhlmann 
and Guilarte, 2000). The demonstration of a subset of TSPO at various subcellular locations (such 
as the plasma membrane) could account for the multiple functions attributed to TSPO and the 
actions of TSPO ligands that do not appear to be related to mitochondrial function.  
TSPO Tissue Distribution 
TSPO is expressed throughout the body, particularly in steroidogenic endocrine producing 
tissues (Papadopoulos et al 1997; De Souza et al 1985; Anholt et al 1986) and in tissues essential 
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for lipid metabolism such as white and brown adipose tissue, gonads, adrenal glands, and lung 
(Selvaraj et al 2015; Tu et al 2016). TSPO is also found in the kidney, heart, platelets (Shoemaker 
et al 1981; Tu et al 2014) as well as in the liver, heart, and muscle (Marangos et al 1982; 
Fairweather et al 2014) and in macrophages, monocytes, bone marrow, spleen (Tu et al 2014).  
TSPO is also found in the brain, however, in physiological conditions, basal TSPO levels 
are low, except for ependymal cells that line the ventricles, the choroid plexus, and the olfactory 
bulb (Cosenza-Nashat et al 2009; Gehlert et al 1983; Benavides et al 1983; Weissman et al 1984). 
Upon brain injury or inflammation, TSPO upregulates in both microglia and astrocytes, though 
the temporal response differs in these two cell types (Chen & Guilarte 2008; Loth et al 2016; Notter 
et al 2018; Lavisse et al 2012; Maeda et al 2007; Wang et al 2014; Cosenza-Nashat et al 2009; 
Kuhlmann & Guilarte 2000)). Additionally, data demonstrating TSPO upregulation in vascular 
endothelial cells in the brain in response to injury has recently been demonstrated (Notter et al 
2018; Cosenza-Nashat et al 2009).  The data regarding if TSPO is expressed in neurons is 
conflicting. Initially neuronal TSPO was observed in rodents, but not in humans (Weissman et al 
1984; Karchewski et al 2004). Cosenza-Nashat et al 2009 published a paper indicating neuronal 
staining of TSPO. However their antibody absorption studies raised some question as to whether 
the antibody was specific. However, the antibodies in question have been validated by 
immunoblotting and subcellular localization confirmed by electron microscopy (Bribes et al 2004; 
Dussossoy et al 1996). Given their staining was punctate which they say is indicative of 
mitochondrial distribution and that different mammalian isoforms of TSPO exist (Zhang et al 
2006; Lin et al 1993; Costa et al 2006), they speculate that possible that the neuronal form 
represents a different isoform or a structurally related molecule that is not yet identified (Cosenza-
Nashat et al 2009).  
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TSPO’s ubiquity in several types in tissue, both in physiological and pathological states, 
suggests pleiotropic functionality. Perhaps this is also why so much conflicting data and/or why 
so many different functions have been attributed TSPO.  
TSPO Physiological Functions 
Over the last several decades, TSPO has had several proposed functions (See Figure 1.3) 
However, the further science progresses, the more questions are raised about TSPO’s physiology 
in both health and diseased states. Currently, the function of TSPO is one of the most fiercely 
debated topics within the field. As the attributed functions of TSPO are numerous, here we will 
primarily focus on those functions most relevant to the function of TSPO in the brain. It is 
important to note that several of early studies examining TSPO function use extremely high 
concentrations of TSPO ligands. Despite the fact that these ligands have nM affinity, researchers 
were often using uM or higher concentrations for function studies, and thus many of the early 
studies may not in fact be mediated by TSPO, but are simply off target effects of high
ligand concentrations.   
Steroidogenesis. One of the most well-studied functions of TSPO is its role in 
steroidogenesis. In order for steroidogenesis to occur, cholesterol must enter the mitochondria for 
P450scc to convert cholesterol to pregnenolone, the precursor of all steroids Traditionally, TSPO 
was thought to translocate cholesterol across the outer mitochondrial membrane (OMM) as the 
first step in steroidogenesis (Papadopoulos et al 1997, 2006). In this way, TSPO was thought to 
modulate steroidogenesis and contribute to the translocation of cholesterol being the rate limiting 
step in steroidogenesis (Privalle et al 1983). Early studies supported this hypothesis in multiple 
ways. First, TSPO’s localization at the OMM (Anholt et al 1986), as well as the high affinity with 
which TSPO can bind cholesterol (Lacapere et al 2001) and the identification of a cholesterol 
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specific binding domain (cholesterol recognition amino sequence, CRAC)  at the C-terminus, all 
supported TSPO’s putative role in translocating cholesterol (Li et al 1998). Further in vitro studies 
demonstrated increases in steroid production after exposure to the TSPO ligands PK11195 or Ro5-
4864 in both murine adrenal cells (Mukhin et al 1989) and Leydig cells (Papadopoulos et al 1990).  
Additionally, the fact that TSPO’s transmembrane domains form a pore-like structure in which the 
interior is lined with hydrophobic residues, also supported TSPO’s putative ability to translocate 
cholesterol (Korkhov et al 2010; Jaremko et al 2014).  
However, in recent years multiple groups have generated TSPO knockout (KO) mice, both 
global and conditional, that have no impairments in steroidogenesis (Tu et al 2014; Morohaku et 
al 2014; Wang et al 2016; Banati et al 2014). Tu and colleagues demonstrate that PK11195’s effect 
on steroidogenesis is merely an off target effect and not mediated through TSPO. When they 
expose both TSPO WT and TSPO KO Leydig cells to increasing concentrations of PK11195, dose-
dependent increases in progesterone production are documented in both cell types, indicating that 
this effect is not modulated by TSPO.  In Morohaku’s study, there were no differences Leydig cell 
TSPO KO in serum testosterone, seminal vesical weight or testis weight as compared to wildtype. 
In the global TSPO KO mice, no differences were seen in steroid biosynthesis, fertility, or 
circulating adrenal or gonadal steroid levels (Banati et al 2014). The debate among the groups 
continues as to the role of TSPO in steroidogenesis. Some are attributing the conflicting studies to 
differences in the genetic background of the mice strains, whereas others explain the mutually 
exclusive results as there being either an adaptive or compensatory mechanism to impairments in 
steroidogenesis (McNeela et al 2018). Or perhaps the differing results can be attributed to the age 
of the animals, as in a recent paper by Barron and colleagues, they observed subtle steroidogenic 
abnormalities (reduced total steroidogenic output, particularly progesterone, corticosterone, and 
13 
androgen) in male TSPO knockout mice that were exacerbated with aging (Barron et al 2018).  
Interestingly, deletion of TSPO was also once considered to be embryonic lethal (Papadopoulos et 
al 1997), but again the generation of global TSPO KO mice has called this conclusion into 
question. Given that TSPO KO animals are able to survive in the new models and have a normal 
length lifespan, this again points towards the potential explanation of how the genetic background 
of a mouse can have a major effect on experimental results.  
Cell survival and apoptosis via the mitochondrial permeability transition pore. 
Several studies have suggested a role of TSPO in apoptosis. This theory began with studies in rat 
cardiac tissue and human glioblastoma cell lines that demonstrated that exposure of TSPO-ligands  
lead to swelling of the mitochondria, a collapse in mitochondrial membrane potential, and a 
decrease in cell viability (Chelli et al 2001; Kugler et al 2008; Costa et al 2015). Additionally, both 
PK11195 and Ro5—4864 are used as chemotherapy coadjuvants in an effort to decrease cell 
proliferation (Walter et al 2005; Mukhopadhyay et al 2010; Sanidrian et al 2007; Hirsh et al 1998; 
Decaudin et al 2002). However, other studies using C6 glioma cells or human colorectal cancer 
cell lines demonstrated that knocking down TSPO reduced cell death by decreasing the number of 
apoptotic cells and increasing cell proliferation (Levin et al 2005; Shoukrun et al 2008). Also, in a 
correlation analysis of TSPO, expression was positively associated with tumor malignancy grade 
and the proliferative index as determined by MIB-1/Ki-67 immunocytochemistry (Miettinen et al 
1995). And in human breast cancer cell lines, highest amounts of both TSPO and
mitochondria were found in cell lines with high mitotic activity, and TSPO expression correlated 
inversely with cell doubling time and positively with Ki-67 expression (Beinlich et al 2000). Based 
on these studies, TSPO’s association with the mitochondrial permeability transition pore (mPTP) 
was suggested by Veenman and colleagues in 2008 as well as Sileikyte and colleagues in 2010. 
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The mPTP is described as a nonspecific pore that opens in response to mitochondrial stress, 
specifically an increase in permeability of the inner mitochondrial membrane (Galluzzi et al 2009) 
This pore allows the passage of molecules < 1.5 kDa, and ultimately functions to decouple 
oxidative phosphorylation (Halestrap et al 1999) which in turn ruptures the outer mitochondrial 
membrane, and releases apoptosis stimulating factors, thereby regulating cell death (Pastorino et 
al 1996; Larochette et al 1999). However, as the field evolves, several studies have challenged the 
involvement of TSPO with mPTP (Sileikyte et al 2014; Bernadi et al 2013; Baines et al 2007; 
Krauskopf et al 2006; Kokoszka et al 2004). These studies propose that the mPTP involves other 
mitochondrial components, but is independent of TSPO as evidenced by TSPO null mitochondria 
demonstrating no differences in the controls of pore function.  
Immunomodulation: pro-inflammatory vs. anti-inflammatory. TSPO’s use as a 
biomarker of brain inflammation is particularly well studied. At baseline, TSPO is at very low 
levels in the brain neuropil. After exposure to toxic chemical stress (endogenous [ROS etc] or 
exogenous [neurotoxicants etc.]) or physical stress (head trauma), TSPO is upregulated in brain 
areas specific to the injury, by glial cells (Chen & Guilarte 2008; Gulyas et al 2012; Lavisse et al 
2012; Cagnin et al 2001a and b; Gerhard et al 2006 a and b; Coughlin et al 2015 and 2017; Zimmer 
et al 2014; Zurcher et al 2015; Politis et al 2012; Pavese et al 2006). These observations have led 
to the development of positron emission tomography (PET) radiotracers for brain imaging. TSPO-
PET imaging represent a unique and valuable tool in that it provides a window to assess active 
brain disease and can be used to track the effect of a therapeutic intervention’s ability to decrease 
inflammation or potentially even to aid in diagnosis of neurological diseases given the regional 
specificity TSPO expression demonstrates.   
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However, despite this extensive history for use as a biomarker of neuroinflammation, little 
is known about TSPO’s function at the molecular level or how TSPO contributes to inflammation. 
Studies have shown both pro and anti-inflammatory effects of TSPO upregulation and/or TSPO-
ligand exposure. At the in vitro level, multiple studies have shown that knocking down TSPO in 
microglia prolongs LPS induced proinflammatory cytokine release, whereas overexpression TSPO 
leads to the converse (Bae et al 2014). Wilms et al 2003 had a similar finding in that exposing 
microglia to TSPO ligands decreased LPS-induced proinflammatory cytokine release. Choi et al 
2011 found that when microglia are activated with either LPS or ATP, TSPO ligands reduced pro-
inflammatory genes expression and cytokine release, and thus may have therapeutic potential. Bae 
and colleagues (2014) hypothesize that this decrease in inflammatory response is mediated through 
the attenuation of the nuclear factor-κB pathway, and through an increase in alternatively activated 
M2 stage related genes, but this remains to be confirmed. Zhao and colleagues (Zhao et al 2011) 
also have some initial data with the TSPO ligand Vinpocetine that supports this initial hypothesis 
as they demonstrated that Vinpocetine exposure inhibited production of nitric oxide and IL-1β, IL-
6, and TNF-α, as well as the expression of NF-κB and AP-1 in LPS-stimulated microglia. This 
indicates that Vinpocetine has an anti-inflammatory effect by partly targeting NF-kappaB/AP-1 
within BV-2 cells, a  microglial cell line in which doubts have been raised regarding how 
synchronous its responses are compared to primary microglia (Hausler et al, 2002; de Jong et al., 
2008; Horvath et al., 2008).  
Additionally, in vivo studies suggest that TSPO overexpression or TSPO ligand exposure 
decreases cellular signs of reactive gliosis in LPS, kainic acid, or quinolinic acid exposed rodents 
(Ryu et al 2005; Veiga et al 2005; Leaver et al 2012; Wang et al 2016). Together, these studies 
suggest that TSPO upregulation in inflammation represents an adaptive response to mitigate and/or 
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resolve inflammation. Furthermore, it will be critical to assess the role of each glial cell type (i.e., 
microglia and astrocytes) and how each contributes to the inflammatory process. Studies 
examining not only the individual response of each cell type, but also the cross-talk between 
microglia and astrocytes in inflammation across time will be important in assessing TSPO’s role 
in inflammation. 
 Mitochondrial respiration and cellular energy production. With the advent of TSPO 
KO mice, TSPO’s role in oxygen consumption and indirectly energy production is being 
examined. In both microglia (Banati et al 2014) and fibroblasts (Zhao et al 2016) cultured from 
TSPO KO mice, these investigations observed decreased rates of oxygen consumption and 
production of adenosine triphosphate (ATP). Additionally, overexpression of TSPO in T-cells 
increased ATP production and motility (Liu et al 2017). Yet, TSPO’s role in mitochondrial 
respiration and energy production appears to be cell specific because while positive results are 
seen in fibroblasts, microglia, and T-cells, the opposite is observed in Leydig cells (Tu et al 2016) 
and certain liver cells (Sileikyte et al 2014).  
Regulation of redox process and oxidative stress. The role of TSPO in the regulation of 
redox homeostasis and in responses to oxidative stress is being examined by multiple groups 
(Guilarte et al 2016; Carayon et al 1996; Zeno et al 2012; Banati et al 2014; Liu et al 2014; Guo 
et al 2015). This appears to be another condition where the cell type, time point examined, 
physiological vs. pathological state, and oligomeric composition generate variable data in regards 
to the role of TSPO. For example, within the data produced by our lab, TSPO ligands induce an 
increase in ROS production in primary microglia (Choi et al 2011). Yet, TSPO ligands also induce 
the translocation of Nrf2, a transcription factor that upon activation, translocates to the nucleus in 
order to bind to antioxidant response element (ARE) and induce the expression of various 
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cytoprotective genes, presumably in order to protect itself from the ROS that it is generating (Loth 
et al 2018, in preparation; See Chapter 3). Taken together, these data indicate that TSPO is 
maintaining redox homeostasis. 
However, in other studies using vascular endothelial cells, overexpression and 
pharmacological activation of TSPO have been demonstrated to inhibit ROS production, 
specifically mitochondrial ROS production (Joo et al 2012 and 2015). In an astrocyte cell line, 
cells that were metabolically injured via glucose deprivation had less free radical production, 
maintenance of mitochondrial function, improved cell viability, and less nuclear 
fragmentation when also exposed to Ro5-4864 (Baez et al 2017). Of note, these cells were 
exposed to ligand concentrations of 10nM, 100 nM, 1 uM, or 10 uM, and lower 
concentrations of ligand were associated with the improved cell viability, less nuclear 
fragmentation, and lower ROS production as measured by DHE, whereas higher concentrations 
of the ligand actually exacerbated effects observed due to glucose deprivation. Furthermore, 
TSPO deletion in Leydig cells increased ROS production (Tu et al 2015). As indicated 
previously, Delavoie’s et al 2003 found that oligomeric TSPO was preferentially expressed 
during periods of increased ROS expression.  
One distinction regarding TSPO’s relationship with ROS production that is made by 
Veenman et al 2016 is that with short durations of TSPO ligand exposures and low 
concentrations of ligands, ROS production is enhanced. This is in contrast with the reduction of 
ROS production induced by long durations of TSPO ligand exposures, and/or the application of 
high concentrations of TSPO ligands. However, it is important to note that at these high 
concentrations of TSPO ligands, we may be observing off target effects as opposed to effects 
truly mediated by TSPO. Therefore, examining both long and short term exposures to 
physiologically relevant 
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concentrations of TSPO ligands will be critical in assessing the role of TSPO in ROS production, 
and whether or not there is indeed this hormetic relationship between TSPO and ROS.  
Heme biosynthesis. Multiple groups have noted that protoporphyrin IX/heme is an 
endogenous ligand for TSPO (Verma et al 1987; Snyder et al 1987; Vanhee et al 2011; Li et al 
2015; Taketani et al 1995; Veenman et al 2016). Several groups have examined heme biosynthesis 
and whether TSPO plays a role (Ginter et al 213; Rampon et al 2009; Taketani et al 1995; Vanhee 
et al 2011; Gemelli et al 2014; Wendler et al 2003) given that protoporphyrin IX is the precursor 
to heme. Specifically, Vanhee and colleagues (2011) have demonstrated that in Arabidopsis 
thaliana, TSPO can bind heme both in vivo and in vitro. Additionally, various point mutations 
altered whether or not heme binds and if TSPO degrades heme, thereby suggesting that heme 
binding regulates TSPO degradation in A. thaliana. The authors suggest that TSPO plays a role in 
heme scavenging given that abscisic acid-dependent TSPO induction was accompanied by an 
increase in unbound heme levels, and downregulation of TSPO was associated with the return to 
steady state levels of unbound heme. In bacterial TspO, Ginter and colleagues (2013) demonstrate 
that TSPO degrades porphyrin in a light and oxygen dependent manner, and this reaction can be 
inhibited by PK11195 or specific point mutations of conserved residues. The authors hypothesize 
that bacterial TspO mediates porphyrin catabolism with the consumption of reactive oxygen 
species, and this is potentially a function conserved across species.  
Calcium signaling.  TSPO has also been implicated in calcium signaling in various 
contexts. In a neuronal cell line, TSPO deregulates mitochondrial Ca(2+) signaling thereby leading 
to an increase in the cytosolic Ca(2+) pools that in turn activate NOX5 (the Ca(2+)-dependent 
NADPH oxidase ) and serve to  increase ROS (Gatliffe et al 2017). The authors demonstrate that 
the inhibition of mitochondrial Ca(2+) uptake by TSPO is a result of the phosphorylation of the 
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voltage-dependent anion channel (VDAC1) by the protein kinase A (PKA), which is recruited to 
the mitochondria, in complex with the Acyl-CoA binding domain containing 3 (ACBD3). Whether 
these studies are actually indicative of what is happening in the brain remains to be determined as 
TSPO is not typically expressed in neurons, and these studies were performed in a neuronal cell 
line, SH-SY5Y cells. Additionally, studies examining PK11195 have shown that this ligand may 
be apoptotic in some contexts through changing cellular Ca2+ homeostasis. Campanella et al 2008 
demonstrated in HeLa cells that PK11195 increased ER Ca2+ and amplifyied IP(3)  which served 
to induce Ca2+ transients in mitochondria and cytosol. The authors hypothesize that PK 11195 is 
acting on Bcl-2 given that Bcl-2 modulates Ca2+ in the opposite way: Bcl-2 overexpression 
reduces Ca2+ in the ER and impairs mitochondrial and cytosolic Ca2+ thereby inhibiting 
apoptosis. Furthermore, in rat heart mitochondria, TSPO has been demonstrated to modulate Ca2+ 
transport through VDAC. Tamse and colleagues tested the hypothesis if the endogenous ligand 
hemin (protoporphyrin IX) to TSPO modified VDAC conductance. They demonstrated that 
initially, hemin reduced the calcium uptake rate in a dose-dependent manner. However, subsequent 
to this inhibitory effect on calcium influx, hemin facilitated mitochondrial permeability transition 
(MPT) as evidenced by greater calcium release following calcium loading. When hemin 
(protoporphyrin IX) binds to TSPO, it induced the closure of VDAC-TSPO-ANT (adenine 
nucleotide translocator) complex, indicating another potential way in which TSPO affects Ca2+ 
signaling and in this case, VDAC conductance. 
TSPO ligands & therapeutic potential 
Multiple studies have shown that TSPO ligands have the potential to exert neuroprotective 
effects in various models of injury and neuroinflammation. However, depending on the injury or 
disease, the ligand that is neuroprotective varies. For example, administration of Ro5-4864 in a 
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mouse model of AD reversed neuropathology and improved behavioral outcomes, whereas 
administration of PK11195 only reduced levels of soluble β-amyloid (Barron et al 2013). 
Administration of Ro5-4684 also decreased reactive gliosis and neuronal death in the hilus of the 
hippocampus in male rats when administered prior to exposure to kainic acid, a well-known 
neurotoxicant that targets the hippocampus (Veiga et al 2005).  Ro5-4864 also prevented 
mitochondrial-mediated apoptosis of neurons in a rat model of cortical injury (Soustiel et al 2008) 
and reduced the severity of diabetic neuropathy (Giatti et al 2009).  In most of these studies, 
PK11195 either showed no effect (Veiga et al 2005; Soustiel et al 2008) or counteracted the effects 
elicited by Ro5-4864 (Mills et al 2005; Lacor et al 1999).  On the other hand, administration of 
PK11195 but not Ro5-4864 reduced microglial activation in the hippocampus of LPS-injected 
male rats (Veiga et al 2007).  PK11195 also reduced microglial activation and expression of pro-
inflammatory cytokines and iNOS in the striatum of quinolinic acid-injected male rats (Ryu et al 
2005) and attenuated kainic acid-induced seizures and hyperactivity in male rats (Veenman et al 
2002).  In addition, in vitro data demonstrated that PK11195 rescued motor neuron death in both 
a familial model of ALS, as well as in a humanized model of sporadic ALS, indicating a potential 
common therapeutic target for sporadic and familial ALS. Furthermore, preliminary in vivo data 
of PK administration in a mouse model of ALS improved Rotarod performance and neuroscore in 
females (Obis et al 2018, in preparation). 
Etifoxine, a clinically approved drug for treating anxiety in humans and identified as a 
TSPO ligand reduced the number of macrophages at lesion, promoted axonal regeneration, and 
improved motor functions after peripheral nerve injury in rat  (Girard et al., 2008).  In a mouse 
model of MS (EAE), administration of etifoxine attenuated EAE severity when administered 
before the development of clinical signs and also improved symptomatic recovery when 
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administered at the peak of the disease (Daugherty et al 2013). The authors determined this by the 
decreased inflammatory pathology in the lumbar spinal cord, as well as the decrease in peripheral 
immune cell infiltration into the spinal cord.  
Thus, it appears that TSPO ligand administration has therapeutic potential, but ligands have 
differential effects. Each ligand will need to be independently evaluated in each disease and injury 
model in both sexes before being used clinically to improve outcomes.  Additionally, whether or 
not each ligand is actually working through modulating TSPO will need to be determined using 
TSPO KO technology. Many of the above studies have not measured TSPO levels, and therefore 
this could again be another circumstance in which off target effects of TSPO are being observed.  
Microglia: the Guardians of the CNS 
Microglia constitute around 10% of the total number of cells in the adult central nervous 
system (CNS), with their density varying across brain regions (Mittelbronn et al 2001). Substantia 
nigra typically has the highest density of microglia (12%), while the cortex and corpus callosum 
have some of the lower densities (5%). Microglia were first discovered by Pio del Rio-Hortega in 
1920 and described as “a unique cell type differing in morphology from other glia and neurons.” 
(Block et al 2007). Indeed, microglia are morphologically and developmentally distinct from other 
cell types in the CNS. They leave the yolk sac between embryonic day 8.5-9.0 and enter the blood 
stream (Ginhoux et al 2010), and thus are erythromyeloid in origin, unlike the rest of the CNS 
(Matcovitch-Natan et al 2016). They are maintained via self-renewal in the healthy CNS and not 
from progenitors in bone marrow where precursors for macrophages typically originate from 
(Ajami et al 2007).  
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Microglia are often referred to as the macrophages of the CNS, with their main perceived 
role being to react to injury, infection, or pathology. However, part of this perception of their sole 
function stems from the fact that functions of microglia are not noticed unless they stop performing 
their physiological functions including general maintenance and clearing cellular debris (Beyer et 
al 2000). Research over the last several years has revealed other distinct roles for microglia 
including sculpting the structure of the CNS, refining neuronal circuitry and network connectivity 
(Barron 19995; Milligan et al 991), and contributing to plasticity (Salter & Beggs 2014). 
Additionally, microglia play a role in cell survival in terms of immune surveillance, clearance 
capabilities and maintenance of local homeostasis (Casan & Peri 2015).  In this way, microglia are 
viewed as instructive in physiological conditions, as opposed to reactive as they are viewed 
following injury or infection or in pathological conditions. For our purposes here, we will primarily 
focus on microglia’s role and function in inflammation and redox homeostasis.  
In a healthy brain, microglia are perceived to be in a resting, non-activated state.  However, 
microglia are hardly “resting” in the normal brain.  In vivo imaging studies with two-photon 
microscopy and time-lapse imaging in mice expressing fluorescently-labeled microglia have 
shown that microglia possess highly mobile ramifications that are constantly surveying their 
environment and are capable of de novo formation, extension, and withdrawal.  Microglia possess 
a lattice-like pattern of adjacent, non-overlapping territories that are capable of responding to 
injury and mobilizing towards the site of injury in less than 30 seconds (Davalos et al 2005; 
Nimmerjahn et al 2005). Thus, in order to maintain brain homeostasis, microglia must be 
constantly and actively surveilling the microenvironment. When there is a more widespread threat 
(injury, infection, or disease), they adopt a stimulus-dependent phenotype that includes 
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cytoskeletal rearrangements to allow for morphological changes, stereotypic transcriptional 
alterations, and proliferation (Salter & Beggs 2014).  
Microglia activation 
Microglia activation can be neurotoxic or neuroprotective, depending on the prior state of 
the brain and injury progression. During a CNS insult, microglia can change from a surveying state 
to an activated state through a series of morphological and functional changes (Town et al 2005). 
Depending on the insult and the current cytokine milieu, microglia will adopt either a pro-
inflammatory M1 state typically viewed as classical activation or a pro-survival M2 state typically 
viewed as alternative activation. While generally viewed as an oversimplification of phenotypes 
in microglia, the M1/M2 nomenclature is still commonly used to classify microglial responses, 
despite the fact these phenotypes most likely occur across a continuum (Aguzzi et al 2013). 
Notably, the “resting” state of microglia is referred to as M0 and is characterized by TGFβ, making 
it distinct from other tissue macrophages (Hickman et al 2013; Butovsky et al 2014). Most chronic 
pathological conditions are characterized by a lack of balance among the various activation states 
of microglia. For example, a predominantly M1 phenotype is characterized by excessive ROS 
production and neuroinflammation, whereas a prolonged M2 phenotype can negatively affect 
immune defense and can contribute to tumorigenesis in gliomas (Cherry et al 2014; Hu et al 2015; 
Komohara et al 2008).  
Much of the research regarding microglia has focused on their effector functions in which 
they are cytotoxic and drive the neuroinflammation that accompanies many forms of acute or 
chronic neuropathology. This includes release of pro-inflammatory cytokines, arachidonic acid 
derivatives, excitatory neurotransmitters, proteinases and ROS. ROS production by microglia in 
particular has been implicated in many neurodegenerative diseases as a major cause of neuronal 
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dysfunction, damage, and cell death through oxidative damage or disruption of neuronal redox 
signaling circuits (Block et al 2007; Gao et al 2012).   
In the early stages of injury, microglia are able to undergo morphological changes in which 
their processes become hyper-ramified and hypertrophic (Hanisch and Kettenmann, 2007; Streit 
et al, 1999). Microglia are able to produce and release neurotrophic factors such as nerve growth 
factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin-3 and -4 (NT-3 and 
NT-4) to support injured neurons (Elkabes et al., 1996; Block and Hong 2005; Hanisch and 
Kettenmann 2007).  If the injured neurons are repaired, then it is possible that microglia can revert 
back to a healthy resting state (Streit et al., 1999).  If injury is significant or persistent, then 
microglia can undergo further activation.  It is upon this “chronic” activation that microglia tend 
to release neurotoxic factors such as ROS that are can damage nearby neurons and other glial cells 
such as oligodendrocytes and astrocytes. Prolonged microglia activation can ultimately result in 
the breakdown of the blood brain barrier resulting in the infiltration of invading monocytes from 
the periphery (Kreutzberg, 1996). 
Oxidant production in microglia. Oxidant generation helps contribute to cell homeostasis via 
the regulation of specific redox-dependent pathways (Holmstrom & Finkel 2014). ROS have 
various potential sources, both exogenous such as radiation, or drugs, and endogenous such as 
mitochondria, peroxisomes, ER, and various enzymes including xanthine oxidase, nitric oxide 
synthetase, cytochrome P450’s, and NADPH oxidase (Brieger  et al 2012). In particular, the family 
of NADPH oxidases are a major source of oxidants used in intracellular and intercellular signaling 
(Sorce & Krasue 2009; Lambeth & Neish 2014; Nayernia et al 2014). As mononuclear phagocytic 
cells, microglia express high levels of superoxide producing NADPH oxidases, and NADPH 
oxidase (NOX) and intracellular ROS together are critical for the regulation of microglia 
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activation. Physiologically, the ROS generated from NOX is important for host defense and redox 
signaling circuits in order to determine the various activation phenotypes of microglia. Of the 
various sources of ROS in a cell, NOX is the only source with the specific and exclusive task of 
producing ROS and is the fundamental source of ROS in the body. Pathologically, over-production 
or dysregulation of ROS-derived NOX are implicated in various neurological diseases where there 
is direct oxidative tissue damage that results in neuron loss or dysfunction.  
The NOX family consists of seven isoforms, NOX1-5 and DUOX1-2. All NOX family 
members are transmembrane electron carriers that use cytosolic NADPH as an electron donor to 
transport electrons through flavin adenine dinucleotide (FAD) and membrane-embedded hemes to 
reduce oxygen to superoxide. NOX4 is the only exception to this as it produces H2O2. Cellular 
expression of NOX isoforms varies across cell types, both in the body and in the CNS. Of these 
isoforms, NOX2 (also known as gp91phox) is highly expressed in microglia both in humans and 
rodents (Sorce et al 2014). NOX1 and NOX4 have been documented in microglia, but there are 
multiple conflicting results within the literature with a lack of specific antibodies being cited for 
the conflicting data (Haslund-Vinding et al 2016).  
In its resting state, NOX2 has 3 cytosolic subunits (p47phox, p67phox, p40phox) the G-
protein Rac. There are also two membrane bound subunits gp91phox (NOX2) and p22phox, 
which are collectively referred to as flavocytochrome b558 (See Figure 1.4). The membrane in 
the case of Cytb558 can refer to either the plasma membrane or vesicle membranes. As 
documented by Ejlerskov, Cytb558 can be stored in small vesicles (<100 nm) through
clathrin-mediated endocytosis. Additionally, NOX2 has also been shown to be 
associated with lipid rafts (cholesterol-enriched membrane microdomains) in a cholesterol-
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dependent manner.  These lipid rafts potentially play a role in creating a platform for NOX2
mobility and signaling (Vilhardt & van Deurs 2004).  
In its activated state, the 3 cytosolic subunits translocate to Cytb558. The rate limiting step 
of activation is the phosphorylation of p47phox. p47 phox has src-homology (SH3) domains that in 
the resting state are hidden due to internal interactions with the polybasic region C-terminal to the 
SH3 domains from residues 286-340 (Leusen et al 1996; Ago et al 1999; Huang & Kleinberg 1999; 
Boussetta et  al 2010). However, the auto inhibited region is revealed when various serine residues 
from 303 to 379 become phosphorylated, typically through PKC, and thus induce a conformational 
change that disrupts the SH3 domain and C-terminus internal binding. This disruptions allows p47
phox to translocate to Cytb558 and bind to the proline rich regions of phosphorylated p22 phox with 
its own SH3 domain (See Figure 1.4; Faust et al 1995; Ago et al 1999; Huang & Kleinberg 1999; 
Sumimoto 2008; Lewis et al 2010; Boussetta et al 2010). p47 phox is further stabilized by its 
interactions with gp91phox (Rastogi et al 2017). Once bound, p47 phox allows for the electron 
transfers to proceed from FAD to the heme groups in Cytb558 in order to reach oxygen (DeLeo et 
al 1995). The transfer of electrons from NADPH to FAD requires p67 phox, which is often referred 
to as the activator subunit (Leusen et al 1996) as well as Rac1/2 (Diebold & Bokoch 2001). 
Receptor-mediated NOX activation in microglia. 
 Microglia, as the “professional” phagocytes in the brain, have an array of surface sensing 
receptors that allow them to rapidly respond to changes in the environment. These pattern 
recognition receptors (PRRs) are expressed constitutively to aid in the recognition and binding of 
pathogen-associated molecular patterns (PAMPs). Below are some examples of PRRs in which 
NOX expression and ROS generation have been implicated in signaling and/or disease.  
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Toll-like receptors (TLR). Microglia express TLRs in their non-activated state and alter 
TLR expression levels when they are activated. (Block et al 2007). At least 12 members of the 
TLR family have been identified in mammals that recognize PAMPs from bacteria, fungi, 
parasites, viruses, and self (the host (Akira et al 2009)). For example, TLR4 is traditionally viewed 
as the LPS receptor as it recognizes the cell wall of this Gram-negative bacteria.  In this way, TLRs 
often contribute to neuropathology due to their association with disease-related molecules such as 
amyloid β (Jana et al 2008), mutant SOD1 (Liu et al 2009), α-synuclein (Codolo et al 2013), 
gangliosides (Jou et al 2006), and oxidized phospholipids (Imai et al 2008). In several of the cases 
listed, NOX and ROS production are upregulated by the binding of the ligands to TLRs (Imai et 
al 2008; Liu et al 2009; Codolo el al 2013), and it has been suggested that TLR’s rely on NOX 
activity to initiate signaling. For example, ROS derived from NOX can aid in the regulation of 
partitioning of lipid rafts to the membrane or help in the assembly of signaling complexes 
(Nakahira et al 2006; Yang et al 2008). Additionally, TLRs can aid in priming the cell to be 
hyperresponsive and prime NOX2 by recruiting cytosolic phox proteins to the membrane by 
initiating phosphorylation of p47 (DeLeo et al 1998; Dang et al 2006). Further TLR signaling is 
also capable of activating IL-1 receptor-associated kinase 4 (IRAK4), which is also capable of 
phosphorylating p47 on several residues (Pacquelet et al 2007). Notably, IRAK4-deficient 
neutrophils are unable to activate NOX2 (Picard et al 2003).  
Complement receptor 3 (CR3; CD 11b/CD18; MAC-1, macrophage antigen complex 
I). CR3 can function as both an adhesion molecule and a PRR that recognizes a diverse set of 
ligands. It is essential for phagocytosis and aids in mediating the activation of phagocytes in 
response to various stimuli (Le Cabec et al 2002). In macrophages and neutrophils, CR3 is 
associated with activation of a respiratory burst (Le Cabec et al 2002) and its expression is partially 
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regulated by NOX 2 (Roy et al 2008). Relatedly, while LPS does bind to TLR4, it also binds to 
CR3, and it is this LPS binding to CR3 that stimulates NOX activity in microglia (Qin et al 2005; 
Pei et al 2007). Additionally, binding of α-synuclein aggregates to CR3 induces NOX-derived 
ROS in microglia (Zhang et al 2005). Given that CR3 is upregulated in neurodegenerative diseases 
(it is often used as a marker for microglia activation), this receptor could represent a mechanism 
of microglial-derived oxidative stress during inflammation-mediated neurodegeneration (Roy et al 
2008).  
Ionotropic & metabotropic purinergic receptors. Both ionotropic P2X and 
metabotropic P2Y purinergic receptors are essential for microglial motility, migration, and 
phagocytosis, as these receptors are involved in the regulation of the microglial actin cytoskeleton 
(Haslund-Vinding et al 2016). In regards to ROS production, multiple groups have noted that ATP 
stimulation of P2X7 receptor induces ROS production in microglia (Choi et al 2011; Mead et al 
2012; Parvathenani et al 2003). However, the direct association between P2X7 and NOX activity 
has not been fully confirmed. P2X receptors are coupled to nonselective cation channels and are 
permeable to K+,  Na+, and Ca2+ (Skaper et al., 2010), and thus calcium entry is required for 
signaling and ROS production to occur following ATP stimulation in microglia (Kim et al 2007). 
Increases in intracellular calcium have also been associated with increases in NOX activity through 
various pathways including ERK1/2 (Apolloni et al 2013), p38MAPK, and PI3K dependent 
pathways (Parvathenani et al 2003).  In addition, activation of microglial purinergic receptors has 
been implicated in various neurodegenerative diseases including ALS, AD, and PD (Parvathenani 
et al 2003). For example, in P2X7 or P2Y receptor deficient microglia, Aβ mediated and α-
synuclein mediated microglia activation is decreased Kim et al 2007). It has been hypothesized 
that this decrease in microglial activation can be attributed to alpha-synuclein not binding to the 
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P2X7 receptor, and thus not signaling through PI3K, and thereby limiting NOX activation (Jiang 
et al 2015).  
Activation of neurotransmitter receptors. Given their role in surveying their 
surrounding environment, microglia express a fair number of neurotransmitter receptors, both in 
their activated and non-activated states (Kettenmann et al 2013). Multiple neurotransmitters can 
induce NOX2 production in microglia. One of the first identified was glutamate through induction 
of the NMDAR (Girouard et al 2009), but since then agonists for glutamate metabotropic (mGlu3), 
GABAA, P2X7, and mGlu5 have all been identified as activating NOX in microglia (Mead et al 
2012). These neurotransmitters had differential effects in that NOX activation with glutamate 
receptor agonists was neurotoxic, and NOX activation by GABA or purinergic receptors was 
neuroprotective. Relatedly, NMDA receptor stimulation was also accompanied by an increase in 
pro-inflammatory cytokines and ROS, that were identified as toxic to neurons (Kaindl et al 2012). 
Scavenger receptors (CD36). Scavenger receptors are a group of PRRs that are 
responsible for recognition of modified lipoproteins and multiple polyanionic ligands in order to 
initiate intracellular signaling for defense against bacterial pathogens (Block et al 2007). 
Activation of scavenger receptors appears to result in the increased production and release of 
reactive oxygen species (Bianca et al 1999; Coraci et al., 2002; Husemann et al., 2002), and CD36 
in particular is essential for NOX-mediated oxidant production in Aβ activated microglia and for 
free radical production and tissue injury in cerebral ischemia (Cho et al 2005; Bianca et al 1999). 
CD36’s interaction with surface receptors CD47 and integrin α6β1 also points to its involvement 
in oxidant production, as all 3 are required for binding, signaling, and oxidant production 
(Bamberger et al 2003). In some instances, CD36 can act as a coreceptor for TLRs as is the case 
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in CNS ischemia where CD36 is required for the development of vascular oxidative stress (Cho et 
al 2005).  
Therapeutic potential of NOX inhibitors.  NOX activity is involved in a large array of 
neurodegenerative and neuroinflammatory diseases including: Alzheimer’s disease (AD), stroke,
traumatic brain injury (TBI), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), 
Huntington’s disease (HD), multiple sclerosis (MS) (Ma et al 2017). In addition, NOX has been 
demonstrated to mediate inflammation-related neurotoxicity in the following models: LPS (Qin 
et al 2004); rotenone (Gao et al 2004); DEP (diesel exhaust particles; Block et al 2004); paraquat 
(Wu et al 2005); MPTP (Gao et al 2003; Wu et al 2003); Aβ (Qin et al 2002); substance P (Block 
et al 2006); thrombin (Choi et al 2005); and α-synuclein (Zhang et al 2005). Given that NOX 
activity is involved in several diseases and neurotoxic exposures, many groups are interested in 
developing NOX inhibitors, specifically those geared towards microglial NOX2 activity. Due to 
the ways in which microglia can cause  neuronal damage due to the ROS they generate, NADPH 
oxidase may represent an attractive therapeutic target for neurodegenerative diseases in which 
microglia are involved. In their 2017 review, Ma and colleagues review the current status of 
preclinical studies examining the neuroprotective effects of NOX inhibition, both genetic and 
pharmacological, in AD, stroke, TBI, PD, ALS, HD, MS. While several of these studies have 
been informative and promising, the authors attribute the lack of translatable results to the clinic 
to three main factors: the timing of application; determining the optimal treatment window; and 
the acute and/or chronic nature of disease models. For example, most studies have initiated NOX 
inhibition either prior to or in the early phases of disease or injury. Not many studies have 
examined NOX inhibition later in the disease process, which is the more realistic scenario within 
a clinical condition. Additionally, assessing the optimal treatment window in neurodegenerative 
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disease is challenging given that these diseases take several years, and sometimes decades,
to develop. Therefore, it is critical to examine NOX inhibition both in acute and chronic models.  
Redox signaling in microglia. Given that microglia are able to produce superoxide and NO, they 
are in close proximity to the reactive reaction products such as H2O2 and peroxynitrite that can 
cause oxidative damage. Therefore, microglia must possess sufficient antioxidative defense 
systems in order to protect themselves and to maintain redox homeostasis. Microglia contain high 
cellular concentrations of GSH (γ-glutamylcysteinyl glycine) and express and upregulate several 
antioxidant enzymes including: MnSOD (super oxide dismutase), Cu/ZnSOD, GPx (glutathione 
peroxidase) GR (glutathione reductase), and catalase (Dringen 2005).   
Redox status. GSH is highly expressed in microglial cells as compared to neurons, 
astrocytes, and oligodendrocytes (Dringen 2005). GSH content has been demonstrated to decrease 
with age (Njie et al 2012), but certain compounds such as docosahexaenoic acid can increase total 
GSH content in microglia and limit proinflammatory cytokine production (Pettit et al 2013). GSH 
functions to scavenge superoxide in two ways: either directly through coupling to GSSG or 
through various enzyme catalyzed reactions. These enzymes include GSH peroxidase (GPx) which 
oxidizes GSH, and glutaredoxin (GRx) which reduces oxidized cysteine residues (Vilhardt et al 
2017). Microglia have been shown to have the highest GPx activity in the brain in both rats and 
humans (Lindenau et al 1998; Power & Blumbergs 2009). GPx expression increases directly in 
response to oxidative stress (Wang et al 2015).   
GSH and NOX2 derived ROS appear to have an inverse relationship, as GSH is consumed 
in the process of scavenging for superoxide. Won et al 2015 found that not only could increasing 
GSH levels by supplementing with N-acetyl cysteine protect again oxidative stress, but also that 
GSH depletion was prevented by blocking superoxide production during reperfusion. 
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Additionally, blocking superoxide production with the NOX inhibitor apocynin increased GSH 
content. Also, p47 KO mice did not show any change in either ROS production or GSH content in 
a model of ischemia-reperfusion, again supporting that inhibition of a functional NOX2 complex 
prevents GSH depletion. The exact nature of GSH and NOX in microglia is not currently fully 
understood: whether the two physically interact or if NOX regulates GSH synthesis through 
another means by acting on cysteine levels or import of cystine into the cell.   
In order to synthesize GSH, cysteine must be available as it the precursor. The reducing 
conditions of the cytosol favor cysteine, but the extracellular environment is more oxidized and 
thus favors cystine. Therefore, importing cystine into the cell is critical for GSH synthesis. Both 
microglia and astrocytes use xc- cystine-glutamate exchanger (xCT; SLC7A11) for this purpose 
(Bannai 1984; McBean 2002). The import of cystine is coupled with the outward flow of 
glutamate. This pairing with glutamate moving down its concentration gradient provides the 
driving force for cystine import (Bannai 1984; McBean 2002). However, microglial release of 
glutamate and upregulation of xCT has been linked to various neurological diseases including 
HIV, EAE, and AD (Gupta et al 2010; Savchenko et al 2013; Evonuk et al 2015). Still, 
upregulation of xCT is regulated by Nrf2 which also upregulates enzymes to catalyze the formation 
of GSH to help minimize microglial glutamate induced toxicity (Shih et al 2003).  
Thioredoxins (Trx) function to reduce protein disulphides to free thiols, and GSH 
peroxidases function to oxidize GSH. Trx protects proteins by reducing oxidized cysteine residues 
and using electrons from NADPH, peroxides and hydrogen peroxide. One of the genes Nrf2 
upregulates in response to oxidative stress is Trx (Vilhardt et al 2017). Currently little is known 
about the actions of Trx in microglia, except that Trx activation is often associated with conditions 
33 
that cause microglia activation such as LPS, Aβ peptide, and IL-1β (Wang et al 2007; Zhang et al 
2010; Sharma et al 2007).  
NOX2-mediated redox signaling. 
NF-κB. The transcription factor nuclear factor kappaB is known to be a redox-sensitive 
factor.  NF-κB is often viewed as a pivotal switch in microglia adapting the M1 proinflammatory 
phenotype. Under basal conditions, NF-κB is inactive in the cytosol due to its binding with IkB. 
However, due to an increase oxidants, IkB will release the catalytic NF-κB subunits to allow it to 
translocate into the nucleus to induce the expression of various proinflammatory genes in microglia 
(Rojo et al 2014). Oxidants in this case can either act directly on IkB or through activation of redox 
sensitive upstream kinases. This increase in transcriptional activity of the NF-κB p65/p50 dimer 
is often associated with MAP kinases downstream of NOX activation and oxidant production in 
microglia (Pawate et al 2004). While NF-κB is not essential for acquisition of the M1 phenotype 
(Taetzxch et al 2015), constitutively active NF-κB in microglia will drive these cells to a 
proinflammatory state that results in motor neuron death in ALS in vitro models (Frakes et al 
2014). Additionally, microglia exposed to H2O2 showed altered NF-κB p50 protein-protein 
interactions and augmented late-stage TNFα expression, indicating that H2O2 impairs NF-κB p50 
function and prolongs amplified M1 activation. In this model DNA binding decreased when NF-
κB p50 was oxidized, and this DNA binding could be restored through addition of the reducing 
enzyme thioredoxin (Kabe et al 2005).  
Nrf2. Nrf2 (is nuclear factor erythroid 2 related factor 2) is considered the master regulator 
of antioxidant responses, as upon its translocation to the nucleus, it binds to genes in the antioxidant 
response element (ARE) to upregulate cytoprotective genes such as HO-1 and other antioxidant 
proteins. Under basal conditions, Nrf2 is bound to Kelch-like ECH-associated protein (KEAP1). 
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Nrf2 is continuously ubiquinated and degraded by the proteasome. However, when the cysteine 
residues in KEAP1 are oxidized, it releases Nrf2 where it is subsequently translocated to the 
nucleus (Niture et al 2014; Ma et al 2013). Thus, inherent with M1 induction and increased NOX2 
activity, there is a level of Nrf2 activation and induction of an antioxidant response that occurs. 
Previous studies have shown that NOX2 activity is an upstream and essential regulator in 
Nrf2/Keap1 signaling (Sekhar et al 2003). Additionally, Nrf2 deficient macrophages have an 
increased NOX2 superoxide production, TLR4 signaling, and IkB inactivation, resulting in a 
prolonged inflammatory response (Kong et al 2010). Relatedly, induction of HO-1 through a Nrf2 
dependent mechanism by activing a7-nAchR in oxygen and glucose deprived microglia cultures, 
also inhibited NOX activity.  
Oxidant production and control of that oxidant production (redox signaling) are of critical 
importance in all cell types, but especially within microglia, cells who produce oxidants as one of 
their main functions. ROS can have a wide range of effects and their rapid production and transient 
nature are exploited by cells for efficient and reversible signaling.  The chemical reactivity of ROS 
allows both cytotoxic effects against pathogens and selective chemical modifications to 
biomolecules in order to regulate various enzymatic functions. The ubiquitous theme of NOX 
activation by environmental stresses likely led to coevolved responses in which redox-dependent 
cellular signaling pathways are hardwired into hermetic and cytoprotective systems. It is when 
these responses are no longer balanced that the relationship with ROS becomes problematic and 
deleterious. Microglia, as guardians of the CNS and major oxidant producers, are charged with 
balancing this delicate relationship both intracellularly and extracellularly across the brain.   
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SUMMARY 
As previously stated, TSPO is a biomarker of brain injury and inflammation that is used in 
preclinical and clinical studies to detect a wide range of brain pathologies. However, there is a lack 
of knowledge on the function of TSPO in microglia and astrocytes, the two cell that express and 
upregulate TSPO as a result of injury. Recent studies using TSPO knockout mice have questioned 
the long-held view that TSPO transports cholesterol into the mitochondria for steroid synthesis. In 
the brain, microglia and astrocytes exhibit distinct spatial and temporal patterns of TSPO 
upregulation, indicating a potentially different function of TSPO in microglia and astrocytes.  
Additionally, TSPO expression prior to clinical expression of diseases has not been fully 
investigated. Many studies are cross-sectional in nature and thus assess TSPO levels when the 
disease is already in the active clinical stage. There is a need to assess TSPO expression not only 
in the progression of clinically active disease, but also in the early non-symptomatic stages of 
disease.  
The main goal of the proposed studies is to address some of the key questions regarding 
TSPO biology and function in microglia and TSPO’s trajectory of upregulation in relation to 
various neuropathological and behavioral endpoints. 
Specific Aim #1: To examine TSPO levels in a neurodegenerative transgenic mouse model of 
Sandhoff disease and longitudinally compare TSPO levels to behavioral manifestations of disease 
and other neuropathological endpoints (neurodegeneration, reactive gliosis, ganglioside 
accumulation). This study will aim to see how early in time TSPO can be used as a biomarker and 
will track the cellular source of the TSPO signal and how it varies across brain regions. We will 
measure TSPO levels ex vivo using quantitative receptor autoradiography and 
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immunohistochemistry, as well as in vivo using SPECT with the novel TPSO ligand [125I]-
IodoDPA-713.   
Specific Aim #2: To examine the source of TSPO-ligand (TSPO-L) induced reactive oxygen 
species (ROS) production in primary microglia. This study will examine other potential sources of 
TSPO-L induced ROS and aim to follow up on the finding that TSPO-L induced ROS production 
can be abrogated with NADPH oxidase inhibitors. Additionally, we will assess the effect of TSPO-
L on the redox sensitive transcription factor nuclear factor erythroid 2 related factor (Nrf2).   
Specific Aim #3: To determine if TSPO is interacting with NADPH oxidase (NOX2) in primary 
microglia. These studies will build off of the finding that TSPO is associated with NOX2 in 
microglia and aim to determine if there is a direct protein-protein interaction and/or functional 
interaction. These studies will employ multiple methods to assess if these proteins are interacting 
including: immunoprecipitation, proximity ligation assay, and immunofluorescence and 




Figure 1.1. Structure of TSPO including indication of cholesterol, PK11195, and Ro5-4864 binding 
sites. The binding sites for cholesterol, PK, and Ro have been determined to be separate and distinct from 
one another. Previously the CRAC motif (residues 147-159) was thought to line the inside of a 
hydrophobic pore that would allow cholesterol to bind and translocate. However, higher resolution 
NMR models demonstrated that the CRAC domain is actually on the outer edge of TSPO, facing the 
membrane environment (Jaremko et al 2014). PK actually has a binding pocket that involves 
several key residues Ala23, Val26, Leu49, Ala50, Ile52, Trp107, Ala110, Leu114, Ala147, and 
Leu150, none of which involve CRAC motif amino acid side chains (Jaremko et al 2014). The 
binding site for Ro is more lateral than that for PK and involves the residues Glu29, Arg32, Lys39, 
and Val154 (Farges et al 1994).  (Image 1A taken from Notter et al 2018 and 1B taken from Selvaraj et 
al 2017).  
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Figure 1.2. TSPO monomer & dimer. Proposed model of TSPO homodimer dissociation (Image taken 
from Jaipuria et al 2017).  
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Figure 1.3. Table summarizing the attributed functions to TSPO across phylogeny. (Image taken 




Figure 1.4. NOX2 Activation & p47 phox Phosphorylation
A. NADPH oxidase (NOX2) is activated through the translocation of 3 cytosolic subunits to the
its 2 membrane bound subunits (Image taken from Hashlund-Vinding et al 2016).
B. p47 phox is phosphorylated at multiple sites in order to reveal  its SH3 domains that allow it to bind
to the proline rich region of p22phox (Image taken from Boussetta et al 2010).
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Figure 1.5 Intracellular ROS levels regulate microglial activation 
The degree of ROS in microglia controls which transcription factors are activated and if ROS are being 
used for redox signaling purposes, or if as ROS levels increases, they initiate transcription factors to 
induce activation of the microglia. If ROS levels become too high, microglia induce cell death either 
through apoptosis or necrosis (Image taken from Block et al 2007).  
42
Figure 1.6. Expression of selected oxidant and anti-oxidant related genes from an adult mouse 
in the cerebral cortex. (Image taken from Zhang et al 2014 and Vilhardt et al 2017).  
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Chapter 2: TSPO in a murine model of Sandhoff disease: presymptomatic marker of 
neurodegeneration and disease pathophysiology 
Reprinted with permission: Loth, M. K., Choi, J., McGlothan, J. L., Pletnikov, M. V., Pomper, 
M. G., & Guilarte, T. R. (2016). TSPO in a murine model of Sandhoff disease: presymptomatic




Translocator protein (18 kDa), formerly known as the peripheral benzodiazepine receptor (PBR), 
has been extensively used as a biomarker of active brain disease and neuroinflammation. TSPO 
expression increases dramatically in glial cells, particularly in microglia and astrocytes, as a result 
of brain injury, and this phenomenon is a component of the hallmark response of the brain to 
injury. In this study, we used a mouse model of Sandhoff disease (SD) to assess the longitudinal 
expression of TSPO as a function of disease progression and its relationship to behavioral and 
neuropathological endpoints. Focusing on the presymptomatic period of the disease, we used ex 
vivo [3H]DPA-713 quantitative autoradiography and in vivo [125I]IodoDPA-713 small animal 
SPECT imaging to show that brain TSPO levels markedly increase prior to physical and behavioral 
manifestation of disease. We further show that TSPO upregulation coincides with early neuronal 
GM2 ganglioside aggregation and is associated with ongoing neurodegeneration and activation of 
both microglia and astrocytes. In brain regions with increased TSPO levels, there is a differential 
pattern of glial cell activation with astrocytes being activated earlier than microglia during the 
progression of disease. Immunofluorescent confocal imaging confirmed that TSPO colocalizes 
with both microglia and astrocyte markers, but the glial source of the TSPO response differs by 
brain region and age in SD mice. Notably, TSPO colocalization with the astrocyte marker GFAP 
was greater than with the microglia marker, Mac-1. Taken together, our findings have significant 
implications for understanding TSPO glial cell biology and for detecting neurodegeneration prior 
to clinical expression of disease. 
Key Words: Translocator protein 18 kDa; TSPO; Sandhoff disease; biomarker; microglia; 
astrocytes; neurodegeneration 
Short Title: TSPO in Sandhoff mice 
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1. INTRODUCTION
Sandhoff disease (SD) is an autosomal recessive disorder characterized by a deficiency in 
the lysosomal enzyme β-hexosaminidase, which leads to the accumulation of gangliosides and 
glycolipids, specifically GM2 and GA2 (Jeyakumar et al., 2002; Mahuran et al., 1999). Because 
gangliosides are expressed at high levels in the central nervous system (CNS), the brain is one of 
the most affected organs (Jeyakumar et al., 2002). Ganglioside accumulation in the brain 
ultimately leads to progressive and widespread neurodegeneration and motor impairments (Wada 
et al., 2000). In humans, the onset of the infantile form of SD occurs around 6 months of age with 
symptoms such as motor weakness, early blindness, macroencephaly, and seizures. Symptoms 
progress rapidly, and death occurs between 3 to 5 years of age (Maegawa et al., 2006). 
β-hexosaminidase is formed by the dimerization of two subunits, α- and β-subunits to form 
β-hexosaminidase A (αβ) or two β subunits to form β-hexosaminidase B (ββ). In the mouse model 
of SD, the gene encoding for the β subunit of β-hexosaminidase (Hexb) is disrupted, resulting in 
the deficiency of both β-hexosaminidase A and B (Yamanaka et al., 1994). This deficiency leads 
to impaired degradation and subsequent accumulation of GM2 and GA2 gangliosides in neurons 
(Sango et al., 1995; Jeyakumar et al., 2002; Mahuran et al., 1999), resulting in severe 
neurodegeneration in the brain (Wada et al., 2000). Sandhoff (Hexb KO) mice exhibit spastic and 
reduced hind limb movements with progressive motor deficits starting at 3 months of age (Sango 
et al. 1995). The life span of SD mice is approximately 5 months of age as the mice lose the ability 
to move and are unable to retrieve food or water (Sango et al., 1995; Tifft and Proia, 1997; 
Jeyakumar et al., 2002). Histopathological studies have shown that excess storage of glycolipids 
in lysosomes leads to neuronal apoptosis in the cerebellum, brainstem, spinal cord, trigeminal 
ganglion, retina, and thalamus in SD mice (Sango et al., 1995; Wada et al., 2000). Tissues from 
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humans diagnosed with SD have also shown neurodegeneration in spinal cord, cerebral cortex, 
and thalamus (Huang et al., 1997; Wada et al., 2000). Thus, the mouse model of SD shares many 
of the clinical symptoms and neuropathology as the human form of the disease. 
Previous work has shown that microglia become activated in both the mouse model and in 
human cases of SD (Wada et al., 2000; Visigalli et al., 2009) and that microglial activation appears 
to precede neuronal degeneration. Furthermore, cDNA microarray analysis has shown increased 
TSPO gene expression in the SD mice (Wada et al, 2000), and using PET imaging, uptake of [11C]-
PK11195, a TSPO-specific ligand, was higher in SD mice at 4 months of age compared to wildtype 
(Visigalli et al., 2009). However, a longitudinal assessment of TSPO expression as a function of 
disease progression using behavioral and neuropathological endpoints has not been investigated. 
Furthermore, it has been previously reported that [11C]-PK11195 PET imaging shows significant 
non-specific binding and poor brain uptake (Boutin et al., 2007; Endres et al., 2009), and thus, 
better ligands are needed for in vivo TSPO PET/SPECT studies. 
DPA-713, also known as N,N-diethyl-2-[2-(4[methoxy-phenyl)-5,7-dimethylpyrazolo[1,5-
a]pyrimidin-3-yl]-acetamide, is a pyrazolo-pyrimidine that is 10-fold less lipophilic than PK11195
but with twice the affinity for TSPO (Wang et al., 2009). [11C]DPA-713 PET imaging has been 
performed in a rodent model of brain injury and in a human study with higher signal-to-noise ratios 
than [11C]-PK11195 (Doorduin et al., 2009; Endres et al., 2009). [125I]IodoDPA-713 is a novel 
TSPO-specific radioligand that has been previously used to detect TSPO in vivo in a mouse model 
of lung inflammation (Wang et al., 2009), but it is unknown whether [125I]IodoDPA-713 can be 
used to detect in vivo TSPO binding in the brain. In this study, we used [3H]DPA713 and 
[125I]IodoDPA-713 to assess the progression of TSPO expression in SD mouse model in a 
longitudinal fashion. The goal of this study was to examine how early in disease progression TSPO 
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levels increased in relation to: 1) neuronal GM2 ganglioside accumulation, 2) activation of 
microglia and astrocytes, 3) neurodegenerative changes based on silver staining, and 4) behavioral 
expression of disease focusing on the presymptomatic phase of the disease. 
2. MATERIALS AND METHODS
2.1. Animal care and use statement 
All animal studies were reviewed and approved by both Columbia University Medical 
Center and the Johns Hopkins University Animal Care and Use Committee. Studies were 
conducted in accordance with the Guide for Care and Use of Laboratory Animals as stated by the 
United States National Institutes of Health. 
2.2. Animal model and tissue preparation 
Mice heterozygous for Hexb were generously donated by Dr. Richard Proia (National 
Institute of Kidney & Digestive Diseases, Bethesda, MD). Wildtype (Hexb +/+) or SD (Hexb -/-) 
mice were euthanized at 1, 1.5, 2, or 3 months of age by either decapitation to obtain freshfrozen 
brain tissue for receptor autoradiography or by transcardiac perfusion for immunohistochemistry. 
Fresh frozen brains were stored at -80°C. For transcardiac perfusion, animals were deeply 
anesthetized with pentobarbital (100 mg/kg body weight) and perfused with 4% paraformaldehyde 
(PFA) in 0.1M phosphate buffer (pH 7.4 at 4°C). Perfused brains were post-fixed overnight in the 
same fixative, cryoprotected with 25% sucrose for 48 h, flash-frozen in dry-ice-cooled isopentane, 
and stored at -80°C. 
2.3. Behavioral assessment 
2.3.1. Motor skill 
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Motor skill was measured using the rotarod apparatus (Columbus Instrument, Columbus, 
OH). The latency time the mouse remained on the rod at accelerating speeds was recorded. Each 
mouse was trained for 5 min at a speed of 4 RPM. Training was followed by a 30-min rest period 
in the home cage. Mice were then placed back on the rotarod for three trials. Each trial began at 4 
RPM and accelerated every 30s by 4 RPM to a maximum of 40 RPM. Trials were separated by a 
10-min rest period. Mice were tested for 3 consecutive days.
2.3.2. Locomotor activity 
Mice were placed in open field activity chambers with infrared beams (San Diego 
Instruments Inc., San Diego, CA) for 1 h. During this time, horizontal activity and rearing were 
automatically recorded. 
2.4. Quantitative receptor autoradiography 
Fresh frozen brains were sectioned at 20 μm on a freezing cryostat (Leica, Nussloch, 
Germany) in the horizontal plane. Brain sections were thaw-mounted onto poly-L-lysine-coated 
slides (Sigma-Aldrich, St. Louis, MO) and stored at -20°C. [3H]DPA-713 autoradiography was 
used to assess TSPO levels in multiple brain regions. Adjacent brain sections were used as follows: 
slides were thawed and warmed on a slide warmer at 37°C for 30 min and prewashed for 5 min in 
50 mM Tris-HCl buffer (pH 7.4) at room temperature. Slides were incubated in a buffer containing 
1.0 nM [3H]DPA-713 for 30 min at room temperature. For non-specific binding, adjacent sections 
were incubated in the presence of 10 μM racemic PK11195. Slides were washed twice for 3 min 
each in 4°C buffer and dipped twice in 4°C deionized water. Sections were apposed to Kodak Bio-
Max MR films with tritium microscales for 4 weeks (GE Healthcare, Piscataway, NJ). Images 




Brain sections from PFA-perfused animals were sectioned at 40 μm using a freezing 
microtome (Leica SM2000R; Leica Microsystems, Wetzlar, Germany). Sections were stored in 
cryoprotectant consisting of 50% glycerol in 0.05M phosphate buffer at -20°C. Sections were 
washed with Tris-buffered saline for 30 min. For GFAP and Mac-1 (CD11b) 
immunohistochemistry, sections were pre-treated with 0.6% H2O2 in TBS for 10 min and blocked 
with a 5% normal goat serum and 0.2% Triton X-100 solution for 1 h. Sections were incubated 
with rabbit anti-GFAP antibody (1:1000, Dako Z-0334, Carpinteria, CA) or rat anti-CD11b 
antibody (1:250, BD PharMingen 553308, San Diego, CA) at 4°C overnight. After washing with 
TBS, sections were incubated with the appropriate biotinylated secondary antibodies (1:200, 
Vector, Burlingame, CA) for 1 h. This was followed by an incubation in ABC elite, an avidin-
biotin-horseradish peroxidase (HRP) complex (Vector) for 30 min. Immunoreactivity was 
visualized with a 0.25 mg/mL 3,3’-diaminobenzidine (DAB) (Sigma) and 0.03% H2O2 solution. 
Sections were mounted on slides, dehydrated in increasing concentrations of ethanol, and 
coverslipped using Permount media (Sigma). For double and triple labeling immunofluorescence, 
sections were washed with TBS for 60 min and then blocked in 5% normal donkey serum with 
0.2% Triton X-100 solution for 1 h. Sections were incubated in primary antibodies diluted in 
blocking solution overnight at 4°C using the following dilutions: rat anti-Mac-1 (1:250, BD 
Pharmingen 553308), rabbit anti-TSPO (1:500, Abcam ab109497), mouse anti-GFAP (1:2000, 
Millipore MAB3402), rabbit anti-GM2 (1:500, Millipore 345759), or mouse anti-NeuN (1:1000, 
Chemicon MAB377). After washing in TBS, sections were incubated with appropriate secondary 
antibodies (1:500, AlexaFluor488, AlexaFluor594, AlexaFluor647; Molecular Probes, Carlsbad, 
CA) diluted in a 2% normal donkey serum with 0.1% Triton X-100 at room temperature for 1 h. 
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Following another series of washes in TBS, sections were mounted onto slides in ProLong Gold 
DAPI mounting media (Molecular Probes). 
2.6. Silver staining for neuronal degeneration 
Free-floating sections from PFA-perfused animals were further fixed in 4% PFA in 0.1M 
phosphate buffer for 48 h before staining. Silver staining was performed using the FD Neurotech 
NeuroSilver Kit (Ellicott City, MD) according to manufacturer’s instructions. 
2.7. [125I]IodoDPA-713 small animal SPECT/CT for dynamic in vivo imaging of 
TSPO 
An X-SPECT small-animal SPECT/CT system (Gamma Medica-Ideas, Northridge, CA) 
was used for image acquisition. Each mouse was anesthetized with isofluorane prior to imaging. 
About 1-2 mCi of [125I]IodoDPA-713 was injected into each mouse via intravenous injection, and 
images were acquired immediately after injection. The SPECT projection data were acquired using 
2 low-energy, high-resolution parallel-hole collimators with a radius of rotation of 4.65 cm (spatial 
resolution, 1.6 mm). The tomographic data were acquired in 64 projections over 360° at 20 s per 
projection. After tomography, CT was acquired in 512 projections to allow anatomic 
coregistration. Data were reconstructed using the ordered subsets-expectation maximization 
algorithm and analyzed using AMIDE software (free software provided by SourceForge). A time 
activity curve of the [125I]IodoDPA713 uptake was generated for each mouse. Three mice per 
genotype were scanned for this study. For the blocking study, nonradioactive IodoDPA-713 (20 
μM) was intravenously co-injected with [125I]IodoDPA-713, and images were acquired 
immediately after [125I] injection. Ligands were synthesized according to the methods described in 
Wang et al., 2009. 
2.8. Imaging and image analysis 
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Immunohistochemistry sections stained using DAB were examined using an Olympus 
BX51 microscope (Proscan II, Prior, Rockland, MA) linked to an Olympus DP70 camera. 
Highresolution imaging and contrast microscopy using oil immersion and 40x (numerical 
apertures 1.00) and 100x (numerical aperture 1.35) were used. Immunofluorescently-labeled tissue 
was imaged at 60x or 96x magnification using a laser scanning confocal microscope (Fluoview 
FV10i, Olympus, Center Valley, PA), utilizing the FV10 image software. All tissues stained under 
the same conditions were imaged using the same scanning parameters on the same day. Five to six 
confocal stacks of each brain region were obtained for each age and genotype for each 
experimental condition. Confocal stacks were projected into single images using the maximum 
fluorescence. All images were analyzed using Metamorph Offline (Molecular Devices, 
Downingtown, PA). The threshold level was kept at the same level for analysis in images obtained 
from the same experiment. For colocalization analyses, gray scale images at each wavelength were 
used to examine the area of colocalized pixels of both wavelengths to calculate the percent 
colocalization of their signals. Percent colocalization was calculated as previously described by 
Stansfield, et al., 2012. For GM2 and NeuN association analyses, GM2 aggregates and NeuN 
positive cells were counted using FV10i software. 
2.9. Statistical analysis 
Repeated measure analysis of variance (ANOVA) was used for comparison of weekly body 
and brain weights across time between wildtype and Sandhoff mice. Student’s t-test was used for 
comparison between wildtype and Sandhoff mice for SPECT imaging, rotarod test, horizontal 
activity, and rearing activity within each age group due to the fact that animals were euthanized at 
each age and that the rotarod and activity cages were different across institutions. Therefore, for 
each age, we normalized the SD results to age-matched wildtype mice. The Bonferroni method 
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was used to correct for multiple comparisons (p = 0.0125). A 1-way analysis of variance (ANOVA) 
was used for comparison between wildtype and SD mice across the 4 ages for the quantitative 
receptor autoradiography, and a 2-way analysis of variance was used for colocalization analyses. 
ANOVA with p values < 0.05 was considered significant, and these data were further subjected to 
post hoc LSD analysis. 
3. RESULTS
3.1 Brain and body weights of wildtype (WT) and Sandhoff disease (SD) mice 
The body weights of mice were taken weekly starting at 6 weeks and ending at 13 weeks 
(3 months, the oldest age used in this study) when brains were extracted. Following extraction, the 
brain weights of WT and SD mice (i.e., Hexb knockout) were measured at 3 months of age. Brain 
weights were not significantly different between WT (425.0 ± 15.1 mg) and SD mice (448.4 ± 
20.3 mg) (n = 13 per group. Data are presented as mean ± s.e.m.). Figure 1A shows that the body 
weight gain differences between WT and SD mice were not significantly different [F(1,25)=0.12, 
p=0.7295; n = 13 per group] up to 3 months of age. 
3.2 Progression of motor function deficits 
Previous studies have documented the progressive decline in motor function in SD mice 
beginning at 3 months of age (Sango et al., 1995). Here, we sought to characterize the motor 
coordination and grip strength of SD mice as a function of age focusing on the presymptomatic 
phase of the disease. This was done in order to compare the TSPO response in relation to the 
behavioral manifestation of disease. Figure 1B shows that at 1, 1.5, or 2 months, WT and SD mice 
showed no significant differences in motor skills as assessed by rotarod performance (Fig. 1B; 
t(16)=0.349, p=0.731; t(14)=1.223, p=0.240; t(17)=0.761, p=0.457 for 1, 1.5, and 2 months, 
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respectively; n=10-13 mice). However, at 3 months, SD mice expressed a dramatic decrease in 
latency time, demonstrating decreased motor coordination and reduced grip strength (Fig. 1B; 
t(27)=5.131, p<0.001). 
We also assessed locomotor activity using activity chambers, specifically examining 
horizontal activity and rearing (ability to stand on hind legs). At 3 months of age, SD mice had a 
lower level of rearing activity compared to age-matched WT mice, indicating motor impairments 
(Fig. 1D; t(26)=3.405, p=0.0022; n=9-14 mice). Statistically significant differences in horizontal 
activity were not seen between WT and SD mice within each age group (Fig. 1C). However, at all 
ages, horizontal activity and rearing appeared to be lower in SD mice compared to agematched 
WT mice (Figs 1C and D). The latter findings suggests that the generation of Hexb(-/-) animals 
affects horizontal activity and rearing at an age when GM2 ganglioside aggregation or 
neurodegeneration are absent, i.e., 1 month of age (see section 2.3.1 and 2.3.3). Therefore, we 
inferred that the difference in horizontal and rearing behavior in SD mice is not associated with 
disease-induced neurodegeneration but is instead associated with a genotype effect of SD mice. 
3.3 Longitudinal assessment of TSPO in relation to neuropathology 
We assessed the age-dependent progression of neuropathology in SD mice by examining 
several pathological endpoints including 1) neuronal ganglioside aggregation (GM2 
immunohistochemistry), 2) brain injury and inflammation using TSPO levels (quantitative 
receptor autoradiography and in vivo imaging), 3) ongoing neurodegeneration using silver staining, 
and 4) reactive gliosis with microglia and astrocyte markers using immunohistochemistry. These 
studies were performed in the thalamus, brainstem, and cerebellum because they are the brain 
regions most severely affected in SD mice (Huang et al., 1997; Sango et al., 1995; Wada et al., 
2000). We should note that we also assessed TSPO levels in other brain regions such as the 
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hippocampus and cerebral cortex (including orbital, motor, and somatosensory cortex) and found 
no effect, showing the regional specificity of the TSPO response, and not a global inflammatory 
response (Supplementary Figs. 1A and B). However, see section 2.3.3. 
3.3.1 Longitudinal assessment of neuronal aggregation of GM2 gangliosides 
To determine the age at which neuronal ganglioside aggregation begins in this mouse 
model, we stained for GM2 gangliosides at each of the four different ages (1, 1.5, 2, and 3 months) 
in both WT and SD mice. We stained for GM2 instead of GA2 as GM2 precedes GA2 in the 
ganglioside catabolic process in mice (Phaneuf et al., 1996; Jeyakumar et al., 2002). We costained 
for GM2-positive gangliosides and NeuN-positive neurons and counted the number of neurons 
that contained GM2 aggregates in different brain regions. In the thalamus, we observed neuronal 
GM2 ganglioside aggregation beginning at 1.5 months, peaking at 2 months, and subsiding at 3 
months of age, possibly due to neuronal loss (Fig. 2A; F(4,14)=18.825; p < 0.001). Significant 
accumulation of neuronal GM2 ganglioside aggregation was not observed in the brainstem or 
cerebellum until 2 months of age (Fig. 3A; F(4,14)=8.711; p = 0.003 for brainstem and Fig. 4A; 
F(4,14)=22.150; p < 0.001 for cerebellum). The level of GM2 ganglioside aggregation at 3 months 
of age remained similar to levels observed at 2 months in these two brain regions. This suggests 
that there is a regional and temporal specific accumulation of gangliosides and that one of the first 
brain regions affected by this disease is the thalamus. 
3.3.2 Age-dependent analysis of brain TSPO levels using [3H]DPA-713 quantitative 
autoradiography 
We examined TSPO levels in different brain regions in SD mice as a function of age to 
determine the association between the initiation of GM2 ganglioside aggregation (the primary 
initiating event that leads to neuronal degeneration) and the TSPO response to this neuronal injury. 
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We performed [3H]DPA-713 TSPO autoradiography and analyzed 5 brain regions: the cerebral 
cortex (including the orbital, motor, and somatosensory cortex), hippocampus, thalamus (ventral 
posteromedial thalamic nucleus), brainstem (parvicellular reticular nucleus), and cerebellum (deep 
cerebellar nuclei) in age-matched WT and SD mice. In WT mice, we found no significant 
differences in [3H]DPA-713 binding to TSPO as a function of age for any of the brain regions 
examined; thus, we combined the [3H]DPA-713 binding data for WT mice from each age and brain 
region (thalamus: F(3,34)=0.066; p=0.978; brainstem: F(3,29)=0.110; p=0.954; cerebellum: 
F(3,32)=0.027; p = 0.994; hippocampus: F(3,34)=0.153; p=0.927; cortex: F(3,33)=0.128; p=0.943; n=9-
14/age group). In the thalamus of SD mice, TSPO levels measured using [3H]DPA-713 
autoradiography were markedly elevated relative to WT beginning at 1.5 months of age (Fig. 2B). 
TSPO levels progressively increased as a function of age in SD mice, reaching nearly 5-fold higher 
levels relative to WT at 3 months of age (Fig. 2B; F(4, 62)=139.144; p < 0.001). It should be noted 
that the earliest significant increase in TSPO levels in the thalamus occurred at 1.5 months of age, 
a time when there was minimal, non-significant GM2 ganglioside aggregation in neurons (Fig. 2A 
and B). Therefore, the TSPO response in the thalamus was measured at the earliest age when GM2 
ganglioside aggregation was observed.  
In the brainstem, we observed a significant increase in TSPO binding beginning at 2 
months of age with further increases at 3 months of age (Fig. 3B; F(4,53)=13.002; p < 0.001). The 
significant increase in TSPO levels in the brainstem coincided with a significant increase in 
neuronal GM2 accumulation in this brain region. In the cerebellum, TSPO binding was 
significantly elevated only at 3 months in SD mice as compared to WT and all other ages (Fig. 4B; 
F(4,59)=6.692; p < 0.001). This was in contrast to the significant ganglioside accumulation seen in 
the cerebellum at 2 months. It is possible that the TSPO glial response in the deep cerebellar nuclei 
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may require a greater amount of time than in other brain regions. Additionally, we found no 
statistically significant differences in TSPO binding in the hippocampus or the orbital, motor, and 
somatosensory cortex at any age (Supplementary Figs. 1A and B; F(4,62)=0.559; p=0.693 for 
hippocampus and F(4,60)=1.191; p=0.324 for cortex). 
3.3.3 Longitudinal assessment of neurodegeneration 
To assess the relationship between TSPO expression and neurodegeneration in the SD 
mouse brain, we used silver staining as a means to evaluate ongoing neurodegeneration. At 1 
month of age, SD mice showed no significant silver accumulation in the thalamus (Fig. 2C), 
cerebellum (Fig. 4C) or brainstem (Fig. 3C) compared to WT. At 1.5 months, there was significant 
silver accumulation in the thalamus of SD mice compared to WT. At 2 and 3 months, SD mice 
showed robust silver accumulation in the thalamus (Fig. 2C) and in both the brainstem (Fig. 3C) 
and cerebellum (Fig. 4C). The cerebral cortex (including the orbital, motor, and somatosensory 
cortex) exhibited minimal silver accumulation by 3 months (Supplementary Fig 2A). Collectively, 
these results indicate that TSPO expression increases in brain areas undergoing neurodegeneration. 
It is notable that we detected significant and selective neurodegeneration in the CA2 region of the 
hippocampus beginning at 1.5 months and increasing with disease progression (Fig. 5A). This is 
in contrast to the fact that we did not detect increased TSPO levels or glial cell activation via 
quantitative autoradiography or immunohistochemistry in the CA2 region of the hippocampus at 
any age. These findings suggest that the CA2 region of the hippocampus is not able to mount a 
glial/TSPO response to ongoing neurodegeneration. Further studies are needed in order to 
understand this unusual and unexpected finding. 
3.3.4 Longitudinal assessment of reactive gliosis 
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Another aspect of this study was to determine the cellular sources of the TSPO response in 
SD mouse brain. It is known that increased TSPO expression in the injured brain is associated with 
both microglia and astrocyte activation (Chen and Guilarte, 2008; Chen et al. 2004; Consenza-
Nashat et al., 2009; Raghavendra et al., 2000; Veenman and Gavish 2000; Venneti et al., 2004). 
Thus, we performed immunohistochemistry using Mac-1 as a microglia marker and GFAP as an 
astrocyte marker. Wildtype mice exhibit morphologically normal microglia and astrocytes at all 
ages examined. On the other hand, in the thalamus of SD mice, microglia activation was first 
observed at 1.5 months of age, peaked at 2 months of age, and decreased at 3 months of age (Fig. 
2D). In both the cerebellum and brainstem, SD mice expressed a progressive age-dependent 
increase in Mac-1 labeling with maximal activation at 3 months relative to WT (Figs. 3D and 4D 
for cerebellum and brainstem, respectively). Neither the cortex nor the hippocampus showed 
activated microglia as demonstrated by Mac-1 labeling (Supplementary Fig. 2B and Fig. 5B). 
For astrocytes, we found that in the thalamus, brainstem, cerebellum, and cerebral cortex 
of SD mice, there was an increased number of astrocytes and increased GFAP levels at all ages 
relative to WT (Fig. 2E, 3E, 4E, and Supplementary Fig. 2C for thalamus, brainstem, cerebellum, 
and cortex respectively). Therefore, it appears that in SD mice, astrocytosis occurs very early in 
time and prior to microglia activation. In all brain regions examined in SD mice, activated 
astrocytes were observed as early as 1 month of age (Fig. 2E, 3E, 4E, and Supplementary Fig. 2C). 
Astrocyte activation became more pronounced with disease progression in the regions of the brain 
that exhibited increasing levels of TSPO as the disease progresses, i.e., the thalamus, brainstem, 
and cerebellum. The astrocytes in the cerebral cortex, which did not show increased TSPO levels 
with disease progression, demonstrated an increase in number based on GFAP 
immunohistochemistry; however, these astrocytes did not appear to be hypertrophic. In contrast, 
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GFAP staining was seen throughout the entire hippocampus in both WT and SD mice (Fig. 5C) as 
is normal for this brain region. 
3.4 In vivo TSPO imaging using [125I]IodoDPA-713 SPECT 
We used [125I]IodoDPA-713 small animal SPECT imaging to measure TSPO expression 
in vivo in SD mice. Small animal SPECT images were co-registered with small animal CT to select 
the appropriate brain regions for analysis. There was a higher brain uptake of [125I]IodoDPA-713 
in the SD mouse compared to WT (Fig. 6A). Time-activity curves in the thalamus showed that SD 
mice had higher uptake of [125I]IodoDPA-713 than WT mice across all time points (data not 
shown). Quantitative analysis of the SPECT imaging showed a trend of increased uptake of 
[125I]IodoDPA-713 in the thalamus, cerebellum, and brainstem with a statistically significant 
increase of [125I]IodoDPA713 uptake in thalamus at 2 months (t(4)=2.81, p=0.0484) and in the 
brainstem at 3 months (t(6)=3.263, p=0.0172) compared to WT (Fig. 6B). To determine that the 
[125I]IodoDPA713 brain uptake was selective for TSPO, we used a pharmacological block in SD 
mice using nonradioactive IodoDPA713 (20 μM), resulting in complete blockade of 
[125I]IodoDPA713 uptake in the brain of SD mouse (Fig. 6A). These findings indicate that the 
increased [125I]IodoDPA713 in the mouse brain is directly related to increased TSPO brain levels. 
3.5 Temporal TSPO expression in glial cell types 
An important aspect in understanding the TSPO response to brain injury is to determine 
the cellular sources of the TSPO response since both microglia and astrocytes express and increase 
TSPO levels following injury (Chen and Guilarte, 2008; Chen and Guilarte, 2006; Kuhlmann and 
Guilarte, 2000; Maeda et al., 2007; Vowinckel et al., 1997). In Figures 2, 3, and 4, we show the 
temporal pattern of TSPO expression and the activation of microglia and astrocytes in SD mice. 
However, this data does not show the temporal expression of TSPO within each glial cell type. In 
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order to understand the contribution of microglia and astrocytes to the TSPO signal during the 
course of neurodegeneration obtained by [3H]DPA-713 receptor autoradiography and [125I]DPA-
713 small animal SPECT, we performed triple-labeled immunohistochemistry and confocal 
imaging of TSPO with Mac-1 and GFAP.  
Figure 7 depicts triple-labeled immunofluorescent confocal images of TSPO, Mac-1, and 
GFAP in both WT and SD mice. Triple-labeled immunofluorescent confocal imaging confirmed 
that TSPO colocalized with both microglia and astrocytes in the thalamus (Fig. 7A-C), brainstem, 
and cerebellum. We also measured the percent colocalization of TSPO with Mac-1 and TSPO with 
GFAP in the thalamus (Figs. 7B and 7C), brainstem (Figs. 8A and B), and cerebellum (Figs. 9A 
and B) at the various ages. In the thalamus, the percent colocalization between TSPO and Mac-1 
followed a similar pattern in both WT and SD mice with a more pronounced effect in the SD mice 
(Fig. 7B). The percent colocalization between TSPO and Mac-1 increased with age in both WT 
and SD mice and peaked at 2 months (Fig. 7B; 2-way ANOVA: Age: F(3,27)=4.386; p=0.016. 
Genotype: F(1,27)=10.740; p=0.004. Age x Genotype: F(3,27)=2.106; p< 0.132. n=3–4 mice per age 
group and genotype). In the brainstem and cerebellum, percent colocalization patterns of TSPO 
and Mac-1 mirrored those seen in the thalamus with levels of percent colocalization being highest 
in the thalamus (Figs. 8A and 9A).  
The percent colocalization between TSPO and GFAP differed significantly between WT 
and SD mice, partially due to the low signal of both proteins in the WT mice. In SD mice, we 
observed high levels of colocalization in the thalamus beginning at 1.5 months and remaining 
elevated until 3 months of age (Fig. 7C; 2-way ANOVA: Age: F(3,29)=2.122; p=0.126. Genotype: 
F(1,29)= 41.309; p < 0.001. Age x Genotype: F(3,29)= 4.136; p = 0.018. 1-way ANOVA: F(7,29)=8.401; 
p < 0.001. n=3–4 per age group and genotype). Similarly, the temporal progression of TSPO and 
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GFAP colocalization observed in the brainstem mirrored what was observed in the thalamus (Fig. 
8B). In the cerebellum, we observed high levels of TSPO and GFAP colocalization beginning at 
1.5 month of age and remained elevated throughout the progression of disease (Fig. 9B). In all 
regions and at all ages examined, TSPO colocalization with astrocytes was greater than its 
colocalization with microglia. 
4. DISCUSSION
The present work provides novel information on the relationship between the TSPO 
response to the initiation and progression of neurodegeneration and glial cell activation during the 
presymptomatic phase of disease in SD mice. The SD mouse provides a well-characterized animal 
model of neurodegeneration where the initiating pathological event (aggregation of GM2 
ganglioside) can be assessed and the magnitude and temporal course of the TSPO response can be 
compared to neuronal GM2 aggregation, as well as pathological and behavioral endpoints. Based 
on the ex vivo [3H]DPA-713 quantitative autoradiography and in vivo [125I]IodoDPA-713 small 
animal SPECT imaging, we were able to map the regional TSPO expression in the SD mouse brain 
as a function of age and pathology. Our findings indicate that the thalamus is the brain region 
where the earliest increases in GM2 ganglioside aggregation and TSPO expression occur, and that 
these increases occur prior to physical and behavioral manifestation of disease. Additionally, the 
magnitude of the TSPO response markedly increases as a function of age as neurodegeneration 
progresses. Our finding that the thalamus is one of the earliest affected brain regions is consistent 
with other studies using this animal model (Maegawa et al., 2006) and in the clinical setting with 
patients that express the disease (Kumar et al., 2014, Wu et al., 2013, Saouab et al., 2011, Yun et 
al., 2005). 
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Importantly, the regional expression of TSPO in the SD brain was consistent with affected 
(thalamus, brainstem, and cerebellum) brain regions. The finding that increased TSPO expression 
in the thalamus occurs with the first observable evidence of GM2 aggregation and prior to 
behavioral manifestation of disease strongly suggests that TSPO can be used for the early detection 
of neurodegenerative disease and to assess its progression. These characteristic make TSPO an 
ideal biomarker to assess the effectiveness of therapeutic interventions by tracking the TSPO signal 
during the presymptomatic stage of the disease. 
It is notable that we were not able to detect an increase in TSPO or glial cell activation in 
the CA2 region of the hippocampus in SD mice despite significant and progressive 
neurodegeneration measured by silver staining. To our knowledge, this pathology has not been 
described previously in either the SD mouse model or in human postmortem tissue from SD 
subjects. As previously noted, one possibility for this discrepancy could be related to the fact that 
the CA2 region of the hippocampus is a very small area and the methods used do not have sufficient 
spatial resolution to detect a TSPO or glial response. Studies using emulsion autoradiography with 
resolution at the cellular level could be useful to provide an explanation to this question. 
Alternatively, it is possible that the CA2 region is unique from other brain regions and is not able 
to mount a TSPO/glial response to injury. For example, a study by Kipp et al., demonstrated that 
astrocytes cultured from different brain areas not only have differences in cytokine profile 
expression and capacity in basal unstimulated conditions, but also have regional and temporal 
specific patterns of activation and cytokine upregulation in response to an inflammatory stimuli, 
such as LPS (Kipp et al., 2008). Taken together, these findings suggest that glial cell activation 
and thus the TSPO response to injury is likely to differ by brain region and one cannot assume that 
different types of injuries will generate the same TSPO/glial cell response. 
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Progressive reactive gliosis is known to occur in this mouse model of SD as demonstrated 
in the present study and by other studies (Myerowitz et al., 2002; Wada et al., 2000; Kyrkanides 
et al., 2005; Kyrkanides et al., 2007). However, no previous study has examined the age dependent 
activation of both microglia and astrocytes. Here, we established the regional and temporal pattern 
of microglia and astrocyte activation over the course of disease progression with astrocyte 
activation occurring earlier in time than microglial activation and confirm that both microglia and 
astrocytes are the source of the observed TSPO response although they express different temporal 
profiles (Figs. 2, 3, and 4).  
To further understand the function of TSPO and its role in the SD process, we first 
confirmed that both microglia and astrocytes expressed TSPO with specific regional and temporal 
patterns. Notably, in this neurodegenerative animal model, TSPO exhibited a higher degree of 
colocalization with astrocytes than with microglia, which is different with has been previously 
observed in other brain injury models (Chen and Guilarte, 2008; Cosenza-Nashat M et al. 2009). 
The greater degree of TSPO expression and colocalization with astrocytes in the SD mouse brain 
may be related to the early (i.e., 1 month) and sustained progression of astrocytosis present in 
several brain regions examined. The early astrocytic response occurred before the upregulation of 
TSPO and before neurodegeneration as assessed by silver staining, indicating that the generation 
of the SD mouse by knocking out the HexB gene may alter astrocyte physiology. This is consistent 
with the fact that abnormal growth patterns in astrocytes cultured from SD mice have been 
documented (Kawishima et al., 2009). Specifically, these studies found significantly faster rates 
of proliferation, increased ERK phosphorylation, and decreased Akt phosphorylation in astrocytes 
cultured from SD mice compared to WT. Another study found that despite conditionally 
expressing β-hexosaminidase in neurons from SD mice, the number of GFAP-positive astrocytes 
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did not decrease and GFAP gene expression remained elevated, whereas the number of MHC-II 
and CD45 positive cells and gene expression levels decreased as a result of expressing β 
hexosaminidase in neurons from SD mice (Kyrkanides et al., 2012). These results suggest that the 
early proliferation response of the astrocytes is independent of GM2 aggregation in neurons and 
that there is likely a disruption of neuron-astrocyte signaling. Taken together, these studies suggest 
that SD mice may have abnormally-functioning astrocytes, potentially explaining the early degree 
of GFAP expression and hypertorphy observed in the present study. However, it is important to 
note that despite the early activation of astrocytes, the TSPO signal does not increase until later in 
the disease process. This finding suggests that the TSPO increase in activated astrocytes starting 
at 1.5 months in the thalamus is the result of injury due to the disease, and not due to alterations in 
astrocyte physiology observed as early as 1 month of age. 
In the present study, we used the second-generation TSPO ligand DPA-713 in the tritiated 
and iodinated forms for TSPO autoradiography and in vivo imaging using small animal SPECT. 
Overall, one advantage of using [3H]DPA-713 for TSPO autoradiography studies is the fact that 
there is virtually no background; thus, a very high signal to noise ratio. Furthermore, using the 
[125I]IodoDPA-713 allows for in vivo SPECT imaging studies in which a single synthesis can be 
used for multiple studies due to the relatively long half-life of 125I. Recent work has shown that 
[125I]IodoDPA-713 can be used for imaging TSPO in the lungs using small animal SPECT (Wang 
et al., 2009; Ordonez et al., 2015). Our current study is the first to demonstrate in vivo 
[125I]IodoDPA-713 small animal SPECT imaging in the brain, with results similar to those 
measured with [3H]DPA-713 autoradiography despite the fact that [125I]IodoDPA-713 small 
animal SPECT does not have the same degree of spatial resolution as [3H]DPA-713 
90
autoradiography. Our findings strengthen the use of [125I]IodoDPA-713 as an attractive radioligand 
for TSPO imaging using small animal SPECT. 
Overall, we have shown that the regional expression of TSPO in SD mice is brain region-
specific and depends on the age of the SD animal as disease progresses with the thalamus providing 
the earliest signal of disease based on TSPO expression and other markers of neurodegeneration. 
Therefore, it is possible that PET, SPECT, or magnetic resonance imaging techniques (if 
developed) of brain TSPO could serve as an early indicator of brain pathology in the clinical 
setting. However, while PET and SPECT imaging of TSPO may be useful in the clinical setting 
as they provide real-time information of ongoing brain inflammation and injury, the potential risks 
of radiation exposure in children expressing the disease must be taken into consideration. From a 
translational perspective, the present work sets the stage to determine if TSPO expression in 
peripheral cells could serve as a surrogate marker for TSPO levels in the brain. For example, using 
this progressive animal model of SD, one can examine the relationship between increases in TSPO 
expression in the CNS and those in TSPO-expressing peripheral cells such as platelets, monocytes, 
and macrophages. The discovery of an early peripheral biomarker of CNS disease would be a 
significant advance for clinical use. 
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FIGURE 1. Characterization of Sandhoff Mice. A) Weekly bodyweights of wildtype and 
Sandhoff mice from 6 to 13 weeks of age (3months of age). There was no significant difference of body 
weight between wildtype and Sandhoff mice at any age (Repeated ANOVA. p=0.7295). Data is 
expressed as the mean of the body weights per week ± SEM. n=13 for both wildtype and Sandhoff 
mice. B) Wildtype and SD mice show no significant differences in motor skills as assessed by 
rotarod performance at 1, 1.5, or 2months of age. However, at 3 months of age, SD mice expressed a 
dramatic decrease in latency time demonstrating their decreased motor coordination and reduced 
grip strength. Data is expressed as mean ± SEM. n=10–13mice per group. C) Horizontal activity and 
D) rearing of WT and SD mice were measured for 1 h using the open field activity chamber at each of
the 4 ages. When correcting for multiple comparisons, a significant difference between age-matched
3monthwildtype and SD mice was seen for rearing activity (t=3.405; p=0.0022). No significant
differences were seen in horizontal activity when applying the Bonferroni method to correct for




FIGURE 2. TSPO levels and neuropathology of Sandhoff disease mice in the thalamus. A) 
GM2 ganglioside aggregation (green) in neurons stained with NeuN (red). Representative images 
show increasing GM2 aggregates with age in SD mice as compared to WT. GM2 aggregation 
begins at 1.5months and reaches significant levels by 2months (F4,14 = 18.825; p < 0.001). B) 
TSPO levels measured by [3H]DPA-713 quantitative autoradiography progressively increased as 
a function of age in SD mice. TSPO levels were significantly increased beginning at 1.5 months, 
the earliest age at which GM2 aggregation is observed, and increased with age (F 4, 62 =139.144; p 
< 0.001). C) Representative horizontal brain photomicrographs of active neurodegeneration as 
detected with silver staining. The top row represents low magnification images with the boxes 
indicating the area of which the high magnification images in the bottom row were generated. At 
1month, SD mice show no significant silver accumulation in the thalamus compared to WT. At 
1.5months, there is slight silver accumulation in the thalamus in SD mice compared to WT, and at 
2 and 3months, SD mice show robust silver accumulation in the fiber tracks of the thalamus. 
D)Microglia activation as indicated byMac-1 labeling occurs as early as 1.5 months, with 2 month
SD mice exhibiting the highest levels of Mac-1 labeling. E) Activated astrocytes are observed as





FIGURE 3: Neuropathological Assessment of Sandhoff disease in the brainstem.  A) 
Representative images showing GM2 accumulation (green) in SD mice compared to WT. Slight 
increase in the levels of GM2 aggregation begins at 1.5 months, reach significant levels by 2 
months, and stay consistent at 3 months (F 4,14 = 8.711; p = 0.003) B) TSPO levels in the 
brainstem, as determined by [3H]-DPA autoradiography, is significant compared to WT mice 
at 2 months, and increases to higher levels at 3 months of age (B; F 4,53 = 13.002; p < 0.001). C) 
At both 2 and 3 months, silver staining shows ongoing neurodegeneration.  The top row 
represents low magnification images with the boxes indicating the area of which the high 
magnification images of the bottom row were generated. D) WT mice exhibit morphologically 
normal microglia and astrocytes. Microglia activation, as indicated by Mac-1 labeling, is 
seen at low levels in the brainstem at 1.5 months.  SD mice demonstrate a progressive increase 
over time in Mac-1 labeling compared to WT mice. E) Activated astrocytes are observed 
beginning as early as 1 month of age in SD mice, and activation becomes more pronounced 




FIGURE 4: Neuropathological Assessment of Sandhoff disease in the cerebellum. 
A) Representative images of GM2 accumulation in SD mice compared to WT. Low levels of
GM2 aggregation (green) begin at 1.5 months, reach significant levels by 2 months, and stay
consistent at 3 months of age (F 4,14 = 22.150; p < 0.001). B) TSPO levels in the cerebellum, as
determined by [3H]-DPA autoradiography, become significantly increased compared to WT mice
at 3 months of age (F 4, 59 = 6.692; p < 0.001).  C) At both 2 and 3 months, representative
horizontal brain photomicrographs reveal robust diffuse neurodegeneration as detected through
silver staining.  The top row represents low magnification images with the boxes indicating the
area of which the high magnification images of the bottom row were generated. D) WT mice
exhibit morphologically normal microglia and astrocytes. Microglia activation, as indicated by
Mac-1 labeling, is observed at 1.5 months and progressively increasing as animals age and the
disease progresses.  E) Activated astrocytes are observed beginning as early as 1 month of age in
SD mice, and activation becomes more pronounced with age and disease progression in SD mice.
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FIGURE 5. Neuropathological Assessment of Sandhoff disease in hippocampus. A) 
Representative horizontal brain photomicrographs reveal neurodegeneration in the CA2 region 
of the hippocampus beginning at 1.5 months and continuing as the diseases progresses. The top 
row represents low magnification images with the boxes indicating the area of which the high 
magnification images of the bottom row were generated.  B) WT and SD mice exhibit 
morphologically normal microglia. Microglia activation, as indicated by Mac-1 labeling, does 
not appear to occur as animals age or the disease progresses in this brain region. C) Activated 
astrocytes are observed at all ages in SD mice at comparable levels to those seen in WT mice.  
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FIGURE 6. In vivo TSPO imaging using [125I]-IodoDPA713 SPECT in the Sandhoff 
disease mouse brain. A) Representative brain uptake of [125I]IodoDPA-713 in wildtype (WT), 
3-month SD mouse, and 3-month SD mouse with pharmacological block using non-radioactive
IodoDPA-713. The CT, for orientation purposes, indicates that slices are at the level of the
thalamus. Tracer uptake is higher in the brain of the SD mouse, and the uptake was blocked by
co-injection of 20 μM non-radiolabeled IodoDPA-713. B) Analysis of [125I]-IodoDPA713
uptake in SD mouse brain. At 2-months of age SD mice exhibited a significant increase in [125I]-
IodoDPA713 uptake in the thalamus (t4=2.81, p=0.0484). At 3-months of age, SD mice
expressed a significant increase in [125I]-IodoDPA713 uptake in the brainstem (t6 = 3.263, p =
0.0172). Images are expressed in units of Standardized Unit Value (SUV) and are normalized for
weight and injected dose. Data is expressed as the mean of SUV ± SEM. n = 3–4 mice per group.
* p b 0.05 compared to WT.
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FIGURE 7. Temporal colocalization of TSPO with glial markers in wildtype (WT) and 
Sandhoff disease (SD) mice in the thalamus. A) Representative triple labeled 
immunofluorescent confocal images in the thalamus of WT and SD mice at the four different 
ages. Triple labeled immunofluorescent confocal imaging confirmed that TSPO colocalized 
with the microglial markerMac-1 as indicated by the purple and magenta colors and astrocyte 
marker GFAP as indicated by the yellow color. B) In the thalamus, the percent colocalization of 
TSPO with Mac-1 follows a similar pattern in both the WT and SD mice, with a more 
pronounced effect in the SD mice. The percent colocalization between TSPO and Mac-1 
increases with age in both WT and SD mice and peaks at the 2 months of age. C) The percent 
colocalization between TSPO and GFAP also differs significantly between WT and SD mice, 
due to the low signal of both in the WT mice. In the SD mice, we observed a high degree of 
colocalization beginning at 1.5 months and remaining at 3 months of age. Each value 
represents the mean ± SEM. n=3–4 animals and experiments. 
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FIGURE 8.  Temporal colocalization of TSPO expression with glial markers in wildtype 
(WT) and Sandhoff disease (SD) mice in the brainstem. A) In the brainstem, the 
percent colocalization between TSPO and Mac-1 increases with age and follows a similar pattern 
in both the WT and SD mice, with a more pronounced effect in the SD mice (2 way ANOVA: 
Age: F3,29 = 11.843; p < 0.001. Genotype: F1,29 = 18.117. p < 0.001. Age x Genotype: F3,29 = 
4.089; p = 0.019. 1 way ANOVA: F7,29 = 9.470; p < 0.001.  Each value represents the mean ± 
SEM. n = 3 – 4)  B) The percent colocalization between TSPO and GFAP differs significantly 
between WT and SD mice.  In the SD mice, we observed high levels of colocalization beginning 
at 1.5 months and this amount of colocalization remained elevated up until 3 months of age (2 
way ANOVA: Age: F3,28 = 6.457; p = 0.003. Genotype: F1,28 = 130.46. p < 0.001. Age x 
Genotype: F3,28 = 18.319; p < 0.0001. 1 way ANOVA: F7,28 = 26.807; p < 0.001.  Each value 
represents the mean ± SEM. n = 3– 4). Within a group, bars with different letters are 
significantly different at p < 0.05. 
103
FIGURE 9.  Temporal colocalization of TSPO expression with glial markers in wildtype 
(WT) and Sandhoff disease (SD) mice in the cerebellum.  A) In the cerebellum, the 
percent colocalization between TSPO and Mac-1 increases with age and follows a similar pattern 
in both the WT and SD mice, with a more pronounced effect in the SD mice (2 way ANOVA: 
Age: F3,26 = 2.8953; p = 0.062. Genotype: F1,26 = 16.433. p < 0.001. Age x Genotype: F3,26 = 
3.778; p = 0.028. 1 way ANOVA: F7,26 = 5.315; p = 0.002.  Each value represents the mean ± 
SEM. n = 3 – 4)  B) The percent colocalization between TSPO and GFAP differs significantly 
between WT and SD mice.  In the SD mice, we observed high levels of colocalization beginning 
at 1 month and these levels of colocalization remained elevated up until 3 months of age (2 way 
ANOVA: Age: F3,27 = 2.560; p = 0.084. Genotype: F1, 27 = 61.830. p < 0.001. Age x Genotype: 
F3,27 = 1.315; p = 0.297. Each value represents the mean ± SEM. n = 3 – 4). Within a group, bars 
with different letters are significantly different at p < 0.05. 
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SUPPLEMENTARY FIGURE 1: TSPO levels in the hippocampus and cerebral cortex of 
Sandhoff disease (SD) mice using [3H]-DPA-713 quantitative autoradiography. TSPO 
binding did not increase in the hippocampus (A; F4, 62 = 0.559, p = 0.693) or cortex (B; F4, 60 = 
1.191, p = 0.324).  Each value represents the mean ± SEM.  
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SUPPLEMENTARY FIGURE 2. Neuropathological Assessment of Sandhoff disease in the 
cerebral cortex. A) Representative horizontal photomicrographs of silver staining reveal slight 
neurodegeneration at 3 months.  The top row represents low magnification images with the 
boxes indicating the area of which the high magnification images of the bottom row were 
generated.  B) WT and SD mice exhibit morphologically normal microglia. Microglia activation, 
as indicated by Mac-1 labeling, does not appear to occur as animals age or the disease 
progresses. C) Activated astrocytes are observed beginning as early as 1 month of age in SD 
mice, and activation remains at similar levels at all ages.  
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Chapter 3: TSPO-ligand induced ROS production in primary microglia: 
experimental evidence supporting NADPH oxidase 
110
ABSTRACT 
Translocator protein 18 kDa (TSPO) is a biomarker of brain inflammation and injury that 
is used in preclinical and clinical studies. However, there is a lack of knowledge on TSPO function 
in glial cells, the brain cells that express and upregulate TSPO as a result of injury. We previously 
demonstrated that TSPO ligands (TSPO-L) (1-100 nM) induced intracellular ROS production 
which was abrogated by NADPH oxidase (NOX2) inhibitors, thereby indicating an association 
between TSPO and NOX2.  
In the present study, we aimed to further investigate the cellular source of ROS production 
from TSPO-ligand exposure in microglia. TSPO-L exposure (1-100 nM) increased extracellular 
superoxide production that was abrogated by an NADPH oxidase inhibitor. Furthermore, co-
exposure of primary microglia to an activator of NADPH oxidase (PMA) with TSPO-L enhanced 
extracellular superoxide production compared to vehicle-treated and PMA treated microglia, 
thereby indicating a positive (additive) relationship between TSPO and NOX2. Neither 
intracellular nor extracellular TSPO-L induced ROS production was inhibited by the mitochondrial 
permeability transition pore inhibitor cyclosporine A suggesting that the source of ROS production 
was not from mitochondria. These findings were further confirmed using MitoSOX, a 
mitochondrial superoxide specific assay. Finally, we examined the effect of TSPO-L exposure on 
the redox sensitive transcription factor, nuclear factor erythroid 2 related factor (Nrf2).  We 
discovered that TSPO-L exposure induced Nrf2 translocation from the cytosol into the nucleus, 
providing supporting evidence for the activation of Nrf2 and for the induction of cytoprotective 
genes that help maintain microglia redox homeostasis.  
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1. INTRODUCTION
Translocator protein 18 kDa (TSPO) has a several decade history as a biomarker of brain 
inflammation and injury (Chen & Guilarte 2008; Papadopoulos et al 2006; Liu et al 2014). 
However, the function of TSPO is currently under debate as recent studies using TSPO knockout 
mice have raised significant questions about TSPO’s traditionally ascribed function of 
translocating cholesterol into the mitochondria as the first step in steroidogenesis (Tu et al 2014; 
Morohaku et al 2014; Banati et al 2014; Fan et al 2015; Papodopoulos et al 1997). Here, we focus 
on the function of TSPO in microglia, one of the brain cell types that expresses and upregulates 
TSPO as a result of brain injury. 
Microglia, the resident central nervous system (CNS) macrophages, perform several 
physiological functions including surveilling the brain to maintain brain homeostasis (Haslund-
Vinding et al 2016; Vildhardt et al 2017). With brain injury, microglia assume an activated 
phenotype which can vary depending on the nature and timing of the insult. These activated 
phenotypes range across a continuum of morphological and molecular changes (Town et al 2005; 
Vilhardt et al 2017). As phagocytic cells, microglia express high levels of NADPH oxidase which 
serve to produce a superoxide burst. The function of this superoxide burst is two-fold. First, the 
superoxide can destroy phagocytized matter and enable microglia’s role in host defense and anti-
microbial functions. Secondly, this superoxide burst can be used by redox signaling circuits that 
contribute to the activation of microglia and the maintenance of brain redox homeostasis (Finkel 
et al 2011; Brieger et al 2012; Holmstrom and Finkel 2014; Haslund-Vindig et al 2016; Vilhardt 
et al 2017).   
Our laboratory has previously demonstrated that physiologically relevant concentrations 
of TSPO-ligands (TSPO-L) induce microglia functions consistent with an activated state (Choi et 
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al., 2011).  This includes increased phagocytosis, ROS production, and cytokine release. In 
particular, the increase of intracellular ROS was abrogated with two different NOX inhibitors, 
apocynin and DPI, indicating an association between TSPO and NADPH oxidase. As TSPO has 
previously been associated at the outer mitochondrial membrane with VDAC (McEnery et al 1992; 
Gatliff et al 2014), we wanted to confirm the cellular source of ROS production.  There are various 
potential sources of ROS within the cell including mitochondria, peroxisomes, and several 
enzymes such as xanthine oxidase, nitric oxide synthetase, p450 cytochromes, and NADPH 
oxidase. (Brieger et al 2012). Previous studies have suggested a role of TSPO in ROS production 
in several types of cells (Zeno et al 2009; Veenman et al 2008, Gatliff et al 2014; Gatliff et al 2017; 
Joo et al 2012; Banfi et al 2004). Here we provide additional support to the initial observation that 
ROS production induced by exposure to TSPO ligands in microglia is a result of activation of 
NADPH oxidase. Further, ROS production and activation of NADPH oxidase through exposure 
to TSPO ligands will also activate cellular processes involved in maintaining redox homeostasis, 
such as nuclear factor erythroid 2 related factor (Nrf2), a transcription factor that maintains redox 
homeostasis by translocating to the nucleus to bind to the antioxidant response element and induce 
the transcription of a battery of antioxidative and cytoprotective genes.  
2. MATERIALS & METHODS
2.1 Primary rat microglia cell culture.  Primary mixed glial cell cultures were prepared using a 
modified version of the glial culture technique as previously described (Giulian and Baker, 1986 
and Choi et al 2011).  Brains from PN1-3 Sprague Dawley rat pups (Harlan, Indianapolis, IN) were 
dissected, meninges removed and cortices isolated.  Tissue was dissociated by trypsination (2.5% 
trypsin at 37°C for 30 minutes), trituration, and filtration through 40 μm cell strainers.  Cells were 
centrifuged at 400 xg for 10 minutes, resuspended, and plated onto 75 cm2 poly-L-lysine coated 
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culture flasks in Dulbecco’s modified Eagle’s medium (DMEM)/F12 (Invitrogen, Carlsbad, CA) 
containing 10% heat-inactivated fetal bovine serum (FBS) (Hyclone, Logan, UT), 100 U of 
penicillin, and 100 μg of streptomycin (Invitrogen).  Cultures were maintained at 37°C in a 
humidified chamber of 95% air/5% CO2 for 12-14 days when the glial cultures reached 
confluency.  Microglia were extracted from the glial cultures by shaking the flasks for 3 hours at 
200 r.p.m. at 37°C and were collected as floating cells in the media.  After centrifugation (400 xg 
for 10 minutes), cell viability was determined by trypan blue exclusion, and cells were plated 
according to the assay being tested.  Non-adherent cells were removed 20 minutes after plating by 
changing the culture medium to DMEM:F12 containing 2% FBS.  Adherent cells were incubated 
overnight before being used for experiments.  More than 95% of the adherent cells were positive 
for microglia-specific marker Mac-1 (Chemicon, Billerica, MA) as determined by 
immunostaining. The animals used for this study had been treated humanely as all the animal 
studies were reviewed and approved by the Columbia University Medical Center Animal Care and 
Use Committee.  
2.2 J774 Macrophages. Mouse macrophage J774 cells lines were maintained in RPMI media with 
10% FBS and 1% (vol/vol) penicillin-streptomycin. 
2.3 Treatments.  (R)-PK11195 (Advanced Biochemical Compounds, Radeberg, Germany), Ro5-
4864 (Sigma-Aldrich, St. Louis, MO), and cyclosporine A (Sigma-Aldrich, St. Louis, MO) were 
dissolved in 100% ethanol. Stock solutions were diluted in ethanol appropriately such that equal 
amount of ethanol was added to each treatment containing DMEM:F12 medium containing 2% 
FBS.  Equal amount of ethanol was added to vehicle as control. The percent of ethanol used for 
treating the cells was less than 0.1%.   
Phorbol-12-myristate 13-acetate (PMA), apocynin, rotenone (Rot), and sulforaphane (SF) 
were dissolved in dimethyl sulfoxide (DMSO), all from Sigma-Aldrich, St. Louis, MO. All stocks 
were then diluted in DMSO so that an equal amount of DMSO was added to each treatment 
containing 2% FBS. Equal amount of DMSO was added to vehicle as control. The percent used 
for treating cells was less than 0.05%. Bacterial lipopolysaccahride (LPS), was dissolved in phenol 
red free media. Microglia were exposed to 10 nM of PK or Ro; 500 nM of rotenone; 1 mM of 
sulforaphane; 100 ng/mL of LPS; 100 ng/mL of PMA; and 1mM of apocynin for time of exposure 
indicated before testing for various assays. 
2.4 Immunocytochemistry.  300Kmicroglia were plated onto glass coverslips in a 6 well plate 
(Corning, Corning, NY). Cells were treated as specified above. Immunocytochemistry was 
performed via conventional techniques before being incubated in primary antibody rabbit-anti 
Nrf2 (Santa Cruz 1:200) overnight at 4°C.  Briefly, cells were fixed with 4% 
paraformaldehyde for 20 minutes; washed with 1X phosphate buffered saline (PBS); 
permeabilized with 0.2% Triton for 10 minutes; washed; and blocked for 1 hour with 10% normal 
goat serum (Vector Laboratories, Burlingame, CA). After primary antibody incubation and three 
5 minute washes, cells were incubated with appropriate Alexa Fluor secondary antibodies 
(Invitrogen; 1:500) for 1 hour. Cells were mounted with Prolong with DAPI (Invitrogen) to 
counterstain for cell nuclei.   
2.5 Measurement of Reactive Oxygen Species (ROS). 
2.5.1 Extracellular ROS was determined by measuring the super oxide dismutase (SOD) 
inhibitable reduction of cytochrome C. Cytochrome c (Sigma-Aldrich, St. Louis, MO) that was 
added exogenously. Due to its size, cytochrome c cannot pass through the cell membrane. The 
exogenous cytochrome c is then reduced by any extracellular superoxide. This produces 
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ferrocytochrome c, whose absorbance is detected at 550 nm and measured via a plate reader. 
Cells were incubated for 1 or 24 hours at 37°C in HBSS containing 100 μM cytochrome c in the 
presence or absence of SOD (600 U/mL) (Sigma-Aldrich, St. Louis, MO). The level of 
extracellular ROS produced was calculated as the difference in the absorbance observed between 
the absence and presence of SOD in each treatment, and the results were expressed as the 
percentage of the vehicle-treated control.  
2.5.2 Intracellular ROS was measured using the dichlorofluorescein diacetate (DCF-DA) assay 
(Molecular Probes, Eugene, OR).  DCF-DA readily crosses the cell membranes and is hydrolyzed 
by intracellular esterases to a non-fluorescent DCF. After oxidation by ROS, DCF-DA is converted 
to the highly fluorescent dichlorofluorescein, which is detectable using a fluorescent plate reader. 
50,000 microglia/well were plated onto a 96-well plate. Cells were incubated for 30 minutes at 
37°C in HBSS containing 10 μM DCF-DA. The fluorescence was measured at 485 nm excitation 
and 530 nm emission with background values subtracted. 
2.5.3 Mitochondrial superoxide was measured using MitoSOX Red (Molecular Probes). MitoSOX 
crosses cell membranes and is targeted to actively respiring mitochondria due to its cationic 
tryphenylphosphonium substituent.  Oxidation of MitoSOX by superoxide results in 2-
hydroxyethidum whose fluorescence is measured by a plate reader. 50,000 microglia/well were 
plated onto a 96-well plate. Cells were incubated for 10 minutes at 37°C in HBSS containing 1 
μM MitoSOX Red. The fluorescence was measured at 396nm excitation and 580 nm emission 
with background values subtracted.   
2.6 Immunofluorescence Imaging and Analysis. All coverslips were imaged at 40x magnification 
with a single point laser scanning confocal microscope (Zeiss LSM 510-Meta) using LSM software 
at CUMC Microscope Facility. All images within an experiment were taken the same day, using 
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the same scanning parameters with at least 120 cells counted per condition per experiment.  
Confocal stacks were then projected into single images. All analyses after image acquisition were 
performed using Metamorph Offline (Molecular Devices) and integrated intensity was measured. 
2.7 Western Blot. J774 macrophages were lysed in radioimmunoprecipitation assay buffer (15 mM 
NaCl; 50 mM Tris; 5 mM EGTA; 1% Triton; 5% deoxycholate; and 20% SDS. Polyvinylidene 
fluoride (PVDF) membranes were incubated with the following primary antibodies: 1:1000 TSPO 
(Abcam ab109497) and 1:10,000 actin (Santa Cruz, sc-1616) in LICOR blocking solution 
overnight at 4 C. After incubation with corresponding IRDye dye-labeled secondary antibodies 
(LI-COR) and appropriate washing, membranes were visualized with the Odyssey Infrared 
Imaging system. Integrated intensity of the protein of interest was normalized to actin levels from 
the same blot and sample. 
2.8 Statistical analysis.  Values are expressed as mean ± standard error of the mean (SEM).  Each 
group consisted of three to four independent trials (experiments) for each concentration studied.  
A one-way ANOVA was used to determine treatment effect followed by Tukey’s post-hoc analysis 
unless otherwise stated.   
3. RESULTS
3.1 Extracellular Superoxide Production 
3.1.1 With a NADPH oxidase inhibitor 
To further explore the relationship between TSPO-ligand exposure and ROS production in 
microglia, we measured extracellular TSPO-L-induced superoxide production. Consistent with our 
previous finding (Choi et al.2011 ), we found that exposure to 10 nM (R)PK-11195 or 10 nM Ro5-
4864  resulted in increased extracellular superoxide production, that could be abrogated with the 
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NADPH oxidase inhibitor apocynin (1mM) (Figure 1A, LPS: t=2.625; p=0.0342. PK: 
F(2,12)=6.543, p=0.015. Ro: F(2,13)=5.475; p=0.019. n=3-6 independent experiments). These results 
provide further supporting evidence that the source of TSPO-L induced ROS production in 
microglia is from NADPH oxidase, a finding that is consistent across both rat microglia and mouse 
macrophages (See Results, Section 3.5).  
3.1.2 With a NADPH oxidase activator 
In addition to blocking NADPH oxidase (NOX2), we activated NADPH oxidase using 
phorbol 12-myristate 13-acetate (PMA). PMA activates NOX2 through stimulation of Protein 
kinase C (PKC) and induces a respiratory ROS burst (Cox et al 1985).  Exposure to 100 ng/mL of 
PMA for 1 hour produced a robust increase in extracellular superoxide production, and co-
exposure with PMA and either 10 nM of (R)PK-11195 or 10 nM Ro5-4864 enhanced extracellular 
superoxide production compared to vehicle treated and PMA treated microglia (Figure 1B, PK: 
F(2,6)=122.3, p<0.001. Ro: F(2,6)=175.0; p<0.001). This data also suggests a relationship between 
NADPH oxidase and TSPO-L induced ROS production.  That is, upregulation of NOX2 enhances 
TSPO-L extracellular superoxide production and inhibiting NOX2 blocks TSPO-L extracellular 
superoxide production.   
3.2 Mitochondrial Superoxide production 
3.2.1 Cyclosporine A  
Previous studies indicate that TSPO is localized at the outer mitochondrial membrane, and 
has been shown to be associated with VDAC, another outer mitochondrial membrane protein 
(McEnery et al 1992; Gatliff et al 2014). Therefore, we needed to assess if ROS were originating 
from the mitochondria, particularly given that the mitochondria are a well-documented source of 
ROS (Brieger et al 2012; Holmstrom and Finkel 2014) and given the question as to the role of 
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TSPO in the mitochondrial permeability transition pore (mPTP) (Sileikyte et al 2010, 2011, and 
2014; Gatliffe et al 2012). To begin to address the involvement TSPO-L induced ROS in mPTP, 
we used a mitochondrial permeability transition pore inhibitor, cyclosporine A. Co-exposure of 
TSPO-ligands with cyclosporine A for 24 hours did not inhibit extracellular superoxide production 
(Figure 2A,  PK: F(2,6)=10.73. p=0.010. Ro: F(2,8)=6.12; p=0.024) or intracellular ROS production 
(Figure 2B, PK: F(2,6)=13.86. p=0.006. Ro: F(2,6)=9.95; p=0.012). Taken together, these data 
indicate that the mitochondria are not the source of TSPO-L induced ROS at 24 hours.  
3.2.2  MitoSOX 
We next measured mitochondrial superoxide production using MitoSox in a time course 
study to rule out the possibility that we may not have been capturing the appropriate time point of 
a mitochondrial superoxide increase. We used the MitoSOX assay to measure mitochondrial 
superoxide production at 2, 4, 8, 18, and 24 hours of 10 nM of TSPO-L, (R)PK-11195 and Ro5-
4864. We also used antimycin A (complex III inhibitor, 2uM) and rotenone (complex I inhibitor, 
500 nM) as positive controls for mitochondrial superoxide production.  At all time-points 
examined, TSPO-L did not induce a significant increase in mitochondrial superoxide, whereas  the 
electron transport chain inhibitors antimycin A and rotenone increased mitochondrial superoxide 
levels at all time points examined compared to vehicle treated cells (2hrs: F(4,13)=6.164; p=0.005. 
4hrs: F(4,15)=8.940; p=0.001. 8hrs: F(4,11)=3.430; p=0.047. 18hrs: F(4,10)=4.929; p=0.019. 24hrs: 
F(4,23)=4.561; p=0.007. n = 3-6 independent experiments per time point). This data further supports 
our hypothesis that TSPO-L induced ROS do not originate from the mitochondria.  
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3.4 Nrf2 translocation from cytosol to nucleus as a measure of Nrf2 activation 
Microglia are one of several cell types that use ROS as signaling molecules (Vilhardt et al 
2017). In order to maintain redox homeostasis, cells use ROS to initiate feedback loop mechanisms 
in order to induce various antioxidant responses (Holmstrom and Finkel et al 2014; Brieger et al 
2012; Rastogi et al 2017; Hoffmann and Griffiths 2018). One such antioxidant response regulator 
is nuclear factor erythroid 2 related factor 2 (Nrf2).  Nrf2 is a transcription factor that is found in 
the cytosol under basal conditions. In the cytosol, Nrf2 is bound to Keap1 to regulate its activity. 
Under conditions of oxidative stress, the cysteine residues are modified so that Keap1 releases 
Nrf2 (Dinkova-Kostova et al 2002; Niture et al 2009; Niture et al 2014; Levonen et al 2004; Ma 
et al 2013), exposing Nrf’s nuclear localization signal (NLS), and translocates to the nucleus to 
bind the antioxidant response element (ARE) in a battery of Nrf2-responsive antioxidant genes. 
Previous studies have shown that NOX2 activity is an upstream and essential regulator in 
Nrf2/Keap1 signaling (Sekhar et al 2003). Therefore, we hypothesized that given TSPO-L may 
induce the translocation of Nrf2 to the nucleus as a cellular response to counter the increase in 
ROS production. Primary microglia exposed to physiologically relevant concentrations of (R)PK-
11195 or Ro5-4864 (1, 10, 100 nM) resulted in a statistically significant increase in the percentage 
of Nrf2 in the nucleus relative to vehicle treated cells (F(8,1602)=19.774; p<0.0001). Interestingly, 
Ro5-4864 induced higher levels of nuclear Nrf2 translocation as compared to (R)PK-11195 at all 
doses examined, indicating differential potency of these ligands. We used sulforaphane as our 
positive control as it is a known Nrf2 activator (Zhao et al 2007) in microglia (Dang et al 2012; 
Brandenburg et al 2010). Our results suggests that the binding of TSPO-L to TSPO may be a signal 
for the production of NOX2-dependent ROS production that can then induce Nrf2 translocation 
and activate ARE target genes to mount a response to increased oxidative stress.  
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3.5 ROS levels and TSPO protein expression 
To explore the relationship between ROS production and TSPO protein expression and the 
time course of an increase in ROS compared to an increase TSPO protein, we used the mouse 
macrophage cell line J774. Both macrophages and microglia are myeloid in origin (Salter and 
Begg, 2014; Butovsky et al 2014; Hickman et al 2013), respond to inflammatory insults, and are 
capable of chemotaxis and pathogen engulfment (Lam et al 2009). Additionally this macrophage 
cell line is a well-established model system in cell biology and immunology (Ralph et al 1975; 
Ralph et al 1977; Unkeless et al 1979; Kant et al 2002) due to the fact that these macrophages can 
be easily maintained and genetically manipulated (Lam et al 2009).  
Importantly, the TSPO antibody (Abcam ab109497) our lab has validated through multiple 
methods (siRNA knockdown in HEK293T cells; shRNA knockdown in J7774 cells;  brain tissue 
from TSPO wildtype, heterozygous, and knockout animals; and primary mouse microglia and 
primary rat microglia) only reacts with human and mouse TSPO, and not rat TSPO (data not 
shown). Therefore, we used a mouse macrophage cell line instead of primary rat microglia for 
these preliminary studies as J774 cells are cells known to express and upregulate TSPO (Pomper 
et al 2016, patent # US 9,498,546 B2). Similar to our findings in microglia, exposure to TSPO-L 
or LPS for 24 hours increased both extracellular and intracellular ROS production (S. Figure 1B 
and 1D). We also examined a 3-hour time point, and we observed an increase in extracellular ROS 
production at all TSPO-L exposures examined (S. Figure 1A), and an increase in intracellular ROS 
production with 100 nM (R)-PK, 10 nM Ro, and 100 nM Ro (S. Figure 1C). LPS exposure also 
increased both extracelullar and intracellular ROS levels at 3 hours.  
We next examined TSPO protein levels at 3 and 24 hours in both control and LPS treated 
macrophages. At 3 hours, TSPO/actin ratios were comparable in Western blot (S. Figure 2). This 
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was in contrast to the increase in extracellular and intracellular ROS seen at 3 hours. At 24 hours, 
TSPO/actin ratio was increased 60% in LPS treated macrophages as compared to control 
macrophages (S. Figure 2), a time when ROS levels are also elevated both intracellularly and 
extracellularly 
4. DICUSSION
In this study, we used two prototypical and specific TSPO ligands, (R)-PK11195 (PK) and 
Ro5-4864 (Ro) to examine their effect on ROS production in primary microglia. Consistent with 
our previous study (Choi et al 2011), both PK and Ro increased extracellular ROS production 
(Figure 1A) at concentrations consistent with their affinity for TSPO (in the nM range). 
Additionally, co-exposure of microglia to a NADPH oxidase inhibitor, apocynin, abrogated the 
TSPO-L induce increase in ROS production. Apocynin is a NOX2 inhibitor which acts by 
preventing the migration of the p47phox subunit to the membrane bound subunits of NOX2, thereby 
preventing assembly of the active NOX2 complex (Rastogi et al 2017; Stolk et al 1994). It has 
been noted that apocynin is not specific to NOX2, and that other isoforms of NOX which include 
the p47phox subunit in the NOX complex will also be affected, notably, the structurally homologous 
subunit NOXO1 in NOX1 (Rastogi et al 2017). However, the presence of NOX1 in microglia is 
mixed across the literature with some studies detecting NOX1 gene or protein expression 
(Savchenko et al 2013), and other studies stating that microglia do not have NOX1 in murine 
cortical microglia (Vilhardt et al 2017). However, regardless of the isoform of NOX affected, 
TSPO-L still increase ROS production that is most likely derived from an isoform of NOX, as it 
can be abrogated by a NOX inhibitor. Additional studies confirming NOX activity induced by 
TSPO-L exposure will be critical in both wildtype and gp91phox knockout mice.  
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It has been previously suggested that increased production of ROS by these two TSPO-
specific ligands may not only be from NADPH oxidase but also from mitochondria (Choi et al 
2011). More specifically some studies have suggested that activation of TSPO can lead to 
increased ROS production by mitochondria via modulation of the proton pump provided by the 
FO unit of ATP(synth)ase (Veenman et al., 2008, 2010; Zeno et al., 2009). Still, our results are 
consistent with a growing body of literature that TSPO ligands increase ROS production in 
microglia and other cell types (Jayakumar et al., 2002). Additionally, we provide evidence that in 
microglia the source of ROS is not mitochondrial as indicated by the cyclosporin A and MitoSOX 
studies. This contributes to the growing number of studies which have challenge the involvement 
of TSPO in the mitochondrial permeability transition pore-associated process (Sileikyte et al 2014; 
Kokoszka et al 2004; Krauskopf  et al 2006; Baines et al 2007 and 2018; Bernardi et al 2013;) 
It is currently unknown exactly how TSPO-L induce functions consistent with an activated 
state in microglia, and therefore, also unclear how TSPO-L exposure results in an increase in ROS 
production. Previously, we have suggested that the TSPO-NOX2 interaction produces ROS which 
in turn causes an activation of Nrf2 to activated downstream antioxidative gene to maintain redox 
homeostasis. Here we confirm that 24-hour TSPO-L exposure induces Nrf2 nuclear translocation, 
though it remains to be confirmed which anti-oxidant genes are upregulated in microglia. 
Preliminary data from our lab suggests that in primary rat microglia, 24-hour exposure to Ro, but 
not PK, induce heme oxygenase 1 (HO-1) expression, one of several Nrf2-dependent antioxidant 
genes that functions to degrade heme. This would again indicate differential molecular signaling 
pathways of how Ro and PK exert varying effects on not only pro-inflammatory genes and 
cytokine release (Choi et al 2011), but also in cytoprotective genes such as HO-1. Here, the 
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induction of Nrf2 translocation was consistent across both ligands, although Ro induced greater 
levels of Nrf2 translocation into the nucleus as compared to PK.  
Additionally, our data obtained in the J7774 macrophage cell line indicates that the LPS 
induced increase in ROS production, seen at 3 hours, precedes the increase in TSPO protein 
expression, seen by 24 hours (S. Figure 1 and 2). It is possible the increase in ROS seen at 3 hours, 
activates Nrf2 (Figure 4) whose translocation is observed by 24 hours. Nrf2 may initially induce 
expression of anti-oxidant genes. However, after sustained exposure to LPS or TSPO-L, and 
therefore prolonged exposure to ROS levels (elevated ROS levels are still seen at 24 hours), other 
transcription factors may also be activated in addition to Nrf2. For example, Novo and Parola 
(2008), propose a model in which at low levels of ROS exposure Nrf2 is translocated into the 
nucleus to induce an antioxidant response; at intermediate levels of ROS, either NF-kB can be 
translocated into the nucleus for a pro-inflammatory and adaptive response or AP-1 can be 
activated for an anti-apoptotic and survival response; and at high levels of ROS, the cell can die 
either through induction of apoptosis or irreversible cell injury that results in death. It is possible 
that after 24 hours of exposure to LPS, the macrophages are beginning to or have already 
transitioned to the recruitment of other transcription factors such as NF-kB and AP-1. Multiple 
studies have shown that LPS exposure in microglia increases NF-kB and AP-1 protein expression 
at time points earlier than 24 hours (Zhao et al 2011; Kang et al 2004; Chen et al 2005). Thus, in 
cases where TSPO becomes upregulated in pathological conditions, the ROS levels have 
overwhelmed the anti-oxidant response system and this is why we see activation of additional 
transcription factors such as NF-kB and AP-1, and ultimately upregulation of TSPO protein levels 
in response to inflammatory agents such as LPS. Using TSPO-L concentrations consistent with 
their affinity is more reflective of what is happening in physiological, non-activated conditions. 
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Further studies examining the time course of the activation of various transcription factors will be 
useful in further characterizing the activation of microglia by TSPO-L. Additionally, studies 
examining ROS levels and TSPO levels within the same cell as can be done via flow cytometry 
will help further elucidate the relationship between TSPO and NADPH oxidase derived ROS in 
microglia.  
Taken together, our findings suggest that the binding of PK or Ro to TSPO in microglia 
induces ROS production that is NADPH oxidase dependent as ROS levels can be abrogated with 
NADPH oxidase inhibitors and upregulated through co-exposure of NADPH oxidase activators 
and TSPO-L. The source of ROS appears to be from NADPH oxidase and not from the 
mitochondria indicating a relationship between TSPO and NADPH oxidase in microglia. We 
provide supporting evidence for TSPO-L’s induction of Nrf2 translocation and may play a role in 
initiating cellular mechanisms to help maintain redox homeostasis.  
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A. B. 
FIGURE 1: TSPO ligands & extracellular ROS production. 
A) TSPO-L induced NADPH oxidase-dependent extracellular ROS production. Primary microglia
were exposed to (R)-PK11195 (10 nM), Ro-5-4864 (10 nM) or LPS (100 ng/mL) for 24 hrs with
or without the NADPH oxidase inhibitor apocynin (1mM). The level of extracellular ROS
production was compared to vehicle-treated microglia. Exposure to TSPO-L increased the level of
extracellular ROS production, and this effect was mitigated by the NADPH oxidase inhibitor,
apocynin (1 mM) (LPS: t=2.625; p=0.0342. PK: F(2,12)=6.543, p=0.015. Ro: F(2,13)=5.475;
p=0.019). Data are normalized to vehicle and expressed as mean ± s.e.m.  n = 3-6 independent
experiments. Bars with different letters are significantly different at p < 0.05.
B) Co-exposure of TSPO-L and phorbol 12-myristate 13-acetate (PMA) produced increased levels
of extracellular ROS production in primary microglia. Co-exposure of 10 nM TSPO-L with PMA
(100 ng/mL for 1 hour), a NADPH oxidase activator, enhanced extracellular ROS production
compared to vehicle-treated and PMA-treated microglia (n=3; PK: F(2,6)=122.3; p<0.0001; Ro:
F(2,6)=175.0; p<0.0001). TSPO-L enhance the effects of NADPH oxidase activation supporting a
relationship between TSPO and NADPH oxidase. Data are normalized to vehicle and expressed
as mean ± s.e.m.  n = 3 sets of independent experiments. Bars with different letters are significantly
different at p < 0.05.
N.B. Experiments in this figure completed by Dr. Judy Choi 
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A. B.
FIGURE 2: TSPO ligands induce extracellular and intracellular ROS production that 
cannot be inhibited by the mitochondrial permeability transition pore inhibitor, cyclosporin 
A. TSPO-L induced ROS production was not inhibited by cyclosporine A (1 µM for 24 hours),
neither extracellularly (A, n=3-4; PK: F(2,6)=10.73; p=0.0104; Ro: F(2,8)=6.12; p=0.0244) nor
intracellularly (B), n=3; PK: F(2,6)=13.86; p=0.0056; Ro: F(2,6)=9.945; p=0.0124), indicating that
the source of ROS is not from the mitochondria. Data are normalized to vehicle and expressed as
mean ± s.e.m. n = 3-6 sets of independent experiments. Bars with different letters are
significantly different at p < 0.05.
N.B. Experiments in this figure completed by Dr. Judy Choi 
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A. B. 
FIGURE 3: TSPO ligands do not increase mitochondria-dependent superoxide production.  
A) Exposure (2 hrs) of microglia to physiologically relevant (10 nM) concentrations of TSPO-L
did not produce an increase in mitochondrial superoxide, whereas mitochondrial electron transport
chain inhibitors antimycin A (2 μM) (AA) and rotenone (500 nM) (Rot) produced an enhanced
mitochondrial-ROS response. Bars with different letters are significantly different from each other
at p < 0.05. Data are expressed as the mean ± SEM of 3-4 independent experiments.
B) Time-course of mitochondria-dependent ROS production in primary microglia. TSPO-L did
not produce an increase in mitochondrial superoxide at any of the time points examined (2, 4, 8,
18, or 24 hours), whereas mitochondrial electron transport chain inhibitors antimycin A and
rotenone produced statistically significant increases in mitochondrial superoxide at all time points
examined. (2hrs: F(4,13)=6.164; p=0.005. 4hrs: F(4,15)=8.940; p=0.001. 8hrs: F(4,11)=3.430; p=0.047.
18hrs: F(4,10)=4.929; p=0.019. 24hrs: F(4,23)=4.561; p=0.007. n = 3-6 independent experiments per
time point) *p<0.05 compared to vehicle-treated microglia which is represented by the dashed






























FIGURE 4. TSPO-ligands induce the translocation of the anti-oxidant transcription factor, 
Nrf2, to the nucleus.  
A) Microglia exposed to physiologically relevant concentrations of TSPO ligands (1, 10, or 100
nM of (R) PK-11195 or Ro5-4864 for 24 hours demonstrated increased Nrf2 levels in the nucleus
as compared to the cytosol relative to vehicle treated cells (F(8,1602)=19.774, p<0.0001)
B) Sulforaphane, a potent Nrf2 activator, was used as a positive control and to assess the time
course of Nrf2 translocation in microglia.
C) Selected images of microglia demonstrating increased Nrf2 labeling in the nucleus of LPS
and TSPO-L treated cells as compared to control (20x and 63x inset). Under oxidative stress,
Keap-1 releases Nrf2, which exposes Nrf2’s nuclear localization signal. In the nucleus, Nrf2
binds to the antioxidant response element (ARE), which induces the transcription of various




Supplementary FIGURE 1. TSPO-ligands induce intracellular and extracellular 
ROS production in a macrophage cell line. To assess whether our finding of TSPO-L induced 
ROS production was specific to microglia, we examined ROS production in a macrophage 
cell line J774. These cells are known to express and upregulate TSPO. At both 3 hours 
(F(5,18)=11.219; p<0.001) and 24 hours ((F(5,19)=10.400; p<0.001), TSPO-L induced an increase 
in extracellular ROS production (A and B). Intracellular ROS production also increased 
at both 3 hours (F(5,19)=3.792; p=0.022) and 24 hours (F(5, 20)=3.750; p=0.021), but had a 
slightly different trend based on ligand dose and time point examined (C and D).  
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Supplementary FIGURE 2. TSPO protein expression in J774 macrophages at 3 & 24 hours.
TSPO protein levels increased with 24 hour LPS exposure compared to 24 hour control cells. 
TSPO protein levels did not differ between 3 hour control and LPS treated cells. This data 
indicates that increases in ROS production precede increases in TSPO protein levels (3 hour 
time point), and that ROS levels remain elevated at a time when TSPO protein levels have been 
increased (24 hour time point). A more thorough time course will be required to elucidate the 
exact nature of the relationship between ROS levels and TSPO protein levels.  
N.B. Transfection and Western blot completed by and courtesy of Dr. Chun Zhou. 
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ABSTRACT 
Translocator Protein 18 kDa (TSPO) is a glial stress response protein that is widely used as a 
biomarker of brain injury and neuroinflammation in preclinical and clinical neuroimaging. TSPO 
ligands have been shown to impart beneficial therapeutic effects in animal models of neurological 
disease.  However, there is a paucity of knowledge on the function(s) of TSPO in glial cells, the 
cells that upregulate TSPO levels in diverse pathologies.  Recent studies using conditional and 
global TSPO knockout mice have questioned the role of TSPO in translocating cholesterol across 
the outer mitochondrial membrane as the first step in steroidogenesis.  Here, we report a novel 
interaction of TSPO with NADPH oxidase in microglia that implicates the production of reactive 
oxygen species for modulation of redox homeostasis.   
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1. INTRODUCTION
Translocator Protein 18 kDa (TSPO) is a clinical neuroimaging biomarker of brain injury 
and neuroinflammation that is able to detect diverse brain pathologies (Chen & Guilarte 2008; 
Papdopoulos et al 2006; Liu et al 2014). TSPO levels are low, nearly undetectable in the normal 
brain neuropil, but they increase markedly and selectively at primary and secondary sites of brain 
injury and neuroinflammation (Chen & Guilarte 2008).  In this way, TSPO can be used to evaluate 
the neurotoxicity of various environmental compounds and to track neuroinflammation in a 
multitude of neurological diseases that include an inflammatory component such as Alzheimer’s 
disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), traumatic brain injury, multiple 
sclerosis, and Zika virus infections, amongst many others (Zimmer et al 2014; Gerard et al 2006; 
Zurcher et al 2014; Couglin et al 2015 & 2017; Politis et al 2012; Kuszpit et al 2017). 
The cellular framework for TSPO as a biomarker is based on the activation of microglia 
and astrocytes, the glial cell types that express and upregulate TSPO levels following nervous 
system insults (Chen & Guilarte 2008; Kuhlmann & Guilarte 1999; Maeda et al 2007).  During 
the last several decades, a number of diverse functions have been attributed to TSPO, including 
the transport of cholesterol into mitochondria as the rate limiting step in steroidogenesis; regulation 
of the mitochondrial permeability transition pore (MitoPTP); reactive oxygen species (ROS) 
production; and porphyrin/heme transport, amongst various other functions (Papadopoulos et al 
1997; Chen & Guilarte 2008; Veenman et al 2008; Sileikyte et al 2010; Batako et al 2015).  Further, 
an early report claimed that knocking out Tspo in mice was embryonic lethal (Papadopoulos et al 
1997).  However, new evidence has emerged that has questioned the dogma that deleting Tspo is 
embryonic lethal and whether TSPO plays an essential role in steroidogenesis or regulates the 
MitoPTP.  Several studies have now shown that TSPO knockout (KO) mice are viable, and that 
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TSPO is not required for steroidogenesis (Banati et al 2014; Morohaku et al 2014; Tu et al 2014;) 
and does not participate in the regulation of the MitoPTP (Sileikyte et al 2014).  Structural biology 
data also shows that oligomerization of TSPO is unlikely to form a pore for cholesterol transport, 
as previously proposed (Li et al 2013).  Thus, different lines of investigation provide evidence to 
support the notion that TSPO may not be directly involved in steroidogenesis.  Understanding the 
functional significance of TSPO upregulation in glial cells under conditions of diverse 
neuropathologies is important in order to advance our understanding of glial cell biology.  Further, 
insight into TSPO function may provide new avenues for devising therapeutic strategies for 
mitigating or modulating neuroinflammation, a common pathology in many neurodegenerative 
disorders.  
Microglia are the resident immune cells of the brain with an ability to sense and respond 
to cellular signals resulting from disruption of brain homeostasis (Hanisch et al 2007; Salter & 
Beggs 2014; Liu et al 2014).  Microglia have a hallmark morphological response and markedly 
increase TSPO levels shortly after brain injury with a time course that is dependent on the type 
and degree of injury (Chen & Guilarte 2008; Maeda et al 2007).  Although TSPO appears to play 
a role in the neuroinflammatory response (Beckers et al 2018; Lavisse et al 2012), there is a lack 
of knowledge on the precise molecular mechanism(s) and function(s) of TSPO in the inflammatory 
response of microglia. Consistent with the notion of a role of TSPO in immune activation, recent 
studies in Tspo-/- mice (versus Tspofl/fl) indicate that the majority of the differentially expressed 
genes were related to the immune response (Jamin et al 2005; Rone et al 2009; Tu et al 2014; Fan 
et al 2015; Taylor et al 2014; Gatliffe & Campenella 2016) providing additional support to a 
functional connection with inflammation.  Further, examination into the microglial phenotype that 
is involved in TSPO upregulation indicates that in M1 proinflammatory microglia, TSPO 
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expression increases, whereas in M2 anti-inflammatory microglia, TSPO expression remains 
constant (Beckers et al 2018). While there is some evidence that overexpression of TSPO increased 
expression of alternatively activated M2 stage related genes, these studies were done in the 
transformed cell line of BV-2 microglia, and therefore may not be as biologically representative 
as studies done in primary microglia (Bae et al 2014).  
Microglia exposed to physiologically relevant concentrations (nM) of TSPO-specific 
ligands increase ROS production that is abrogated by different types of NADPH oxidase (NOX2) 
inhibitors (Choi et al 2011).  These experiments provided the first evidence of a potential 
relationship between TSPO and NOX2 in microglia.  NOX2 is a major source of ROS production 
in the central nervous system, and similar to TSPO, NOX2 is highly enriched in microglia.   
(Nayernia et al 2015; Papadopoulos et al 2006).  NOX2 is a multi-subunit enzyme composed of 
the cytosolic subunits p40phox, p47phox, p67phox, the small G-protein Rac1, and the plasma 
membrane subunits p22phox and gp91phox. The plasma membrane subunit gp91phox is processed and 
matured in the endoplasmic reticulum (ER) via the incorporation of two heme molecules into its 
precursor gp65, followed by glycosylation to form the mature form of gp91phox (Yu et al 1997, 
1998, and 1999; DeLeo et al 2000).  In the ER, the mature gp91phox is then able to dimerize with 
p22phox to form flavocytochrome b558 (Cytb558), the main subunit of NOX2 (DeLeo et al 2000; 
Yu et al 1997, 1998, and 1999).  This heterodimer traffics to relevant locations within the secretory 
pathway to membrane compartments and lipid rafts. In phagocytes such as neutrophils and 
macrophages, activation of NOX2 occurs when a stimulus promotes the phosphorylation of 
p47phox.  The cytosolic subunits subsequently translocate to the membrane where they assemble 
with Cytb558 to form a membrane-bound complex to generate superoxide (Yu et al 1998).  Studies 
have shown that cholesterol is also needed for the NOX2 cytosolic subunits to translocate to the 
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plasma membrane or lipid rafts in order to form an active NOX2 complex (Vilhardt et al 2004; 
Shao et al 2003).  Therefore, a potential interaction of TSPO with NOX2 may be based on the 
ability of TSPO to bind cholesterol (Li et al 1998) and heme (Taketani et al 1995; Vanhee et al 
2011) both of which are required to form an active NOX2 complex.  In this study, we provide new 
evidence of a direct molecular interaction between TSPO and NOX2 in microglia that may form 
the basis for the regulation of NOX2-dependent reactive oxygen species (ROS) production for 
redox homeostasis. 
2. MATERIALS & METHODS
2.1 Primary microglia cell culture:  Primary mixed glial cell cultures were prepared using a 
modified version of the glial culture technique as previously described with PN 1-3 C57/Bl6 mouse 
pups (Gordon et al 2011; Giulian & Baker 1986).  At 12-14 days, microglia were separated from 
the glial cultures by shaking the flasks for 3 hours at 120 r.p.m. and collected as floating cells in 
the media. After centrifugation for 10 minutes at 400 x g, cell viability was determined by trypan 
blue exclusion, and cells were plated at various densities according to the assay being tested. 
Around 94% of the adherent cells were positive for microglia-specific marker Mac-1 as determined 
by immunostaining. Cells rested overnight (16-20 hours) before any dosing or assays were 
performed. The animals used for this study had been treated humanely as all the animal studies 
were reviewed and approved by each institutions Animal Care & Use Committee.  
2.2 Treatments: Bacterial lipopolysaccahride (LPS) was dissolved in phenol red free media to 
create a stock solution of 1 mg/mL.  A solution of 100 ng/mL of LPS was made fresh for each 
experimental exposure.  Microglia were exposed to 100 ng/mL of LPS for time of exposure 
indicated.  
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2.3 Antibody Validation via gene silencing by spinoculation using shRNA lentiviral particles: 
Validation of TSPO, gp91, and p22 antibodies was performed using shRNA transduction in J7774 
cells a gift from Dr. Martin Pomper’s laboratory. All shRNAs and empty vectors (EV) used in this 
study were from Sigma MISSION. (St. Louis, MO). Clones tested included TSPO: 
TRCN00000102106 (#102106); TRCN00000102107 (#102107); TRCN00000102109 (#102109). 
gp91 (Cybb): TRCN00000435339 (#435339); TRCN00000422819 (#422819); 
TRCN00000240564 (#240564). p22 (Cyba): TRCN00000240562 (#240562); 
TRCN00000240565 (#240565); TRCN00000011889 (#011889). Clones #102106 (TSPO), 
#435339 (gp91), and #240565 (p22) results are pictured in Figure 1A. A suspension of 100,000 
cells/ml was treated with 8 μg/ml of hexadimethrine bromide (107689, Sigma, St. Louis, MO), 
exposed to lentiviral particles at a multiplicity of infection (MOI) of 15, centrifuged at 800xg for 
30 min at room temperature. Cells were then resuspended and plated at a density of 20,000 
cells/well. After 48 hr, cells were selected by 1 μg/ml puromycin (A11138, Invitrogen, Carlsbad, 
CA) for 4.5 days to select for cells which had been transduced. After puromycin selection, cells 
were put in fresh media for 7 days before being harvested for Western blot.  
2.4 Transgenic mice: The animal procedures described in this study were approved by Florida 
International University Institution Animal Care & Use Committee. Mice heterozygous for 
translocator protein kDa (TSPO) were obtained from Helmholtz Zentrum Munich (GMC) as part 
of the International Mouse Phenotyping Consortium (IMPC) and INFRAFRONTIER/European 
Mouse Mutant Archive (EMMA). TSPO tm1b mice were produced on a C57BL/6NTac 
background and mice were produced by treating 2-cell embryos with Cre enzyme as described 
previously (Ryder et al., 2014). Tm1b allele embryos have a reporter-tagged deletion allele (post-
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Cre). Critical exons, in this case exons 2 and 3 of Tspo, are deleted by creating a frame shift using 
the Cre method. 
2.5 Immunoprecipitation & Western Blots: Cells were plated onto 60-mm dishes at a density of 
500,000 cells per dish. Cells were harvested in a mild lysis buffer containing 0.2 mM sodium 
orthovanadate, 5 mM sodium fluoride, 0.5% NP-40, 2.5 mM EDTA, 150 mM potassium chloride, 
and 10mM Tris, pH 7.4 (adapted from (Miao & Degterev, 2009). Multiple microglia extractions 
were combined in order to load 415 ug protein per treatment condition for each 
immunoprecipitation experiment. Cells were harvested for whole cell protein levels using the same 
method of Brewer et al 2007. Protein concentration was determined using the Lowry assay. 
For each immunoprecipitation experiment, cell lysates were pre-cleared by incubating the lysate 
with IgG beads for 2 hours to eliminate any nonspecific binding to beads. Samples were then 
incubated with the anti-TSPO antibody (Abcam, ab109497, 1:10) overnight at 4˚C. Next, lysate 
was incubated for 2 hours with 200 uL of Protein G Dynabeads to allow the Fc region of the 
antibody to bind to the IgG coated beads. All immunoprecipitation-related incubations were 
performed at 4˚C. A sample of the initial lysate was retained for analysis of total protein and is 
referred to as the “input” fraction.  Proteins were separated on 4-15% TGX Precast Gels, (Biorad, 
Hercules, CA.) and transferred to polyvinylidene difluoride (PVDF) membranes. For non-
immunoprecipitation samples (i.e. the Input fraction), 25 ug of protein were loaded per condition 
per lane. Immobilon-FL PVDF Western blot membranes (EMD Millipore IPFL00010) were 
incubated with corresponding primary antibodies: goat anti-TSPO (Abcam, ab118913, 1:1000); 
rabbit anti-TSPO (Abcam, 109497, 1:1000); mouse anti-gp91phox (BD Transduction Laboratories, 
611415, 1:200); mouse anti-p22phox (Santa Cruz, sc-130551, 1:100); rabbit anti-mouse VDAC 
(Abcam, ab15895, 1:500). Quick Western Kit-IRDye 680RD was also used as it does not bind to 
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denatured mouse or rabbit monoclonal antibodies. Standard Western blot LICOR secondary 
antibodies (IRDye 800 CW Donkey anti-Mouse and IRDye 680LT donkey anti-rabbit, 1:10,000) 
were also used to confirm specificity of Quick Western Kit IRDye 680RD.   
2.6 Gene Expression & RT-PCR: Gene expression for Tspo, Cybb, Cyba,, VDAC1, and GAPDH.  
RNA was isolated from primary mouse microglia cells treated with vehicle or 100ng/mL of LPS 
for 18 hours by using RNAqueous Micro Kit (AM1931, Invitrogen, Carlsbad, CA). RNA content 
was measured using NanoDrop spectrophotometer (Thermo Scientific, United States). Reverse 
transcription of RNA was performed with High-Capacity RNA-to-cDNA kit (Applied Biosystems, 
Invitrogen, Carslbad, CA). qRT-PCR was performed using 1ul of cDNA diluted to 20ng/ul, 
TaqMan multiplex master mix (Applied Biosystems, Invitrogen, Carslbad, CA) and TaqMan 
mouse primers into a final reaction of volume of 10ul. Primers used included: TSPO 
(Mm00437828_m1-FAM-MGB); Cybb (Mm01287743_m1-FAM-MGB); Cyba 
(Mm00514478_m1-FAM-MGB); Vdac1 (Mm00834272_m1-FAM-MGB); and GAPDH 
(Mm999999915_g1-VIC-MGB). The results were evaluated using QuantStudio Real-Time PCR 
Software v1.3. Amplification specificity was confirmed by melting curve analysis and the 
quantification was carried out using the ΔΔCt method (Schmittgen & Livak, 2008). All samples 
were normalized to GAPDH. Data is 6 independent experiments run on the same plate for each 
gene. All samples were run in triplicate. 
2.7 Immunocytochemistry: 100,000 microglia were plated onto PLL glass coverslips (Fisher 
Scientific, 08-774-383) in 12 well plates. Cells were treated for 18 hours with vehicle (media) or 
100 ng/mL lipopolysaccharide (LPS) in media supplemented with 2% FBS. Immunocytochemistry 
was performed via conventional techniques: fixing cells with 4% paraformaldehyde; 
permeabilizing cells with 0.2% Triton; blocking with 10% normal donkey serum (Jackson 
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Laboratories, Bar Harbor, ME) for 3 hrs before being incubated with primary antibodies:  goat 
anti-TSPO (Abcam, ab118913, 1:500); mouse anti-gp91phox (BD Transduction Laboratories,  
611415, 1:100); mouse anti-p22phox (Santa Cruz, sc-130551, 1:100); rabbit anti-mouse VDAC 
(Abcam, ab15895, 1:500). After washing, cells were incubated with appropriate Alexa Fluor 
secondary antibodies for 1 hr  (Life Technologies; AF 488, 594, and 647, 1:500). Cells were 
mounted with Prolong with DAPI (Life Technologies) to counterstain for nuclei. 
2.8 Immunohistochemistry. Free-floating brain sections from PFA-perfused mice were sectioned 
using a freezing microtome (Leica Microsystems Inc., Bannockburn, IL).  For 
immunofluorescence triple labeling of Mac-1, TSPO, and gp91phox, free-floating brain sections 
were blocked with 5% normal donkey serum containing 0.2% Triton X-100 for 1 hour followed 
by primary antibody incubation: rat-anti-Mac-1 (BD Pharmigen; 1:250), rabbit-anti-TSPO 
(Abcam; ab109497, 1:500), and goat-anti-gp91phox (Santa Cruz, (sc-5827) 1:150) at 4°C overnight. 
Sections were incubated with appropriate Alexa Fluor secondary antibodies (Life Technologies; 
1:500). 
2.9 Immunofluorescence Imaging and Analysis. Immunofluorescence-labeled cells were 
imaged at 60x magnification with a 1.6x zoom using a laser scanning confocal microscope 
(Fluoview FV10i, Olympus, Center Valley, PA), utilizing the FV10 image software. All coverslips 
stained under the same conditions were imaged using the same scanning parameters on the same 
day. Five to six confocal stacks were obtained for each experimental condition with at least 25 
cells counted per condition. Confocal stacks were projected into single images using the maximum 
fluorescence. All images were analyzed using Metamorph Offline (Molecular Devices, 
Downington, PA). The threshold level was kept at the same level for analysis in images obtained 
from the same experiment for each channel. For colocalization analyses, gray scale images of each 
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wavelength (each protein) were used to examine the area of colocalized pixels of both wavelengths 
to calculate the percent colocalization of their signals. Percent colocalization was calculated as 
previously described by Stansfield et al 2012. Briefly, Colocalization of Protein A with Protein B 
= Area (A with B) / Total Area (A) where A and B are individual wavelengths for the same image. 
To assess colocalization of 3 proteins (Proteins A, B, and C), a binary image was created where 
when A and B colocalized, a pixel was generated. This was done for the entire image to create 
image AB’ representing pixels where A and B colocalized. The colocalization of proteins (A+B) 
with C was then quantified using images AB’ and C.  
2.10 Duolink Proximity Libation Assay. Duolink experiments were performed according to 
manufacturer’s instructions with minor modifications (Sigma, Duolink In Situ Detection Reagents 
Red, DUO92008). After vehicle or LPS treatment, cells were fixed with 4% paraformaldehyde. 
Cells were permeabilized with 0.2% Triton for 25 minutes and  blocked with 10% normal donkey 
serum before being incubated for corresponding primary antibodies for 72 hours at 4˚C: goat anti-
TSPO (Abcam, ab118913, 1:500); mouse anti-gp91phox (BD Transduction Laboratories, 611415, 
1:200); mouse anti-p22phox (Santa Cruz, sc-130551, 1:100); rabbit anti-mouse VDAC (Abcam, 
ab15895, 1:500). After washing, cells underwent exposure to PLA Probes (Goat PLUS and Mouse 
MINUS; or Goat PLUS and Rabbit MINUS); ligation solution, and amplification solution as per 
manufacturer’s instructions.  
2.11 Immuno-Electron Microscopy for TSPO labeling of microglia: 
Microglia were plated at a density of 500,000 in a 6 cm plate. Cells were treated with either vehicle 
or LPS (100 ng/mL) for 18 hrs. Following exposure, media was removed and cells were fixed with 
0.1% glutaraldehyde (GRA) + 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB) for 
60 m. Cells were rinsed, cryoprotected and placed in a -80 C freezer for 30 m. Cells were allowed 
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to thaw in chilled cryoprotectant, which was removed by using subsequent changes of increasingly 
diluted cryoprotectant. Cells were blocked in 10% Normal Goat Serum with 0.1% Bovine Serum 
Albumin in PB for 1 h. Cells were then incubated in rabbit anti-TSPO (Abcam, MA, USA) at a 
1:100 dilution for 24 hr at RT followed by an incubation at 4 C for 48 h. Cells were washed then 
incubated in a 1:100 dilution of goat-anit-rabbit 1.4 nm gold particle conjugated secondary 
antibody (Nanoprobes, NY, USA) for 2 h at RT. Secondary antibody was rinsed and gold particles 
were enhanced using HQ silver enhancement (Nanoprobes, NY, USA) for 2 m. Silver 
enhancement was removed, and cells were fixed in 2.5% GTA for 30 m. GTA was rinsed off and 
cells were post-fixed in 1% osmium tetroxide for 20 m. Osmium was rinsed and cells were 
dehydrated using successively increasing concentrations of ethanol, including a 70% mixture of 
ethanol with uranyl acetate to increase membrane contrast. After cells reached 100% ethanol, they 
were gently scraped from the dish and spun down at 800 g for 10 m. Cells were placed in the 
transition solvent propylene oxide and left overnight in a 1:1 mixture of propylene oxide and 
Spurr’s low viscosity resin (Electron Miscroscopy Sciences, PA, USA). Cells were transferred to 
pure SPurr Resin for 24 h then allowed to polymerize in fresh resin for 8 h at 70 C. Resin blocks 
were cut from microfuge tubes and sectioned to a thickness of ~60 nm. Floating sections were 
picked up on a 200 mesh copper grids, counterstained with lead citrate for 5 m and examined under 
a FEI Ecnai Spirit Transmission Electron Microscope (FEI, OR, USA) operated at 60 kV.   
2.12 Data analysis:  Values are expressed as mean ± standard error of the mean (SEM).  Student’s 
paired t-tests were performed for Western Blot analyses and colocalization analyses. A two-way 
measure of analysis of variance was performed for colocalization analysis between wildtype and 
Sandhoff mice at 4 different ages. For all tests, significance level was set at p < 0.05. Outliers 
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determined to be greater than or less than two standard deviations above or below the mean were 
excluded. For percent vehicle values, statistics were run on log-transformed values.  
3. RESULTS
3.1 Co-immunoprecipitation of TSPO, gp91phox, p22phox, and VDAC: To explore the 
relationship between TSPO and the NOX2 subunits gp91phox and p22phox, we performed TSPO 
immunoprecipitation experiments in primary mouse microglia using antibodies independently 
validated in our lab (Figure 1) under both LPS activated and non-activated conditions. Our primary 
murine microglia cultures are approximately 94% pure as determined by Mac-1 immunostaining 
(Figure 2), and LPS concentration and duration of exposure were determined to be non-cytotoxic 
to microglia (Figure 3).   We used voltage-dependent anion channel (VDAC) as a positive control 
for the TSPO immunoprecipitation studies because TSPO and VDAC have been shown to 
colocalize and co-immunoprecipitate (McEnery et al 1992; Gatliffe et al 2014).  Figure 4, panels 
A and B show that TSPO, gp91phox, and p22phox protein levels in the input fraction (whole cell 
lysate) increase significantly following LPS activation (100 ng/mLfor 18 hr) of microglia relative 
to non-activated conditions.  VDAC protein levels did not change with microglia activation.  This 
pattern of protein expression with activated microglia is consistent with gene expression changes 
determined by quantitative real-time PCR (Figure 4, panel C).  Panels D and E in Figure 4 depict 
TSPO immunoprecipitation results probing for the presence of TSPO, gp91phox, p22phox, and 
VDAC protein. Western blot of the TSPO-immunoprecipitated fraction shows that gp91phox, 
p22phox, and VDAC co-immunoprecipitate with TSPO providing the first direct evidence of 
protein-protein interactions with NOX2 subunits.  When we compared the level of these proteins 
in LPS activated vs non-activated microglia, we found a significant decrease in gp91phox and 
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p22phox protein levels that co-immunoprecipitated with TSPO, with no change in VDAC protein 
levels (Figure 4, panel E).  Overall, these findings indicate that gp91phox and p22phox are associated 
with TSPO, and that this interaction is partially disrupted by LPS activation.   
3.2 Immunofluorescence confocal imaging studies: To further confirm the TSPO-NOX2 subunit 
interaction, we performed triple-labeled immunofluorescent confocal imaging studies of TSPO, 
gp91phox, p22phox, and VDAC in non-activated and LPS activated microglia.  Figure 5 shows 
TSPO’s colocalization with gp91phox, p22phox, or VDAC, in Mac-1 labeled microglia at both high 
and low magnification.  These images show extensive colocalization of TSPO with gp91phox, 
p22phox, and VDAC. Figure 8 depicts a summary view of the quantification of the colocalization 
of TSPO with gp91phox, p22phox, VDAC, and LAMP-2 confocal imaging (representative images 
used for colocalization quantification are in Figure 6 and Figure 7). The percent colocalization of 
TSPO with gp91phox, p22phox, and VDAC ranged from approximately 60-80%, whereas TSPO’s 
colocalization with the lysosomal marker, LAMP-2 was approximately 20% (Figure 8, Panel A).  
When we compared the colocalization of TSPO with the NOX2 subunits and VDAC in LPS 
activated versus non-activated primary microglia, we again observed an effect of microglia 
activation on these protein-protein interactions similar to the co-immunoprecipitation studies. The 
percent of gp91phox or p22phox that colocalized with TSPO decreased significantly from 
approximately 60% to 40% in activated versus non-activated microglia (Figure 8, Panel B).  A 
similar effect was observed with VDAC suggesting that a putative TSPO-gp91phox-p22phox-VDAC 
complex is disrupted when microglia are activated with LPS (Figure 8, panel B).  Moreover, when 
we analyzed the fraction of the TSPO-p22phox, or TSPO-gp91phox colocalization that also 
colocalizes with VDAC, we observed the same decrease with LPS activation (Figure 8, panel C).  
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(Additional colocalization analyses are depicted in Figure 9). These findings suggest that under 
non-activated conditions, there is a TSPO complex with gp91phox and p22phox that is associated 
with VDAC.  However, when microglia become activated, a significant fraction of gp91phox and 
p22phox appears to dissociate from TSPO. This dissociation may reflect the movement of gp91phox 
and p22phox (possibly as a Cytb558 complex) to other subcellular compartments, such as lipid rafts 
or the plasma membrane, to form an active NOX2 complex with the cytosolic subunits.  
3.3 Proximity Ligation Assay supports a TSPO-NOX2-VDAC interaction in microglia: To 
provide further validation and scientific rigor and of a TSPO-gp91phox-p22phox-VDAC complex in 
microglia, we used a proximity ligation assay (PLA) approach.  This is a powerful and sensitive 
method that can detect protein-protein interaction(s) in the native state of cells when proteins are 
in close proximity to each other, in this case about 40 nm apart (Bagchi et al 2015; Fredriksson et 
al 2002; Gullberg et al 2004).  Briefly, samples are incubated with primary antibodies to bind to 
the two proteins of interest. Secondary antibodies conjugated with positive and negative 
oligonucleotides (PLA probes) are then incubated with the samples.   Next, ligase and two 
additional oligonucleotides are introduced. These oligonucleotides will hybridize to the PLA 
probes, and if in close enough proximity (~40 nm), form a closed circle. In the DNA circle, one of 
the antibody conjugated DNA probes serves as a primer for rolling circle amplification (RCA) and 
a repeated sequence (concatemeric) product is generated when DNA polymerase and nucleotides 
are added. Fluorescently labeled oligonucleotides proceed to bind to the RCA product and 
ultimately allow visualization of the protein-protein interaction via fluorescence microscopy. 
Figure 10, Panels A-C depict confocal images of TSPO-gp91phox, TSPO-p22phox and TSPO-VDAC 
interactions respectively using PLA in overlay with phase imaging of microglia. The different 
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protein-protein interactions are clearly visible throughout the cell providing further support of 
direct interactions of TSPO with gp91phox, p22phox, and VDAC.  Figure 10, Panels D-F depict the 
PLA quantitative results.  Notably, it appears that the rank order of the degree of the colocalization 
of TSPO with gp91phox followed by p22phox and VDAC are similar in both the 
immunocytochemistry results (see Figure 8, panel A) and the proximity ligation assay results (see 
Figure 10, panels D-F). Unlike the co-immunoprecipitation and immunofluorescence confocal 
imaging studies, we did not observe an effect of LPS activation in decreasing the number of TSPO-
NOX2 interactions.  The lack of the difference between vehicle and LPS activated cells in the 
degree of protein-protein interactions in the PLA assay could be due to several reasons. First, the 
primary antibody concentration is specifically optimized to detect a portion of the interactions 
occurring within the cell, but not all of the interactions occurring in the cell. The purpose of not 
detecting all interactions is so that we can detect positive PLA signals, without the fluorescent 
signals coalescing, which would prevent quantification of the signal and full resolution of the 
subcellular localization of where the interaction is occurring. Since PLA is a highly sensitive 
method of protein-protein interaction detection, we still detect the interactions that are present, but 
are no longer detecting the difference in the degree of the interaction between the two treatments. 
This is in contrast to the co-immunoprecipitation and whole cell confocal imaging data that detect 
these proteins in the entire cell versus the PLA only detecting a fraction on the total protein-protein 
interactions.  Additionally, Jalili et al 2017 published a paper examining how the kinetic properties 
of antibodies can affect PLA performance.  More specifically, the Kc of an antibody affected the 
limit of detection in that low-affinity antibodies had higher limits of detection and high affinity 
antibodies had lower limits of detection. Therefore, if one of the antibodies we are using has a 
different Kc than another, it is not appropriate to compare the degree of interactions across the 
154
three sets of experiments of gp91phox, p22phox, and VDAC given that the affinity of the antibodies 
could affect PLA performance. Nevertheless, the PLA method also confirmed that TSPO interacts 
with the NOX2 subunits and VDAC.   
3.4 What are the subcellular localization(s) of a TSPO-NOX2 subunit interaction in 
microglia?  It is known that TSPO and VDAC are present at the outer mitochondrial membrane 
and that gp91phox and p22phox mature and form the Cytb558 heterodimer in the ER.  We have 
proposed that these proteins are interacting at the mitochondria-associated endoplasmic reticulum 
(ER) membrane or MAM (Guilarte et al 2016).  To examine whether TSPO is found at the MAM, 
we performed immuno-electron microscopy of TSPO in LPS-activated and non-activated primary 
microglia.  Figure 11 depicts images of microglia under normal culture conditions in Panel A, and 
after LPS exposure in Panel B.  Overall, there is an increase in TSPO labeling in the mitochondria 
(see yellow stars) as well as in other subcellular compartments such as the plasma membrane 
(arrows in panel B) in LPS-activated microglia.  Panels C and D are higher magnification images 
of non-activated microglia indicating high TSPO levels in the outer mitochondria membrane and 
at the MAM (see arrows in panel C) as well as in the ER (yellow arrow heads in panel D) and at 
or just below the plasma membrane (arrows in panel D).  This figure demonstrates that while TSPO 
is highly expressed in the outer mitochondria membrane, it is also expressed in other cellular 
compartments including the MAM (large, thick arrows in Figure 11, panel C).   
3.5 The TSPO-NOX2 interaction also occurs in murine brain tissue: The studies presented so 
far have been performed in primary microglia cultures. To show that the TSPO-NOX2 interaction 
is not merely an epiphenomenon of culturing primary microglia, we performed studies in the intact 
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mouse brain in situ.  For this aim, we performed triple-label immunofluorescence confocal imaging 
in Sandhoff disease transgenic mice, a model in which we have previously shown substantial 
neurodegeneration and increased TSPO levels in the thalamus, cerebellum and brainstem (Loth et 
al 2016).  Figure 12 shows that TSPO and gp91phox do colocalize in microglia in situ. Thus, the 
TSPO-NOX2 interaction not only occurs in primary microglia in culture, but also in situ in the 
intact brain.  Furthermore, the TSPO-NOX2 interaction in the brain of Sandhoff disease mice 
increases as a function of age and progression of neurological disease expression (Figure 12, panels 
B-D).
4. DISCUSSION
The main finding of the present study is the demonstration, using multiple experimental 
approaches, of a direct molecular interaction of TSPO with two subunits of NOX2 in microglia.  
We also provide new evidence that the TSPO-NOX2 interaction is associated with VDAC as a 
putative complex at the MAM.  Moreover, the TSPO-NOX2-VDAC complex is disrupted by LPS-
mediated microglia activation.   
A functional association between TSPO and the NOX2 subunits gp91phox and p22phox and 
VDAC is possible for 3 primary reasons: 1) TSPO can bind both cholesterol (Li et al 1998) and 
heme (Taketani et al 1995; Veenman et al 2011), 2) TSPO is found at the MAM, a point of 
communication between the mitochondria and the ER and 3) the MAM is a subcellular site where 
heme transport to heme acceptor proteins is known to occur (Asagami et al 1994) and where there 
are high concentrations of cholesterol found due to lipid raft microdomains, that can serve as a 
platform for the binding of cholesterol to TSPO (Fujimoto et al 2011).  We propose a working 
model in microglia in which heme is bound to the TSPO dimer. When microglia are activated, 
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cholesterol is mobilized, binds to TSPO at the CRAC (cholesterol recognition/interaction amino 
acid consensus) domain, and promotes the dissociation of TSPO from VDAC as well as the 
dissociation of TSPO dimers, thereby reducing the affinity of TSPO for heme; this reduction in 
heme affinity, promotes heme efflux from mitochondria through the MAM for transfer to the gp65 
precursor of gp91phox at the ER (Figure 13).  We propose that this molecular mechanism allows 
TSPO modulation of gp91phox formation and maturation, and through this mechanism, TSPO is 
able to regulate NOX2 activity and redox homeostasis in microglia.   
This model is consistent with several independent lines of evidence: 1) the TSPO homolog 
in the Gram-negative bacterium Rhodobacter sphaeroides TspO is able to control efflux of 
tetrapyrole intermediates of the heme/bacteriochlorophyll biosynthetic pathway (Yeliseev et al 
1999), 2) structural biology studies demonstrate that cholesterol and porphyrin/heme are bound at 
two distinct sites of RsTSPO, and that both cholesterol and porphyrin/heme inversely and 
allosterically influence the binding of one another (Li et al 2013), 3) porphyrins/heme can induce 
the dimerization of RsTSPO (Yeliseev et al 2000), 4) porphyrin/heme binding to TSPO initially 
inhibits VDAC conductance of Ca2+ in a dose-dependent manner that is not altered by mPTP 
inhibitors (Tamse et al 2008), 5) cholesterol binding at the CRAC domain promotes the 
dissociation of TSPO dimers in reconstituted mammalian TSPO in liposomes (Jaipuria et al 2017) 
and 6) TSPO can affect subcellular localization of proteins, as has been demonstrated in A. thaliana 
where TSPO binds to PIP2;7 to prevent PIP2;7’s translocation to the plasma membrane in response 
to abiotic stress (Hachez et al 2014). We will elaborate on these 6 supporting points below. 
rsTSPO has been shown to function as a membrane-bound protein for the transfer of heme/ 
porphyrins to control the efflux of tetrapyrole intermediates of the heme/bacteriochlorophyll 
biosynthetic pathway (Yeliseev and Kaplan 1999).  This is relevant to the function of the 
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mammalian TSPO because the ability of RsTSPO to efflux tetrapyrroles can be replaced by the 
mammalian TSPO, indicating a highly conserved function (Yeliseev, Kruegar, & Kaplan, 1997). 
A heme transfer function for TSPO also arises from the highly-conserved tryptophan residues in 
the first periplasmic loop between the first and second membrane-spanning domains (Yesileev & 
Kaplan 2000; Li et al 2013).  These tryptophan residues are similar to WWD heme-binding motifs 
found in proteins involved in transmembrane heme delivery (Goldman et al 1998; Richard-Fogal 
and Kranz 2010).  The WWD domain binds heme to present it to an acceptor protein such that the 
heme vinyl group attaches to the reduced cysteinyl residues in the acceptor hemoprotein (Goldman 
et al 1998; Richard-Fogal and Kranz 2010).  This process prevents heme oxidation at the site of 
the transmembrane heme transfer.   
Consistent with this hypothesis, the MAM is a subcellular site where heme transport occurs 
from the mitochondria to the ER (Asagami et al 1994).  Studies have shown that the MAM is a 
preferential site for heme transport to heme acceptor proteins such as cytochrome P450 (Asagami 
et al 1994).   Our TSPO-IEM results indicate that TSPO is at the appropriate subcellular location 
for the transfer of mitochondrial-synthesized heme to heme-accepting proteins in the ER, such as 
gp65, the precursor of gp91phox.  As noted previously, gp91phox is processed and matured in the ER 
via the incorporation of two heme molecules into its precursor gp65, followed by glycosylation to 
form the mature gp91phox.  In the ER, the mature gp91phox is then able to dimerize with p22phox to 
form Cytb558. This heterodimer then traffics to relevant locations within the secretory pathway to 
membrane compartments such as lipid rafts (Shao et al 2003; Vilhardt et al 2004; DeLeo et al 
2000; Yu et al 1997, 1998, and 1999).   
Additionally, there are high concentrations of cholesterol in MAM lipid raft microdomains 
that may serve as a platform for both the binding of cholesterol to TSPO and for the efflux of heme 
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out of mitochondria (Fujimoto et al 2011). Therefore, the MAM may be a subcellular site where 
TSPO, cholesterol, and heme are found in lipid rafts that serve as a platform for the formation of 
a TSPO-gp91phox-p22phox-VDAC complex.   
Therefore, it is possible that under physiological conditions, heme is bound to TSPO and 
microglia activation mobilizes cholesterol to promote TSPO dimer dissociation and transfer of 
heme from mitochondria to the MAM.  Consistent with this hypothesis, a study using high 
resolution solid-state NMR of reconstituted mammalian TSPO in liposomes shows that cholesterol 
binding at the CRAC domain promotes the dissociation of TSPO from a homodimer to monomers 
through an allosteric mechanism that connects the cholesterol binding motif (the CRAC domain) 
at the cytosolic end of TSPO with a GxxxG oligomerization motif on the opposite end of the TSPO 
structure (Jaipuria et al 2017).  Notably, VDAC, is a protein that also contains GxxxG domains 
(Thinnes et al 2012) and cholesterol binding may not only influence the TSPO-NOX2 interaction, 
but also the TSPO-VDAC interaction by conformational changes in which this TSPO-VDAC 
association can be disrupted by microglia activation as noted in our immunofluorescence confocal 
imaging studies.  Relatedly, Tamse and colleagues demonstrated that increased porphyrin limits 
the conductance of VDAC in rat cardiac mitochondria by decreasing Ca2+ influx and inducing 
VDAC closure. The authors hypothesize that due to the nanomolar affinity of porphyrin to TSPO 
and given TSPO’s interaction with VDAC, porphyrin modulates VDAC conductance through its 
binding to TSPO (Tamse et al 2008). When porphyrin is no longer bound to TSPO, VDAC can 
flux as needed. These data indicate another way in which TSPO’s interaction with 
porprhyrin/heme can affect its association with other proteins and in this case VDAC.  
Collectively, our findings suggest that TSPO may be able to regulate the synthesis of the 
principal NOX2 subunit (i.e., gp91phox), and thus be able to modulate NOX2 activity in microglia.  
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This finding is consistent with a known function of TSPO in the plant Arabidopsis thaliana in 
which the homologous TspO responds to abiotic stress (Vanhee et al 2011).  Abiotic stress in A. 
thaliana increases TSPO levels, and TSPO regulates the cell surface expression of the aquaporin 
PIP2;7 by interacting with PIP2;7 at the ER and Golgi membranes (Hachez et al 2014).  The 
interaction of TSPO with PIP2;7 provides a mechanism by which TSPO can modulate the 
expression of plasma membrane proteins. Similarly, TSPO may be able to modulate the expression 
of gp91phox at the plasma membrane by regulating the synthesis of its heme-containing subunit. 
One question that arises is whether the interaction of TSPO with the NOX2 subunits is 
specific to microglia. Microglia are cells that have high levels of NOX2 relative to other cell types, 
given their function as the “macrophages of the brain” and use of ROS as a signaling molecule 
(Harisch et al 2009). Microglia are also one of the two cell types in the brain that express TSPO, 
the other being astrocytes. However, microglia and astrocytes exhibit different temporal responses 
in their inflammatory response and specifically in their TSPO up and down regulation (Chen and 
Guilarte 2008; Loth el al 2016). Therefore, TSPO may be serving a different function in astrocytes 
that is not associated with NOX2.  
One potential explanation is that TSPO could still be binding heme, but given that 
astrocytes have a different proteomic profile than microglia, the proteins which would require and 
receive heme in astrocytes would be different. One such candidate would be heme oxygenase 1 
(HO-1), an antioxidant enzyme which not only requires heme in its structure, but also degrades 
cellular heme into carbon monoxide and biliverdin. Previous studies have shown that HO-1 is 
upregulated in multiple cell types that involve oxidative stress, and that the time course of 
upregulation of HO-1 is dependent on cell type. For example, HO-1 in cultured astrocytes is 
upregulated earlier in time as compared to neurons in response to neurotoxic models of Parkinson’s 
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disease (MPP+ or α-synuclein) (Yu et al 2016). This implies differential mechanisms for HO-1 
induction in astrocytes and neurons. We know that TSPO upregulation can occur in both microglia 
and astrocytes, and currently, there is limited evidence that TSPO is found in neurons. Perhaps 
part of TSPO’s ability to transfer heme to relevant enzymes involved in ROS production and 
antioxidant responses is related to microglia and astrocytes being more resistant to oxidative 
damage than neurons (Yu et al 2016).  
In addition to different functions in different cell types, the interaction of TSPO and NOX 
to microglia will undoubtedly vary over time, as ROS levels change, as the cytokine milieu shifts, 
and as TSPO is upregulated and downregulated. There is preliminary evidence in Leydig cells that 
as ROS levels increase due to photoirradiation, an increase in TSPO oligomers is seen with 
molecular weights observed at multiple values: approximately 36, 72, 90 kDa depending on the 
length of exposure and presence of progesterone (Delavoie et al 2003). Thus, we could be 
capturing the time point where TSPO is being upregulated (as per input fraction and gene 
expression levels in Figure 4) in order to create oligomers, potentially larger than dimers. Teboul 
et al 2012 identified tetramers in mouse histidine tagged reconstituted recombinant TSPO in a lipid 
environment and dimers in the bacterial equivalent. The oligomeric status of TSPO in microglia 
remains to be determined in either physiological or pathological conditions. Whether or not a 
tetramer of TSPO can bind heme is also unknown. Furthermore, depending on how the microglia 
are activated whether via LPS, photoirradiation, ATP, could vary how TSPO responds. Choi et al 
2011 saw differential responses when activing microglia with ATP vs LPS. Similarly, Veenman 
et al 2016, observed that short durations and low concentrations of TSPO ligands generally 
enhances ROS production, whereas long durations and/or high concentrations of TSPO ligands 
generally reduces ROS production. However, based on the conflicting literature, the response of 
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TSPO appears to be extremely context dependent which may in fact be a reflection of TSPO’s 
function to maintain homeostasis, and therefore help preserve its ability to respond differently in 
different situations.  
Taken together, our findings provide confirmation of the protein-protein interactions 
among TSPO-gp91-p22-VDAC at the MAM in primary mouse microglia.  These protein-protein 
interactions appear to vary in strength depending on whether microglia are activated or non-
activated, or in other words in physiological vs pathological conditions. We provide supporting 
evidence for a model in which the TSPO-NOX2-VDAC interaction modulates the subcellular 
localization of gp91phox and p22phox proteins through the supply of heme, in order to ultimately 
alter NOX2 activity, to help maintain redox homeostasis.  
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A. B. 
FIGURE 1: Antibody validation: We confirmed the specificity of each antibody used for the 
immunoprecipitation, colocalization, and proximity ligation assay experiments using shRNA 
knockdown in the J774 murine macrophage cell line (A) and with TSPO wildtype (WT), 
heterozygous (Het), and knockout (KO) mice  (B). shRNA experiments were done via lentiviral 
transduction and used an empty vector as control. Multiple shRNA’s were tested for each 
protein of interest with one specific shRNA shown here (#102106 (TSPO), #435339 (gp91), and 
#240565 (p22)). Brains were dissected from TSPO mice, and protein acquired from the 
brainstem and cerebellum is shown here. Actin was used as a loading control. 
N.B. shRNA transduction experiments performed in conjunction with Dr. Diane B. Re  
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FIGURE. 2: Purity of Microglia Cultures. Purity of cultures was assessed via microglia Mac-1 
immunostaining. Of the cells extracted from mixed glial cultures via the shaking method, 93.6% 
of cells were positive for Mac-1, with 6.4% of cells being positive for DAPI only (n=6, mean ± 
s.e.m.).
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FIGURE 3. Cytotoxicity of lipopolysaccharide (LPS). Primary murine microglia were dosed 
with specified doses of LPS for 18 or 24 hours and the percentage of live and dead cells were 
counted via the Live/Dead assay. Increased toxicity was seen with 1 ug/mL of LPS at both 18 
and 24 hours. With 100 ng/mL of LPS, about 10-15% of cells were dead at 24 hours, as 
compared to less than 3% at 18 hours. n = 3 independent experiments for each time point.  
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FIGURE 4: Effect of lipopolysaccharide (LPS) activation of primary microglia on TSPO, 
gp91phox, p22phox, and VDAC protein and gene expression levels. Western blot of primary 
microglia whole cell extracts (input) after 18 hour exposure to vehicle (media) or 100 ng/mL LPS-
activated conditions (A). TSPO, gp91phox, and p22phox protein levels were increased as a result of 
LPS stimulation, while VDAC levels did not change. Quantification of protein levels (B) and gene 
expression levels (C). Data are normalized to vehicle and expressed as mean ± s.e.m.  n = 8 
independent experiments. *p<0.05 compared to vehicle-treated microglia. Student’s paired t-test: 
TSPO: p = 0.001; gp91: p < 0.001; p22: p < 0.001; VDAC: p = 0.346.C: Quantification of gene 
expression levels.  Data are normalized to vehicle and expressed as mean ± s.e.m.  n = 6 
independent experiments. *p<0.05 compared to vehicle-treated microglia. Student’s paired t-test: 
TSPO: p < 0.001; gp91: p = 0.002; p22: p < 0.001; VDAC: p = 0.382. 
Co-immunoprecipitation of TSPO, gp91phox, p22phox, and VDAC. Western blot of TSPO pull-
down (IP) after 18 hour exposure to vehicle or 100 ng/mL LPS-stimulated conditions (D). gp91phox, 
p22phox, and VDAC proteins co-immunoprecipitate with TSPO. LPS stimulation increased the 
amount of TSPO protein compared to the vehicle condition. Interestingly, the amount of gp91phox 
and p22phox protein levels decreased in the LPS condition relative to vehicle treated cells, 
suggesting that the TSPO-NOX2 subunit interaction weakens under LPS-stimulated conditions. 
No effect was found with VDAC (E). Data are normalized to vehicle and expressed as mean ± 
s.e.m.  n = 4-6 independent experiments. *p<0.05 compared to vehicle-treated microglia. Student’s
paired t-test: TSPO: p = 0.036; gp91: p = 0.005; p22: p < 0.045; VDAC: p = 0.743.
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FIGURE 5. TSPO, gp91phox, p22phox, VDAC, and Mac-1 immunolabeling in primary 
microglia. Triple labeled immunofluorescent confocal images of TSPO and gp91phox in 
microglia (Mac-1 labeled) cells. Confocal images confirmed that TSPO and gp91phox colocalized 
as indicated by the yellow color. Confocal images also confirmed that TSPO and VDAC, and 
TSPO and p22phox colocalized in microglia. Low magnification scale bar = 40 um. High 





FIGURE 6: TSPO/gp91/VDAC and TSPO/p22/VDAC immunolabeling in primary 
microglia. Representative triple labeled immunofluorescent confocal images of microglia used 
for analyses represented in Figure 8. Imaging and analyses confirmed that TSPO colocalized 
with the mitochondrial protein VDAC, as represented by the yellow color, and that TSPO 
colocalized with both gp91phox and p22phox as represented by the purple/magenta colors. Images 
were taken with a 60x objective with a 1.6x zoom.  
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FIGURE 7: TSPO/LAMP2 immunolabeling in primary microglia. Representative double 
labeled immunofluorescent confocal images of microglia used for analyses represented in Figure 
8. Imaging and analyses confirmed that TSPO had low levels of colocalization with the
lysosomal marker, LAMP-2 (Vehicle = 20.13% ± 7.25%; LPS = 12.46% ± 5.76%). n = 3
independent experiments for TSPO/LAMP2 labeling with 35+ microglia counted per treatment
condition per experiment. Scale bar = 20 um.
DAPI LAMP2 TSPO Merged 




FIGURE 8. TSPO, gp91phox, p22phox, VDAC, and LAMP-2 colocalization 
quantification summary in primary microglia. Colocalization analyses revealed that TSPO 
had high levels of colocalization (>60%) with gp91, p22, and VDAC and low levels of 
colocalization with  the lysosomal marker, LAMP-2 in vehicle treated microglia (A). The 
percentage of gp91phox, p22phox, and VDAC that colocalized with TSPO decreased when 
microglia were treated with 100 ng/mL of LPS for 18 hours (B) as compared to vehicle 
conditions (Student’s paired t-test: % gp91 with TSPO: p = 0.004; %p22 with TSPO: p = 
0.002; % VDAC with TSPO: p = 0.003). Under stimulated conditions, TSPO associated 
with gp91 and TSPO associated with p22, exhibit significantly decreased colocalization 
with VDAC suggesting a movement from the mitochondria to other cellular compartments (C) 
(Student’s paired t-test: % (TSPO with gp91 )/ VDAC: p < 0.001. % (TSPO with p22) / 
VDAC: p = 0.004). Data are expressed as mean ± s.e.m.  n = 5-7 independent experiments 
with 35+ microglia counted per treatment condition per experiment. n = 3 independent 
experiments for TSPO/LAMP2 labeling with 35+ microglia counted per treatment 
condition per experiment.   
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FIGURE 9. 
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FIGURE 9. Colocalization quantification: detailed view. The data demonstrates that LPS 
stimulation decreased the degree of colocalization of gp91, p22, and VDAC with TSPO (A). 
Additionally, LPS stimulation also decreased the degree of the colocalization of TSPO with 
VDAC; gp91 with VDAC; and of TSPO+gp91 with VDAC (B), indicating movement of the 
TSPO-NOX2 complex away from the mitochondria. The same data pattern was also shown when 
examining p22 colocalization with TSPO and VDAC (B). TSPO and VDAC both independently 
colocalized with both subunits, but only the colocalization of VDAC with gp91 exhibited a 
statistically significant trend of decreased colocalization with LPS stimulation (C). Summary of 
A, B, and C in Panel D. Vehicle treated cells are solid bars, and LPS treated cells are patterned 
bars (n = 7 in TSPO/gp91/VDAC experiments. n = 5 in TSPO/p22/VDAC experiments. *p<0.05 
compared to vehicle treated microglia. 35+ cells counted per condition). Paired t-tests (Vehicle 
vs. LPS): % gp91 with TSPO: p = 0.004. % p22 with TSPO: p = 0.002. % VDAC with TSPO: 
p = 0.003. % TSPO with VDAC: p = 0.005 % gp91 with VDAC: p = 0.002. % (TSPO+gp91) 
with VDAC: p < 0.001. % p22 with VDAC: p = 0.004. % (TSPO+p22) with VDAC: p = 0.004. 
% TSPO with gp91: p = 0.053. % TSPO with p22: p = 0.129.  % VDAC with gp91: p = 0.006. % 
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FIGURE 10. TSPO Duolink Proximity Ligation Assay in vehicle and LPS-
stimulated primary microglia. Representative Duolink, phase & pseudo-colored confocal 
images of dual labeling condition: TSPO + gp91 (A); TSPO + p22 (B); TSPO + VDAC (C) with 
quantification of average number of Duolink signals per microglia in both vehicle and 
LPS (100 ng/mL) conditions at 18 hours (D, E, F). PLA experiments confirm that TSPO 
interacts with the NOX2 subunits gp91phox and p22phox, as well as the mitochondrial 
protein, VDAC. Imaging and quantification included negative controls for labeling conditions 
of single antibody only, as well as no primary antibody, to ensure signal specificity. Data are 
expressed as mean ± s.e.m. n = 6-7 independent experiments with 30+ cells counted per 
treatment and per labeling condition. 
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FIGURE 11. Immunogold electron microscopy of TSPO in primary microglia. TSPO 
labeling in vehicle (A) and LPS treated (B) cells.  Yellow stars indicate TSPO labeling at the 
mitochondria, and black arrows indicate TSPO labeling at the plasma membrane. Higher 
magnification images (C and D) show TSPO is present at the mitochondria (M), the 
mitochondrial associated membrane (MAM) arrows)), and in the endoplasmic reticulum (ER) 
membrane as indicated by the yellow arrow heads.  N= nucleus. 
N.B. Immunogold electron microscopy completed by and courtesy of Dr. Sara Rose Guariglia. 
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FIGURE 12. TSPO & gp91 in microglia ex vivo. TSPO & gp91 in microglia in situ 
A) Representative triple labeled immunofluorescent confocal images in the thalamus of a 2 month
Sandhoff disease mouse. Imaging confirmed that TSPO in Mac-1 labeled microglia colocalized
with gp91phox. B-D) Quantification of percent colocalization of TSPO in microglia with gp91phox
in brain regions that demonstrate TSPO upregulation and neurodegeneration: the thalamus (B),
cerebellum (C), and brainstem (D) in wildtype and Sandhoff disease mice. Percent colocalization
appears to increase as a function of disease and age. (2-way ANOVA: Thalamus: Age: F3,7=
4.257; p=0.017. Genotype: F1,7=11.081; p = 0.003; Age x Genotype: F3,7=1.548; p=0.232.
Cerebellum: Age: F3,7= 8528; p=0.001. Genotype: F1,7=11.093; p = 0.003; Age x
Genotype: F3,7=0.896; p=0.460. Brainstem: Age: F3,7= 1.827; p=0.170. Genotype: F1,7=7.298; p =
0.013; Age x Genotype: F3,7=0.399; p=0.755.) Each value represents the mean ± SEM. n = 4
animals and experiments.
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FIGURE 13. Working model of TSPO function in microglia. In a physiological state, TSPO 
exists as a dimer with 2 heme molecules bound at the outer mitochondrial membrane in 
conjunction with VDAC (A). When microglia are activated to a pro-inflammatory state (M1) via 
LPS, cholesterol binds to TSPO, the TSPO dimers dissociate from each other and VDAC at the 
GxxxG motif, and heme is effluxed from TSPO across the MAM to the ER. In the ER, gp65, the 
precursor of gp91phox, receives the 2 heme molecules and is glycosylated to generate mature 
gp91phox (B). gp91phox is able to bind to p22phox  via the 2 heme molecules, and this heterodimer 
(Cytb558) is able to traffic to other parts of the cell to form the active NOX2 enzyme complex 
(C). When microglia return to their physiological state, cholesterol is no longer bound to TSPO, 
TSPO reforms as a dimer and its association with VDAC, and heme rebinds to TSPO (D). In 
this way, the TSPO-NOX2-VDAC interaction modulates the subcellular localization of gp91phox 
and p22phox proteins, in order to ultimately alter NOX2 activity and help maintain redox 
homeostasis.  
N.B. Figure design by Jennifer Dziedzic; Conceptualized by Dr. Tomás Guilarte and Meredith 
Loth 
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CONCLUSIONS 
In summary, this series of studies generated some potential answers and raised several 
critical questions about TSPO in the brain. First, in specific aim 1, we confirmed the use of TSPO 
as a biomarker of brain injury in a genetic model of neurodegeneration, Sandhoff disease. 
Upregulation of TSPO was regionally and temporally specific and appeared prior to detection of 
neurodegeneration and behavioral manifestations of disease. Additionally, this is one of the first 
studies to longitudinally track the cellular source of TSPO (microglia or astrocytes) and how the 
TSPO cellular signal varied across brain region and disease progression. As we come to understand 
the function of TSPO, it will be critical to understand which cell type the TSPO signal is originating 
from in the onset and progression of neuroinflammation.  
Second, we confirmed the use of a novel TSPO ligand [125I]-IodoDPA-713 for both in vivo 
imaging and ex vivo quantitative autoradiography. The use of an iodinated ligand has two major 
technical advantages. Development of an autoradiogram changes from 6 weeks with the tritiated 
ligand, to 1 hour for an iodinated ligand. In regards to in vivo imaging, the ability to use [125I]-
IodoDPA-713 in SPECT studies eliminates the need to have an in-house cyclotron for ligands that 
are labeled with 11C for PET studies.  
Given that we have characterized TSPO so extensively in the CNS, this model would also 
be useful to examine TSPO in the peripheral blood cells to determine if TSPO levels in the CNS 
correlate with TSPO levels in the blood. Non-invasive and low cost techniques would be extremely 
valuable to assessing neuroinflammation given the only way to currently determine TSPO levels 
in the brain is through PET imaging (high cost) or biopsy (highly invasive). 
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In conjunction with our TSPO-related discoveries, we also added two novel pathological 
findings in the Sandhoff disease murine model. We detected neurodegeneration in the CA2 region 
of the hippocampus, which to our knowledge, has not been previously documented. We also 
confirmed prior in vitro studies indicating that astrocytes cultured from Sandhoff disease mice 
have increased proliferation (Kawashima et al 2009) and increased number of GFAP-positive 
astrocytes, even when β-hexosaminidase was conditionally expressed in neurons (Kyrkanides et 
al 2012). At the whole animal level, we detected an increase in hypertrophic and GFAP-positive 
astrocytes at 1 month, further supporting increased proliferation and potentially abnormally 
functioning astrocytes in this Sandhoff disease animal model.  
In addition to our TSPO biomarker studies, we have contributed significantly to questions 
on the function of TSPO, specifically within the context of microglia. In specific aim 2, we have 
explored the relationship between TSPO and NADPH oxidase (NOX2), both in terms of ROS 
production, as well as protein-protein interactions. First, we provided multiple lines of evidence 
supporting that the TSPO-ligand induced increase in ROS production in microglia is derived from 
NOX2 and not from the mitochondria. Further, we have done preliminary assessment in regards 
to the antioxidant response being mounted after 24 hours of TSPO-ligand exposure through 
activation/translocation of Nrf2 to the nucleus and activation of HO-1 by Ro, but perhaps not PK. 
To expand on the TSPO and NOX2 relationship, we examined whether TSPO was 
physically interacting with NOX2. We confirmed that TSPO is interacting with the NOX2 
subunits, gp91phox and p22phox, as well as the mitochondrial protein VDAC using three independent 
experimental methods: 1) colocalization analyses of triple labeled immunofluorescence; 2) TSPO 
immunoprecipitation that confirms co-immunoprecipitation of gp91, p22, and VDAC; and 3) 
TSPO Duolink Proximity Ligation Assay that confirms TSPO interacts with gp91phox, p22phox, and 
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VDAC. Our immunofluorescence and immuno electron microscopy data suggests that the putative 
TSPO- gp91phox-p22phox-VDAC complex may occur at the mitochondrial associated ER membrane 
(MAM). Our data also indicates that TSPO’s interaction with both of the NOX2 subunits and 
VDAC is disrupted by microglia activation.  
Collectively, these results are consistent with the model we propose in Figure 13, Chapter 
4. As our model rests on TSPO’s well-documented ability to bind both heme and cholesterol (Li
et al 2014; Jaipuria et al 2017; Yeliseev and Kaplan 1999), several questions relating to heme and 
cholesterol binding and subcellular localization in microglia arise. Can we detect heme binding to 
TSPO in microglia, specifically within a TSPO pulldown? Based on our IP results, we would 
expect to see more heme bound to TSPO in the non-activated condition vs the LPS-activated 
condition. Does adding cholesterol (or blocking cholesterol synthesis) change the degree of the 
TSPO-NOX interaction? We would hypothesize that adding cholesterol would increase 
dissociation of the TSPO homodimers, as presumably the cholesterol would bind to the CRAC 
domain and shift the equilibrium towards monomers. If cholesterol is bound, then TSPO’s affinity 
for heme is decreased, and hence we would expect to see a decrease in the TSPO-NOX2 subunits 
interaction since TSPO would not be able to bind heme.  
How does LPS treatment affect cholesterol levels? Perhaps part of the reason we are seeing 
a decreased TSPO-NOX2 subunit interaction is because LPS treatment actually increases 
cholesterol synthesis, and thereby increases the cholesterol available to bind to TSPO and 
encourages dissociation of the TSPO homodimers.  
What is the monomer:dimer (oligomer?) ratio in activated and non-activated conditions 
and how does adding cholesterol change this ratio? Is the TSPO-NOX interaction occurring in 
other compartments in the cell?  Is TSPO interacting with other proteins besides NOX and VDAC? 
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These are just some of the several interesting lines of investigation that arise based on our current 
findings. 
Limitations & Future Directions 
In addition to the questions stated above, there are additional lines of evidence that can be 
pursued in addressing the specific aims. While we have gained a better understanding of how the 
TSPO-NOX2 interaction changes when stimulated with the M1 proinflammatory activator LPS, it 
would be beneficial to examine the TSPO-NOX2 interaction with more endogenous activators 
such as ATP. While both are documented to generate a pro-inflammatory response in microglia, 
LPS and ATP act through different mechanisms. LPS is derived from the outer membranes of 
Gram-negative bacteria, and therefore, microglia recognize the material as foreign and non-self. 
LPS triggers a pro-inflammatory response by binding to toll-like receptor 4 (TLR 4) (Block et al 
2007). This subsequently leads to the activation of the IKK complex, degradation of IκB, and 
activation of the NF-κB pathway (Akira and Takeda, 2004). In contrast, ATP effects are mediated 
through purinergic receptors (Haynes et al 2006; Skaper et al 2010). ATP is a chemical signal 
released by injured neurons and can be detected by microglia via P2X and P2Y purinergic 
receptors (Haynes et al., 2006; Skaper et al., 2010).  Neurons can release ATP during neuronal 
injury, and microglia can rapidly respond to ATP via chemotaxis and binding to purinergic 
receptors such as P2X7, which results in the opening of channels permeable to Na
+, K+, and Ca2+.  
Subsequently, P2X7 receptor activation can lead to activation of phospholipases A2 and D and 
MAP kinases, which can influence the transcriptional activities of not only NF-κB but also CREB 
and AP-1. Thus, particularly in neurodegenerative diseases, ATP may be a particularly relevant 
activator of microglia and worthy of investigating as a model of activation and mediator of the 
TSPO-NOX2 interaction.  
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Additionally, it would be valuable to induce an anti-inflammatory “M2” phenotype 
(perhaps by using IL-4) in microglia and asses TSPO levels and TSPO’s interaction with NOX2. 
Previously, IL-4 exposure has been shown to have an effect on NOX2 subunit gene expression 
with gp91(CYBB) and p22(CYBA) being up regulated at 4 hours, and being down regulated at 8 
hours and further downregulated at 24 hours in primary rat cortical microglia (Savchenko et al 
2013). In regards to TSPO, there is conflicting evidence as to whether TSPO is associated with 
more of a M1 or M2 phenotype. Bae and colleagues found that TSPO negatively regulates 
inflammation in microglia and increased TSPO expression is associated with increased M2 stage 
related genes at 24 hours in BV-2 cells, a transformed microglia cell line (Bae et al 2014). 
However, Beckers et al 2018 found that TSPO gene expression was increased at 24 hours through 
M1 phenotype induction (by either LPS or IL-1β/IFNγ) and not through M2 phenotype induction 
via IL-4 in primary mouse microglia. Taken together, these studies demonstrate how different cell 
models can generate conflicting data (BV-2 cells vs primary microglia), and also how critical it is 
to do time course experiments to better perceive and clarify  molecular pathways and trajectories 
(upregulation of CYBB and CYBA at 4 hours and down regulation at 8 and 24 hours).  
Further, to gain more insight into how TSPO-ligands are working to activate microglia and 
why it is that one TSPO ligand is protective and the other is not, it would be interesting to examine 
whether the TSPO-NOX2 interaction changes when exposing the cells to the TSPO-ligands PK or 
Ro. For example, we have not yet examined if TSPO ligands change protein levels or activity 
levels of NOX2. It will be interesting to determine if TSPO-L exposure changes protein expression 
of NOX2 subunits and if these exposures also have a functional effect in terms of NOX2 activity 
levels. As previously stated, PK and Ro have different binding sites on TSPO (Figure 1, Chapter 
1). Traditionally, PK has been viewed as an antagonist and Ro has been viewed as an agonist. 
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Thermodynamic analysis has shown that [3H]-Ro5-4864 binding is enthalpy driven while [3H]-
PK11195 is entropy driven.  Thus, it has been suggested that Ro5-4864 might be a TSPO agonist 
or partial agonist while PK11195 might be a TSPO antagonist (Le Fur et al 1983).  However, this 
classification is not definitive as reports have indicated that these ligands exert similar or opposite 
effects under various physiological conditions such as apoptosis (Veenman et al2007). In our 
model of primary microglia, we have seen similar effects of PK and Ro (increase in ROS 
production; increase in Nrf2 translocation). However, as documented in Choi et al 2011, there are 
differential effects of these ligands in primary microglia as well. For example, exposure to Ro in 
the presence of LPS increased the number of apoptotic microglia, an effect that could be blocked 
by PK. These differential effects are also seen within various models of disease. In a model of 
Alzheimer’s, Ro ligand administration has been shown to improve both behavioral outcomes and 
pathology associated with AD, whereas PK only demonstrated modest improvement in reduced 
levels of soluble β-amyloid (Barron et al 2013). However, in other disease models such as ALS, 
PK ligand administration has been shown to improve behavioral outcomes in females and decrease 
motor neuron death in vitro whereas other TSPO ligands had no effect (Obis el al 2018, in 
preparation). Taken together, these data further support that TSPO-ligands may have different 
mechanisms of action and initiate different molecular signaling cascades, and therefore need to be 
studied independently.  
Species differences 
It is important to note that there have been some studies that indicate species differences, 
particularly within regards to ROS production. Colton and colleagues assessed both ROS and nitric 
oxide (NO) production in human, hamster, rat, or mouse microglia. After 2 hours stimulation with 
opsonized zymosan, human and hamster microglia generate similar levels of superoxide, whereas 
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rat microglia produced significantly less superoxide. When measuring NO, microglia were 
stimulated with LPS 5ug/mL, rIL-1β (200U/mL), and TNF-α (1000U/mL) for 48 hours. Human 
and hamster microglia responded similarly, whereas mouse microglia had a much larger response. 
This study indicates that perhaps hamster microglia may be more representative of human 
microglia in terms of the magnitude and timing of their response. However, it is important to note 
that the dose and time point for the NO production assay are particularly high (5 ug/mL LPS) and 
long (48 hours) respectively, particularly for microglia. Thus, the viability of these cells should be 
confirmed at these doses and time points in order to confirm that cells are still alive, and a 
physiological effect is being measured as opposed to an effect in a dying cell.  
Related to these species differences reported, a report by Owen et al 2017 documented no 
change in TSPO gene expression levels in human adult microglia or human fetal microglia when 
stimulated with IFN-γ/LPS or IL4/IL13 for 48 hours. This was in contrast to murine primary 
microglia which had a 9 fold increase in TSPO gene expression when stimulated with IFN-γ/LPS 
for 48 hours. While human microglia were confirmed to be live and responsive to stimulation as 
assessed by increased TNF-α levels, it would still be beneficial to again examine different time 
points to assess if human microglia do not actually upregulate TSPO in response to these stimuli, 
or if it is merely a missed window of detection. Given the drastically different life spans of rodents 
and humans, it would not be entirely surprising if their molecular temporal responses to various 
stimuli varied even slightly. It should also be noted that the human adult microglia were isolated 
from epileptic patients, and thus may not be representative of the physiological response of 
microglia. Additionally, this data calls into major question, if microglia are not responsible for the 
upregulation of TSPO, then exactly which cell type is upregulating TSPO in the human PET 
studies? 
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Cell culture models 
All cell culture studies in this dissertation were performed in microglia only cultures, 
(~94% pure). While this is critical in isolating how TSPO and NOX2 interact in microglia, it is not 
necessarily indicative of what is happening at the whole brain level and the cross-talk among the 
various cell types. While we did confirm that TSPO colocalizes with gp91phox in Mac-1 labeled 
cells in the Sandhoff disease brain, and thus verified that the TSPO-NOX2 association is not 
merely an epiphenomenon of cell culture conditions, it would be useful to look in a model that is 
more representative of what is happening in the brain.  A potential stepping stone before moving 
to the whole animal, would be to examine TSPO within a mixed glial culture. In this way, microglia 
and astrocytes, both of which express and upregulate TSPO, would be able to communicate with 
each other. The cross-talk between these two cell types is well documented in studies by Liddelow 
et al 2017 and Rothhammer et al 2018, among several others, and in particular, the ways in which 
microglia modulate pro-inflammatory and neurotoxic activities in astrocytes. It is possible that 
without the astrocyte input and trophic support, microglia behave slightly differently in their 
activation response. For example, experiments in primary mouse microglia only are generally not 
performed at time points outside of 48 hours due to the fact that more than 50% of the plate pure 
primary microglia die after 48 hours of incubation under normal culture conditions. This severely 
limits the types of experiments that can be done with primary microglia. Therefore, doing 
experiments in a mixed glial culture, as well as microglia only cultures and astrocyte only cultures, 
would provide insight into the communication between these two cell types and how together they 
contribute to TSPO biology.  
Astrocytes, as previously mentioned, are the other type of cell within the brain that express 
and upregulate TSPO in response to brain injury. However, astrocytes and microglia have different 
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temporal responses in their TSPO response (Loth et al 2016; Kuhlman & Guilarte 1999 and 2000; 
Chen et al 2004; Maeda et al 2007; Lavisse et al 2012). This differential response indicates that 
TSPO is potentially serving different functions in microglia vs astrocytes. Astrocytes are cells that 
are more steroidogenic in nature, and thus it is plausible that the function of TSPO in astrocytes is 
more closely related to steroidogenesis. Preliminary data from out lab indicates that Cyp11a, the 
gene that encodes cytochrome P450scc to convert cholesterol to pregnenolone as the first step in 
steroidogenesis, is expressed 10 fold higher in rat astrocytes as compared to microglia (Figure 1). 
Of note, microglia are of myeloid origin whereas astrocytes originate from progenitor cells in the 
neuroepithelium of the developing CNS (Salter & Beggs 2014). 
Sex differences 
Additionally, it will be useful to examine if there are sex specific differences in cells 
cultured from male pups only vs female pups only, in both microglia and astrocytes. Up until 
recently, only a handful studies have controlled for sex when culturing cells from neonates. Both 
astrocytes and microglia are known to be sexually dimorphic in number, differentiation, and 
function (Santos-Galindo et al 2011; Kopec et al 2017; Lenz et al 2013; Prilutsky et al 2017;), even 
before sexual maturity. There is also evidence that even neonatal exposure to steroids can affect 
the inflammatory response of astrocytes as cultures generated from males only or females only 
show different inflammatory response profiles (Kuo et al 2010; Santos-Galindo et al 2011). 
Additionally, TSPO upregulation has been shown to be sexually dimorphic in some contexts 
including the heart in a myocarditis model (Fairweather et al 2014), renal tissue in an inescapable 
shock model (Drugan et al 1991); adrenal, renal, and gonadal tissue in an early handling and 
environmental stress model (Weizman et al 1999); endocrine and immune tissues in a prenatal 
diazepam exposure model (Burgi et al 2000); and proximal tubules in renal tissue in a model of 
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renal  ischemia reperfusion model (Robert et al 2011).  Only a handful of studies have examined 
sexual dimorphism and TSPO in the brain (Mirzatoni et al 2010; Santos-Galindo et al 2011; Garcia 
et al 2008), and two out of three of these studies looked at TSPO at the whole brain or brain region 
level (cerebellum), with the Santos-Galindo study being the only study to examining TSPO sexual 
dimorphism on the cellular level (astrocytes).  
Related to sexual dimorphism in seen in TSPO, several neurological diseases including 
multiple sclerosis, Parkinson’s disease, schizophrenia, stroke, Alzheimer’s disease, ALS, and 
substance abuse show sex differences in incidence, age of onset, symptomatology or outcome 
(Clayton and Collins 2014). Of the neurological diseases mentioned above that demonstrate sex 
differences, several of these are also diseases in which TSPO, a biomarker of brain inflammation 
and injury, has been shown to be involved. The sex differences seen in cell number, differentiation, 
and function are thought to underlie some of the differences seen between males and females in 
the brain’s response to pathological insults. Furthermore, studies have shown that astrocytes 
cultured from male or female postnatal day (PND) 1 mice, demonstrate differential responses to 
inflammatory challenges, not only in cytokine and chemokine expression, but also in TSPO 
expression (Santos-Galindo et al 2011). This variance in response appears to be mediated by 
testosterone, as astrocytes cultured from androgenized PND 1 females exhibited and mounted a 
similar inflammatory response as astrocytes cultured from PND 1 males (Santos-Galindo et al 
2011). These results were in line with other studies demonstrating that cortical astrocytes from 
female mice are more resistant than male cortical astrocytes to oxygen-glucose deprivation (Liu et 
al 2007 and 2008). This protection was found to be associated with enhanced aromatase activity: 
the female cortical astrocytes had higher levels of aromatase expression and activity, and cell death 
can be prevented in the male astrocytes by either giving them the female astrocyte conditioned 
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media or by supplementing with estradiol. Additionally, cell death in female astrocytes could be 
induced by administering an aromatase inhibitor (Liu et al 2007 and 2008). Thus, if the 
inflammatory response of these two cell types is sexually dimorphic, then this has the potential to 
affect TSPO biology and thus is a critical avenue of study so that effects are not masked by not 
controlling for sex when generating cells for cell culture. 
TSPO KO mice 
The advent of the TSPO knockout mouse, which have no impairments in survival or 
steroidogenesis, was a major contradiction to the leading central dogma. This knockout mouse has 
completely redefined the TSPO field and will be a major tool in discovering what the actual 
function of TSPO is in various cell types in physiological and pathological conditions. In 
particular, these mice are particularly advantageous for microglia studies as siRNA and shRNA 
work are extremely challenging given the sensitivity of microglia in culture (i.e. more than 50% 
of the plated pure primary microglia die after 48 hours of incubation under normal culture 
condition) and the low yield of microglia per dissection. While other methods exist to increase the 
number of microglia extracted from a mixed glial culture (CD11b coated beads (Gordon et al 
2011), mild trypsinization (Saura et al 2003)), these methods have the potential to increase the 
degree to which microglia are primed for activation. Our goal is to measure physiological 
responses of microglia, and not the responses of an already activated microglia. Cell culture 
conditions already put microglia in a slightly primed state, and thus adding a chemical component 
of activation, whether that is binding to a CD11b coated bead or through exposure to trypsin, has 
the potential to skew our results. Thus, we have made the decision to solely work with microglia 
that have been activated mechanically via  shaking for 2-4 hours only (some groups do overnight), 
and allow the microglia to rest and reacclimate for 16-20 hours before using them for our studies. 
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We have recently acquired heterozygous TSPO knockout mice from Helmholtz Zentrum 
Munich (GMC) as part of the International Mouse Phenotyping Consortium (IMPC) and 
INFRAFRONTIER/European Mouse Mutant Archive (EMMA). TSPO tm1b mice were produced 
on a C57BL/6NTac background and mice were produced by treating 2-cell embryos with Cre 
enzyme as described previously (Ryder et al., 2014). Tm1b allele embryos have a reporter-tagged 
deletion allele (post-Cre). Critical exons, in this case exons 2 and 3 of Tspo, are deleted by creating 
a frame shift using the Cre method. Notably, our TSPO antibodies that we have validated bind to 
amino acids 161-169 which are located in exon 4 of Tspo.  
While several lines of experiments are planned with these mice, we have generated some 
preliminary data to guide our future experiments in regards to examining the TSPO-NOX2 
relationship. The rationale behind these preliminary studies is that if TSPO is interacting with these 
two NOX subunits, what happens to NOX levels when TSPO is no longer present? Our microglia 
data indicates a protein-protein interaction between TSPO and NOX2. Further, studies from 
neutrophils in patients with chronic granulomatous disease (CGD), also suggest a functional 
relationship between TSPO and NOX2. CGD is characterized by a mutation in one of five NOX 
subunits.  X-CGD has a mutation in CYBB, the gene that encodes for gp91phox.  In patients with 
X-linked CGD, they have low superoxide activity and thus cannot generate a bactericidal response,
presumably due the mutations in the heme binding domain of gp91phox that renders NOX2 non-
functional and incapable of producing a superoxide burst. In these patients, Zavola et al 1990a 
noted that they had decreased levels of TSPO binding in the membrane of polymorphonuclear 
neutrophils (PMN’s). This was in contrast to those patients with the autosomal recessive form of 
CGD, mutations in one of the other 5 NOX subunits, who do not have impairments in superoxide 
burst production from neutrophils and also had normal levels of TSPO binding in PMN’s. Notably, 
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one X-CGD patient as noted in Lane 10 of Figure 3 of their paper, still had comparable levels of 
TSPO binding as compared to control patients. The authors of this paper acknowledge this case 
and attribute it to the patient being a variant for TSPO expression. However, other studies by 
Zavola’s group have strengthened the direct relationship between TSPO binding and gp91phox, in 
that treating monocytes from X-CGD patients with IFN-γ partially restores Cytb558 expression 
and phagocyte bactericidal activity, as well as TSPO levels in monocytes (Zavola et al 1990b). 
The authors suggest that TSPO is another NOX2 molecular component target of IFN-γ in CGD 
associated with Cytb558 deficiency.  
However, most of the above mentioned studies have examined the relationship of TSPO in 
regards to CGD in neutrophils, with the exception of the IFN-γ studies using monocytes. Whether 
or not the TSPO-gp91phox relationship remains and/or is the same in other cell types such as 
microglia, remains to be determined. The relationship could potentially differ in that, at rest, 
neutrophils already have high levels of TSPO, whereas at rest, microglia have low levels of TSPO. 
A study by Canat et al 1992 and colleagues measured TSPO ligand binding and mRNA expression 
in human blood cell populations. The highest levels of TSPO were seen in neutrophils and 
monocytes, with intermediate levels in lymphocytes, and low levels in platelets and erythrocytes. 
Canat’s study also suggested that in addition to the mitochondria, there must an additional 
subcellular location for TSPO, in addition to the mitochondria. Erythrocytes extrude their 
mitochondria before they leave the bone marrow, and neutrophils decrease mitochondrial content 
along the granulocyte differentiation pathway (Woods & Williams 1996). Both sets of authors 
suggest that TSPO can also be at the plasma membrane, one reason being that exposing intact 
PMNs to a TSPO antibody stimulated an oxidative burst (Zavala et al 1990).  Similarly, Woods et 
al 1996 documented TSPO having two different subcellular localizations in two different rat liver 
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cell types, and Berkovich et al 1993 documented two different DBI binding sites in human 
leukocytes, presumably mitochondrial and plasma membrane, that demonstrated different 
affinities for two different endogenous ligands.  However, our immunofluorescence studies 
indicate that in vehicle treated microglia, nearly 80% of TSPO is associated with VDAC, a 
mitochondrial protein. Therefore, potentially different subcellular localizations of TSPO could 
contribute to a different function of TSPO and therefore, a different relationship with NOX2.  
It is also important to reiterate that the dose used in studies will have a major impact on 
whether TSPO will enhance an oxidative response. As Woods and Williams mention, 
benzodiazepines [TSPO] have biphasic effects where they will be stimulatory at low 
concentrations and inhibitory at high doses. They cite 4 studies: three indicating how picomolar 
concentrations of Ro induce chemotaxis (Ruff et al 1985) and how nanomolar concentrations of 
TSPO ligands induce a superoxide burst (Zavala et al 1987 and 1990; Choi et al 2011). In contrast, 
in vivo studies using 1 mg/kg  TSPO-L i.p injections decreased the oxidative response in that there 
was less IL-1, IL-6, and TNF released. Thus, TSPO’s relationship with NOX will likely vary based 
on TSPO ligand, TPSO ligand concentration, basal TSPO levels of that cell type, subcellular 
localization of TSPO, as well as the oxidative/redox state of the cell type.  
In our initial studies with the TSPO KO mice, we have confirmed that TSPO is indeed 
deleted from knockout animals (Figure 2), both at the gene and the protein level. To begin to 
explore how a global knockout of TSPO affects NOX levels in brain tissue, we are starting by 
assessing gp91phox and p22phox protein expression in brain regions dissected from 3 month male 
and female wildtype (WT), heterozygous (Het), and knockout (KO) mice. We have performed 
Western blot in 6 brains regions (brainstem, cerebellum, cortex, hippocampus, midbrain, striatum) 
for 1 female wildtype and 1 female knockout (Figure 4), as well as in the brainstem and cerebellum 
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of 2 male wildtype, heterozygous, and knockout animals (Figure 3), and are in the process of 
collecting tissue to have n = 6 for each group. While the n is low (n=3), current data suggests that 
global TSPO KO mice have increased gp91phox protein levels in certain brain regions as compared 
to WT mice. We see a 1.5 fold increase in the midbrain in TSPO KO female mouse as compared 
to the female wildtype. (Notably, the midbrain which contains the substantia nigra, has been 
documented to have the greatest density of microglia in the brain (Mittelbronn et al 2001)). In 
TSPO KO males, we see a 2.2 fold increase in brainstem and a 1.6 fold increase in the cerebellum 
of gp91phox protein levels as compared to the male wildtype. It is important to note we cannot 
compare across brain regions, as each region contains its own proportion of microglia, astrocytes, 
neurons, oligodendrocytes, etc and only certain cell types are documented and/or expected to 
express NOX2 or TSPO. It will be critical to assess protein levels at the cellular level in cells (e.g., 
microglia) cultured from TSPO WT, Het, and KO brains.  
Interestingly, the molecular weight of gp91phox is around 91 kDa in tissue samples, whereas 
the molecular weight of gp91phox in our microglia cultures was about 58 kDa. This molecular 
weight in cell culture corresponds with the specified molecular weight on the product sheet, as 
well as several other groups reporting this molecular weight in cell culture (Yu et al 1998; Zhen et 
al 1998; Argawal et al 2012; Jacobsen et al 1999). This discrepancy in our data regarding the 
molecular weight can potentially be attributed to the fact that microglia may depend on signals 
from other cells within the brain to initiate glycosylation of the precursor of gp91phox, gp65. It will 
be critical to assess NOX2 activity levels both in microglia cultures, mixed glial cultures, and 
within brain tissue. 
We have also generated some preliminary immunocytochemistry data from microglia 
generated from TSPO WT and KO mice. Triple-labeled immunofluorescence again confirms the 
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deletion of TSPO. Additionally, in measuring total gray value, gp91 signal was greater in TSPO 
KO microglia as compared to TSPO WT microglia (Figure 5).  
Thus far the preliminary studies have only examined basal levels of proteins. It will be 
interesting to see how a TSPO KO mouse responds when a biological challenge is presented (i.e. 
LPS, PMA, etc) at the behavioral and pathological level.  Most studies using TSPO KO mice have 
mainly focused on characterizing the mouse and these studies have found few differences 
compared to WT mice (Tu et al 2014; Morohaku et al; Banati et al 2014). While Banati and 
colleagues did determine that in response to a facial lesion axotomy, microglia could still activate 
without expressing TSPO, it will be vitally important to see how the inflammatory response 
trajectory is different in the TSPO KO mice.   
Thus, given the background of uncertainty regarding the function of TSPO, it has become 
critical to re-examine the function of TSPO in all contexts, not only including cell type, but also 
within regards to sex, species, inflammation activation models, time course and TSPO genotype. 
This increase in knowledge will serve to maximize TSPO’s potential not only as a biomarker of 
brain injury and disease progression, but also its promise as a therapeutic target in 
neurodegenerative disease and neurotoxicant exposure.  Our studies examining TSPO’s 
relationship and interactions with NOX2 and VDAC in particular have the potential to 
revolutionize and redefine the TSPO field and aid in designing better therapeutic interventions for 
the multitude of neurological diseases that involve neuroinflammation as assessed by TSPO and 
excessive/pathological levels of ROS production as assessed by NOX2 activity. However, as 
alluded to earlier, TSPO modulation of ROS production is bimodal, and the effects are highly 
dependent on TSPO ligand concentration and duration of exposure, as well as the cell types used. 
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These differential effects support TSPO’s role in maintaining homeostasis and how its role may 
vary in physiological (healthy) and pathological (diseased). As researchers, we will need to be 
meticulous in documenting conditions so that we can fully and accurately ascertain when and in 
which contexts TSPO-ligand administration may be therapeutic and useful in ameliorating 
neuroinflammation. 
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FIGURE 1. CYP450scc mRNA Levels in Rat Microglia & Astrocytes 
Measuring the mRNA levels in the first enzyme of the steroidogenesis pathway, CYP450scc 
which converts cholesterol to pregnenolone, in microglia vs. astrocytes. Astrocytes have about 
10 fold greater levels of this enzyme indicating potentially higher levels of steroid synthesis 
occurring in astrocytes as compared to microglia.  




FIGURE 2. Genotype confirmation of TSPO wildtype, heterozygous, and knockout mice. 
TSPO endpoint genotyping representing wildtype (WT), heterozygous (Het), and knockout (KO) 
mice (A). The lower band represents TSPO (188 bp), and the higher band represents LAR3 (244 
bp), which is inserted when TSPO is deleted to confirm that the gene is in fact deleted and 
not merely the absence of detection. Therefore, two bands represent a Het mouse (Lanes 1, 2, 3, 
and +/-  as a positive Het control). One upper band represents a KO (Lanes 4, 5, and 7). One 
lower band represents a WT (Lanes 6, 8, and WT the positive control).  Western blot confirms 
genotypes of the animals as assessed by TSPO protein levels in the dissected brains regions of 
the brainstem and cerebellum (B). Based off of the TSPO Het animals, one allele does not appear 
sufficient to compensate for normal TSPO protein levels.  
N.B. Genotyping in Panel A done by and courtesy of Ms. Deborah Brooks 
203 
A. B. 
FIGURE 3. gp91phox Protein Levels in Brain Tissue: Males 
Preliminary data suggests that in the brainstem (A) and cerebellum (B), gp91/actin ratios are 
elevated in TSPO male knockout mice as compared to TSPO wildtype mice. n = 2 animals per 



























































































FIGURE 4. gp91 Protein Levels in Brain Tissue: Females 
Preliminary data suggests gp91/actin ratios are similar in WT and KO female animals, except for 
the midbrain, where gp91 levels were 44% higher in the KO as compared to WT. Figure 3 and 4 
suggest that there may be sex differences in the TSPO KO mice in regards to gp91 protein levels. 
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FIGURE 5. TSPO and gp91phox Immunocytochemistry in TSPO WT & KO Microglia 
Preliminary confocal imaging of TSPO WT and KO microglia at low magnification (A) and high 
magnification (B) confirms the deletion of TSPO. Quantification of the total gray value for gp91 
indicates higher levels in TSPO KO microglia as compared to TSPO WT microglia. Scale bar = 
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